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Summary
Breast cancer is the most common female malignancy and a major cause of
death in middle-aged women. It results from genetic and environmental
factors leading to the accumulation of mutations in essential genes, BRCA 1
and BRCA2. To date, germline mutations in the BRCAI and BRCA2 genes
in patients with early-onset breast and/or ovarian cancer have not been
identified within the Iranian population.
This study was set for two main purposes, in first for a cohort study of
selected population (Iranian women) with early-onset breast cancer and
secondly to evaluate and improve upon existing mutation detection
techniques with respect to the BRCA genes.
With the collaboration of two main centres for cancer research and
treatment in Tehran-Iran, clinical information, family history and
peripheral blood were obtained from 96 unrelated families for scanning of
germline mutations in the BRCA 1 and BRCA2 genes. These sets of
samples consists of 104 women under the age of forty-five, 88 patients
affected with early-onset breast cancer or ovarian cancer and 16 unaffected
individuals with strong family history of breast and/or ovary cancer.
II
BRCA1 exons 11 and BRCA2 exons 10 and 11 by the Protein Truncation
Test (PTT) and BRCAI exons 2, 3, 5, 13 and 20 and BRCA2 exons 9, 17,
18 and 23 with the Single Strand Conformation Polymorphism (SSCP)
assay were analysed on genomic DNA amplified by polymerase chain
reaction.
Ten sequence variants were identified: five are frameshift (putative
mutations-four novel); three missense changes of unknown significant and
two polymorphisms, one seen [BRCA2 (IVSI6-14T>C)] commonly in both
Iranian and British population.
Identification of these novel mutations suggests that any given population
should develop a mutation database for its breast cancer screening. The
pattern of mutations seen in the BRCA genes does not appear to differ from
other populations studied. Early-onset breast cancer (less than 45 years)
and a limited family history is sufficient to justify mutation screening with
a detection rate of over 250/0 in this group, whereas sporadic early-onset
breast cancer (detection rate less than 5%) is unlikely to be cost-effective.
To address the penetrance and mutation spectrum of germline mutation of
the contributed genes within Iranian population further studies should be
performed.
Meta-PCR technique was evaluated for its implication of BRCA genes
scanning. Three distinct sets of BRCA gene fragments were selected to
assemble with different approach for downstream analysis: the first set
consisted of BReA1 exons 2, 20 and BRCA2 exon 18 and their subsequent
analysis by Protein Truncation Test; the second set comprised BRCAI
exons 2, 20, 23 and 24 and their subsequent analysis by direct sequencing;
and the last one contained six key coding regions from the BRCA genes,
the 5' and 3'termini of exon 11 from both BRCAI and BRCA2 genes and
III
exons 2 and 20 from BRCAI. Downstream analysis of Meta-PCR products
by Protein Truncation Test was used rather than direct nucleotide
sequencing because the total assembled above fragments size (~2.8kb) is
sufficiently big to ignore analysing by the latter approach. PTT and direct
sequencing were chosen because of their high sensitivity and specificity.
These three trials were performed successfully suggesting that it may be
possible to assemble the entire of coding regions of BRCAI and BRCA2
genes in a multi-step procedure.
IV
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Chapter 1
1 Introduction
1.1 Cancer is the natural end-state of multicellular organisms
The evolution from a normal somatic cell to a malignant tumour takes
place within the life of an individual, and has to start afresh with each new
individual. However, an individual with a sound anti-tumour mechanism
transmits it to its offspring, where it continues to evolve. A billion years of
evolution have endowed us with sophisticated overlapping mechanisms to
protect us against tumours, at least during our reproductive life. Potential
tumour cells are either repaired and brought hack into line, or made to kill
themselves (apoptosis). No single mutation can escape these mechanisms
and convert a normal cell into a malignant one. Long ago, studies of the
age-dependence of cancer suggested that on average 6-7 successive
mutations are needed to convert a normal cell into an invasive carcinoma
[I]. In other words, only when half a dozen independent defences are
disabled by mutation can a normal cell progress into a malignant tumour.
The chance of a single cell undergoing six independent mutations is
negligible, suggesting that cancer should be vanishingly rare. However,
two general mechanisms exist that can allow the progression to happen
(Box 1.1).
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1.2 Mutations in cancer cells typically affect a limited
number of pathways
Cancer is a multifactorial disease involving the interplay of environmental,
hormonal, and dietary risks in addition to genetic predisposition.
However, progression of a single cell from a normal to a neoplastic state
always involves a series of genetic changes that alter either the regulation
or the function of a variety of different genes. Such genes may play roles in
a number of overlapping physiologic processes, including genome
maintenance, cell cycle control, apoptosis, contact inhibition, invasion and
metastasis, or angiogenesis [3]. These cancer genes are often classified in
two main categories, oncogenes and tumour suppressor genes.
1.2.1 Oncogenes
Oncogenes are a class of genes that play a role in the growth of cells but
when overexpressed by mutation, amplification, translocation, or other
means, they can foster the growth of cancer, uncontrolled by the normal
signalling pathways of the cell. Oncogenes typically encode for proteins
that stimulate mitosis or inhibit apoptosis [4. 5]. The classic defmition of an
oncogene is a cancer-causing gene carried by an acute transforming
retrovirus that has a normal counterpart (homologue) referred to as a proto-
oncogene [4]. Cancer-causing oncogenes were identified and generally
named based on the virus in which they were originally carried. For
example, SRC is an oncogene from the Rous sarcoma virus, SIS from the
Simian sarcoma virus, RAS from the Rat sarcoma virus, and so forth [6].
In the 1970s it was discovered that oncogenes and proto-oncogenes encode
proteins involved in signal transduction, the orderly and specific
transmission of growth-regulatory messages from outside the cell to the
machinery controlling replication inside the cell's nucleus ['].
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When signalling growth in a normal orderly fashion, oncogenes are termed
proto-oncogenes. Mutations and other alterations of the proto-oncogenes
turn them into oncogenes, which are unresponsive to outside influences,
leading to a permanent activation of the pathway promoting cellular
division and growth, thus leading to cancer.
Oncogene mutations are dominant at the cellular level. In other words, they
produce an effect when only one allele is altered, regardless of the presence
of the corresponding wild-type protein. Most oncogenes are altered in
somatic and not germline cells. The notable exception is the RET gene.
Mutations in this oncogene can be inherited and can cause multiple
endocrine neoplasia type 2, medullary thyroid cancer, and/or Hirschsprung
disease [8. 9].
1.2.2 Tumour suppressor genes
Tumour suppressor (TS) gene products inhibit events leading towards
cancer. Such genes exert their influence predominantly at or before DNA
synthesis in S phase of the cell division cycle. Some TS gene products
prevent cell progression, some steer deviant cells into apoptosis, and others
(Mutator genes-DNA replication repair genes) keep the genome stable and
mutation rates low by ensuring accurate replication, repair and segregation
of the cell's DNA in G2 phase for mitosis. By definition, both alleles of a
TS gene must be inactivated to change the behaviour of the cell (4, 10).
The distinction between these two categories is that tumour progression is
promoted by over-expression or gain of function in oncogenes but by non-
expression or loss of function in tumour suppressor genes.
Loss-of-function mutations are much more common than gain-of-function
mutations in inherited predisposition, presumably because the loss of
function is masked by the remainirtg normal allele during development
7
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(except in the recessive DNA-repair deficiencies), whereas a gain-of-
function cancer-promoting mutation might well be lethal [11).
1.2.2.1 Loss-of-function genetic events
Tumour suppressor mutations are also known as loss of function mutations,
because they inactivate the protein and act in a recessive manner, i.e., they
are silent in the presence of the corresponding wild-type protein. The first
evidence for loss-of-function genetic changes came from studies of
children's cancers, in particular retinoblastoma. Like many cancers,
retinoblastoma occurs in an inherited and a sporadic form. Knudson [12)
described the distribution of age at diagnosis in inherited and sporadic
cases. In inherited cases the distribution was consistent with a requirement
for one further event for tumour formation. This event occurred with
constant probability over time. In sporadic cases, the age distribution was
more complex, and consistent with a need for two events. The inference
was that in either case, two rate-limiting events were needed to form the
tumour, and that in inherited cases one of these was already present in the
germline. Comings et aI, 1973 [13) suggested that the two events might
affect the two alleles of a single gene, implying that their effects would be
recessive at the cellular level. Subsequently, in some inherited cases, a
germline deletion was found on chromosome 13, implying that loss of a
gene in that region might be the first event. This led to biochemical and
molecular studies, which showed that tumour development did indeed
require loss of both copies of that region of chromosome 13 [14] ~ using the
chromosomal deletions as signposts, the Rb gene was ultimately cloned and
found to be mutated in both copies in the tumours. Rb is thus the prototype
of the class of tumour-suppressor genes [10] where, in contrast to
oncogenes, loss of function is required for tumourigenesis.
8
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Kinzler and Vogelstein (1997) proposed that the BRCAI and BRCA2
genes should be added to the list of caretaker genes. Consistent with this
hypothesis, mutations in BRCAI and BRCA2 gene are rarely found in
sporadic cancers [15].
1.3 Breast Cancer
1.3.1 History
Familial clustering of breast cancer was first reported in the Roman
medical literature of 100 A.D. [16, 17]. In 1886, Paul Broca a French surgeon
reported breast cancer in 10 members of his wife's family (in her pedigree
at 4 generationsj]"], Since then, many studies have shown an increased
risk of breast cancer in relatives of breast cancer cases, compared to the
general population. It has been revealed that risk of breast cancer in
relatives' increases with the decreasing age of the index case. The risk is
also higher for women with several affected relatives in the family than
those with one affected relative [19, 20].
1.3.2 Breast cancer definition
Breast cancer is a disease in which breast cells proliferate abnormally. The
diagnosis of breast cancer is established histologically. Breast cancer may
present as a breast lump, thickening, or skin change. Non-palpable cancers
may be detected by mammography. A biopsy is necessary to confirm the
diagnosis and determine the type of cancer present. When breast cancer
cells metastasise from the original tumour and enter the blood stream or
lymphatic system, they can form secondary tumours in other parts of the
body. Bilateral cancer is diagnosed when separate primary breast cancers
arise in each breast; multifocal breast cancer is diagnosed when breast
cancer is present in more than one site in the same breast. Breast cancer is
staged from 0 to IV, where 0 is a non-invasive tumour, Stage I is a small
locally invasive tumour without lymph node involvement, Stage II IS a
10
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medium-sized tumour with or without nodal metastases, Stage III cancer is
a locally advanced cancer, usually with axillary node metastases, and Stage
IV cancer has already metastasised to distant sites [21]. The survival rate is
dependent upon the stage at which breast cancer is diagnosed.
Approximately 5% of benign breast biopsies reveal both excessive cell
growth (hyperplasia) and cells that are abnormal (atypia). A diagnosis of
atypical hyperplasia increases the risk for future breast cancer.
1.3.3 Breast cancer classification
Breast cancer has been subdivided into two main types, early-onset and
late-onset, a division that is based on an inflection in the age-specific
incidence curve around age 50. Mutation of one gene, BRCAI, is thought
to account for approximately 450/0 of families with significantly high breast
cancer incidence and at least 80% of families with increased incidence of
both early-onset breast cancer and ovarian cancer e2] Figurel.3.
Late-onset breast cancer is often familial in origin, although the risks in
relatives are not as high as those for early-onset breast cancer [23. 24]. The
percentage of such cases that are due to genetic susceptibility is unknown.
Breast cancer is considered a multifactorial disorder caused by both non-
genetic and genetic factors. It has been categorised into three groups:
Hereditary, familial and sporadic [16].
11
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that one or more first-degree relatives have had breast cancer and some
familial factors are thought to underlie development of the disease and dose
not fit to the hereditary breast cancer definition [29].
1.3.3.3 Sporadic breast cancer
In contrast to the above, sporadic breast cancer is associated only with
acquired or somatic mutations that occur during a person's lifetime. An
individual is the only one with breast cancer among her family and has no
family history of breast cancer in her two generations e6, 27]. Since 30-700/0
of sporadic breast and ovarian cancers exhibit LOH on chromosome
17q12-q21, it was expected that somatic BRCA1 mutations would exist in
breast and ovarian tumours [30]. However no BRCAI somatic mutations
have been described in sporadic breast cancer.
1.3.4 Genetic syndromes
Less than 1% of all breast cancer is associated with the genetic syndromes:
Cowden syndrome (adenomas and follicular cell carcinomas of the thyroid
gland, polyps and adenocarcinomas of the gastrointestinal tract, and
ovarian carcinoma), Li-Fraumeni syndrome (childhood leukaemias, brain
tumours, adrenal carcinomas and soft tissue sarcomas), Peutz-Jeghers
syndrome (characterized by hamartomatous polyps in the small bowel and
pigmented macules of the buccal mucosa, lips, fingers and toes), Werner's
syndrome, and xeroderma pigmentosum ell. However, patients with these
disorders may have a high breast cancer risk.
1.3.5 Breast cancer formation
Cancer results from the accumulation of mutations in genes that regulate
cellular proliferation. These mutations can occur early in the process of
malignant transformation or later, during progression to an invasive
carcinoma. The earliest mutations occur in the germline, as in the case of
14
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cancer-prone families. In these instances, the inheritance of a mutated allele
is commonly followed by the loss of the second allele from a somatic cell,
leading to the inactivation of a tumour-suppressor gene and triggering
malignant transformation. A classic example is hereditary retinoblastoma,
in which there is inheritance of a mutant germline RBI allele (a tumour-
suppressor gene) followed by somatic mutation of the normal RB1 allele
[12, 32, 33]. Genes important to the development of cancer regulate diverse
cellular pathways, including the progression of cells through the cell cycle,
resistance to programmed cell death (apoptosis), and the response to signals
that direct cellular differentiation [3]. Moreover, the inactivation of genes
that contribute to the stability of the genome itself can favour the
acquisition of errors in other genes that regulate proliferation [34, 35]. Errors
in DNA that arise during normal replication of the molecule (nucleotide
mismatches) or that are induced by ionising radiation or genotoxic drugs
can cause mutations in coding sequences or breaks in double-stranded
chromosomal DNA. If the nucleotide mismatch is not repaired before a
round of DNA replication occurs, that mutation is transmitted to daughter
cells. An unrepaired break in double-stranded DNA can cause a mitotic
catastrophe when the cell attempts to segregate broken chromosomes.
Genes that sense damaged DNA and cause the arrest of the cell cycle allow
time for the molecular defect to be repaired. These genes operate at several
specific "checkpoints" in the cell cycle as a means of ensuring genomic
integrity before DNA is synthesized. The most critical checkpoint gene yet
identified that is related to cancer in humans is the tumour-suppressor p53.
This gene is not essential for cell viability, but it is critical for monitoring
damage to DNA. Inactivation of p53 is an early step in the development of
many kinds of tumours [36,37] (Figure 1.8 and 1.9).
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contribution of BRCA2 gene to male breast cancer suggests that these two
genes may have different functions.
1.3.7 BRCA 1 and BRCA2 gene functions
The breast cancer susceptibility genes BRCA1 and BRCA2 encode
multifunctional proteins, the mutant phenotypes of which predispose both
to breast and to ovarian cancer [38, 39, 43]. Tumourigenesis in individuals
with germline BRCA mutations requires somatic inactivation of the
remaining wild-type allele [46]. Thus far, the following important biological
roles for BRCAI and BRCA2 have been demonstrated.
1.3.7.1 Role in genomic maintenance and DNA repair
A variety of lines of evidence now point to BRCAI and BRCA2 genes as
being directly involved in the DNA repair process. The involvements of
BRCAI and BRCAl gene in complexes that activate double-strand break
repair and initiate homologous recombination links the maintenance of
genomic integrity to tumour suppression [47, 48, 49]. Therefore, mutations
that result in loss of BRCAI or BRCAl function might lead to an overall
decrease in a cell's ability to repair damaged DNA, resulting in increased
somatic mutation, abnonnal chromosomal segregation and aneuploidy.
BRCAl and RAD51 interact and co-localize in a BRCAI-BRCAl-RAD51
complex [47, 50]. Eukaryotic RAD51 proteins are homologues of bacterial
RecA and are required for recombination during mitosis and meiosis and
for recombinational repair of double-strand DNA breaks [51].
Multiple changes occur in BRCAI in response to DNA damage. It
undergoes distinctive phosphorylation that differs from the phosphorylation
during the GI-S transition [52]. RAD51, BRCAI and BARDl collectively
relocate to chromosomal regions of DNA replication, marked by the
18
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proliferating cell nuclear antigen, PCNA [52]. Phosphorylation of BRCAl
in response to DNA damage is dependent on AIM [34].
Several experiments suggest a role for p53 (IP53) in the development of
BRCAl and BRCA2 tumours in mice. BRCAl orland BRCA2 knockout
mice can be partially rescued by crossing with a p53 knockout strain
suggesting that these genes interact with the p53 mediated DNA damage
checkpoint C3 ] . Therefore, the available evidence indicates that BRCA
genes serve as a "gatekeeper," like p53, helping to maintain genomic
integrity [54]. When this function is lost, it probably allows for the
accumulation of other genetic defects that are themselves directly
responsible for cancer formation. Possible models for the involvement of
BRCAI and BRCA2 in response to DNA damage are shown in Figure 1.8.
1.3.7.2 Role in development and normal cell proliferation
BRCAl and BRCA2 are required for a normal proliferative burst in early
embryogenesis, as revealed by the phenotypes of knockout mice [55. 56], and
are upregulated with proliferation of breast epithelial cells during puberty,
pregnancy and lactation [57]. In order to study the function of BRCAl,
homozygous knockout mice have been developed. In most cases, the
complete loss of function of BRCAI results in embryonic lethality
characterized by a lack of cell proliferation [58. 59, 60]. Cells derived from
mouse embryos lacking BRCA genes are defective in their repair of DNA
damage [56, 61, 62].
Embryos deficient for BRCAI exhibit phenotypic variation and die
between 5.5 and 13.5 days of gestation [55, 58, 59]. BRCA2-deficient embryos
die between 8.5 and 9.5 days of gestation [58, 60]. Homozygous mice
harbouring a mutation truncating BRCA2 in exon 11 die prenatally or
perinatally; however, the few that survive to adulthood develop thymic
19
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1.3.7.4 Roles in transcriptional regulation
BRCAI and BRCA2 play a role in transcriptional regulation, in that
BRCAI complexes with RNA polymerase II and both BRCAI and BRCA2
interact with transcriptional regulators [69, 70, 71, 72].
Disease-associated mutations that truncate the BRCAI C-terminus are
inactive in transcriptional activation assays. Full-length BRCAI is also an
activator of transcription: when co-transfected with p53, it induces
transcription of reporter genes cloned down-stream of the promoters of p2l
and MDM2, an oncogene that serves as a negative regulator of p53 (3, 74).
BRCAI protein-truncating mutations that lack the extreme C-terminal
portion of the transactivation domain do not induce transcription of
reporters, suggesting a relationship between transcriptional regulation and
tumour suppression. It is not yet clear whether BRCAI and/or BRCA2
interact directly with p53 to regulate transcription. When BRCAI and p53
are co-transfected into cells, their interaction modulates p53-mediated
transcription [74]. BRCAI also appears to stimulate p53-dependent
transcriptional activation from the p21 promoter [73,74].
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1.3.8 Future directions
As Figure. 1.8 suggests, genetic instability caused by loss of BRCAI or
BRCA2 could trigger mutation, including mutations in checkpoint genes
such as p53 [53]. In this scheme, mutant p53 would overcome incomplete
proliferation and lead, instead, to uncontrolled proliferation and invasive
growth.
Rapid proliferation of breast epithelial cells during puberty and pregnancy
offer the ideal opportunity for somatic mutation, including loss of a
BRCAI or BRCA2 allele. In this context, somatic mutation of BRCAI or
BRCA2 virtually always involves the loss of a large genomic region,
whether the loss is of the remaining wild-type allele in a BRCAI or
BRCA2 tumour, or the somatic loss of BRCAI and BRCA2 in sporadic
breast cancer.
But why do some breast and ovarian epithelial cells with complete loss of
BRCAI or BRCA2 function survive, whereas embryonic cells with loss of
BRCAI or BRCA2 function die?
It might be that BRCAI -/- or BRCA2 -/- breast epithelial cells are
protected by their hormonal environment, especially during puberty,
pregnancy and lactation. That is, the growth stimulatory effects of
estrogenic hormones might tip the balance in favour of growth rather than
death of some mutant cells. However, the rare surviving BRCAI -/-
BRCA2 -/- cell would be defective in DNA repair, and hence accumulate
mutations at many sites, including in checkpoint genes. As expected,
BRCAI and BRCA2 tumours harbour multiple aberrations and mutations
. [76]III many genes .
These new insights raise important questions about the genetic events that
lead to breast cancer. Why should breast epithelial cells be more
susceptible than other types of cells to the consequences of the genomic
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instability caused by loss of function of the BRCAI orland BRCA2 genes?
In addition, why should breast cancer develop in carriers of a mutant germ-
line BRCAI allele after the somatic loss of the second BRCAI allele,
whereas BRCAI is rarely if ever inactivated in patients with sporadic
breast cancers?
This argument suggests that tissue specificity of BRCAI and BRCA2
tumourigenesis might be attributable both to the hormonal environment of
breast and ovarian cells, especially during proliferative bursts, as well as to
tissue-specific expression of as-yet-unknown genes.
1.3.9 Cellular expression ofBRCAI and BRCA2 gene
In normal cells, BRCAI and BRCA2 are nuclear proteins [45.69]. BRCAI
protein expression is reduced or absent in most sporadic, advanced (grade
III) ductal breast carcinomas (7]. BRCAI and BRCA2 mRNA and protein
are preferentially expressed during the late GI-early S phase of the cell
cycle (8. 79]. BRCAI function is regulated by phosphorylation: it is
hyperphosphorylated during late Gland S phases by an endogenous kinase
activity with dephosphorylation occurring at M phase [80].
A function of BRCA1 at the GI-S transition might be to arrest cell cycle
progression by binding hypophosphorylated retinoblastoma protein
(RB)[81]. In addition to a role at the GI-S transition, BRCAI might
regulate the G2-M checkpoint by controlling the assembly of mitotic
spindles and the appropriate segregation of chromosomes to daughter cells
[82]. In a significant fraction of cells, centrosomes were amplified, resulting
in abnormal chromosomal segregation and aneuploidy.
Proteins that regulate the G2-M checkpoint, including p53 and RB,
localize to the centrosome (Figure 1.9).
BRCAI also localizes to centrosomes during mitosis [83]. Mutant BRCAI
might induce genetic instability by disrupting regulation of centrosome
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(85]. Loss of function of both alleles of a tumour suppressor gene is usually
required for expression of the associated turnourigenic phenotype.
The first mutation may occur as a somatic event, or in an inherited form in
the germline from a parent. In either case, the second mutation occurs
somatically and is usually extended over large genetic distances (loss of all
or part of chromosome). This is detectable as a loss of heterozygosity of
polymorphic DNA markers located at or close to the gene. When the first
inactivating mutation is present in the germline, the second hit deletes the
allele of the susceptible gene (plus nearby polymorphic markers) that has
been inherited from the normal parent. This model has been substantiated
in breast and ovarian cancers developing in individuals carrying BRCA1
(46. 86] and BRCA2 gene mutations [87. 88].
To date, however, only a handful of somatic mutations have been described
in sporadic breast and ovarian cancers [89. 90]. Such studies of mutational
inactivation of BRCAI and BRCA2 in sporadic disease suggest that
familial and sporadic breast and ovarian cancer may be fundamentally
different diseases at a molecular genetic level.
There is growing evidence that epigenetic silencing rather than mutation is
a common mechanism for loss of suppressor gene function.
1.3.11 Epigenetic pathway events
Epigenetic regulation of gene expression by methylation is an important
mechanism of the determination of cell fate in embryogenesis. It has been
shown that methylation of regions rich in cytosine-guanine doublets ('CpG
islands') in the promoter region in somatic cells is a common mechanism of
epigenetic silencing of one or sometimes both alleles of tumour-suppressor
genes such as BRCAI [91. 92]. It is unclear what determines whether a
particular gene will lose function by an epigenetic or a mutational
mechanism [91].
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substitution changes a single amino acid but does not affect the remainder
of the protein open reading frame, it is termed a missense mutation.
Nonsense mutations occur when the nucleotide substitution produces a stop
codon (TGA, TAA, or TAG), and translation of the protein is terminated at
that point. Frameshift mutations occur when one or more nucleotides are
either inserted or deleted. If the number of bases inserted or deleted is not
divisible by three, a change in the reading frame alters the remainder of the
translation of the protein being altered; most often a stop signal is
encountered prematurely. Another class of mutation, intron/exon splice-site
mutations, can result from either single base changes or the insertion or
deletion of one or more nucleotides in the intronic sequence, leading to the
presence of a stop codon at a splice site. Splice-site mutations cause
abnormal inclusion or exclusion of DNA in the coding sequence, resulting
in an aberrant protein. A [mal class of mutation occurs when a mutation in
a gene's regulatory region causes reduction or loss of protein synthesis from
the mutant chromosome through a direct effect on mRNA biosynthesis.
Such regulatory mutations usually occur outside of the coding sequence of
a gene and can be either nucleotide substitutions or insertion/deletion
events.
1.3.14 The frequency of BRCA1 and BRCA2 mutation in familial
breast cancer
The frequency of BRCAI was estimated to be 0.051% (950/0 CI: 0.021-
0.125%) and of BRCA2 0.0680/0 (95% CI: 0.033-0.1410/0). The breast
cancer risk by age 70 years, based on the average incidence was estimated
to be 35.30/0 for BRCAI and 50.3% for BRCA2. The corresponding
ovarian cancer risk was estimated 25.9% for BRCAI and 9.1% for
BRCA2. This low association of BRCAI and BRCA2 mutation to breast
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cancer suggest that other low penetrance gene may contribute to the most
breast cancer families [95].
1.3.15 BRCAI and BRCA2 mutation rate in early-onset breast
cancer
Peto et al (1999) reported that only 5.9% of women who diagnosed with
breast cancer before age 36 years carried BRCAI or BRCAl mutations.
For women with breast cancer between age 36 and 45 years the rate was
even lower (4.1%). The corrected percentage (due to limitation of
sensitivity of screening methods) was 9.4% and 6.6% for BRCAI and
BRCAl respectively [96]. These rates are much lower than predicted for
probability of mutation in rare autosomal dominant gene (36% in
individuals aged 20-29 years) that was estimated earlier e7] .
Two independent population based studies using young women with breast
cancer in West Washington [97] and North Carolina [98] also reported result
consistent with these data C6] .
1.3.16 Double heterozygotes mutation in both BRCAI and
BRCA2 gene
The mutation 185delAG in BRCAI and 6174deiT in BRCAl has been
reported in Hungarian patients who developed breast cancer at age 48 and
ovarian cancer at age of 50 years [99].
The mutation G2508T in BRCAI and 3295insA in BRCAl has been
reported in Canadian patients who developed breast cancer and ovarian
cancer at age of 35 years. The probability of finding a double heterozygote
in this population was estimated at I in 250000 [100].
1.3.17 Significance of mutations
Perhaps the most difficult aspect of sequence-based BRCAI predisposition
diagnostic testing is interpretation of sequence variants other than chain-
terminating mutations. These fall primarily into two categories: potential
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splice alterations and rare missense polymorphisms. From the present data
relating to allele frequencies of common polymorphisms in BRCAI, it is
estimated that about 60% of people carry at least one polymorphism within
the expressed exons of the gene that can be used to distinguish between
transcripts originating from each of their two alleles [101]. For individuals
who carry rare nucleotide substitutions near a splice junction or an
insertion/deletion polymorphism in intron sequences proximal to a splice
junction, the exonic polymorphisms can often be used to test for
proper/improper splicing of both alleles. This may be carried out by
comparing the genotype of a genomic DNA PCR products that contains the
polymorphism to the genotype of a cDNA PCR products that crosses the
splice junction in question and should contain the polymorphism.
1.3.18 Mutation-specific variation in cancer risk
The expression of BRCAI and BRCA2 mutations is variable. Mutation
carriers may develop breast cancer, ovarian cancer, other types of cancer,
or no cancer at all. Some of the variation in expression is due to chance and
some may be attributable to risk modifiers. However, a further component
appears to be due to mutation-specific differences in cancer risks.
Understanding these differences is potentially important in refining the
clinical management of susceptible individuals.
1.3.18.1 BReA1 genotype-phenotype correlation
Mutations at the 3' end of the BRCAI gene that cause truncated proteins
have been correlated with a larger increase in ovarian cancer risk than
mutations in the 5' end [102, 103, 104]. The junction between the two areas
was best characterized as a sharp demarcation point (rather than a gradual
transition region) located between codons 1435 and 1443.
Relatives of carriers of BRCAI 5382insC (which is close to the 3' end of
the gene) are reported to have a higher risk of ovarian cancer than relatives
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of carriers of BRCA1 185delAG (which is close to the 5' end of the gene),
although the difference was not statistically significant [105].
Overall, the balance of evidence remains in favour of heterogeneity of risk
of different BRCA1 mutations. There is also reasonable support for a
higher risk of ovarian cancer associated with mutations at the 5' end
compared with the 3' end of the gene, although the difference is modest.
This pattern is most consistent with the existence of a domain in the
vicinity of the transition point that specifically confers protection against
ovarian cancer. Truncating mutations 5' to the transition point, which
disrupt critical functions of the domain, lead to a high risk of ovarian
cancer, whereas mutations 3' to the transition point, which leave the domain
intact, confer lower risks of ovarian cancer.
1.3.18.2 BReA2 genotype-phenotype correlation
There is strong evidence for heterogeneity in cancer risks conferred by
different BRCA2 mutations. Families with truncating mutations located
approximately between codons 1000 and 2000 are characterized by a high
ratio of ovarian cancer to breast cancer compared with mutations located 50
or 30 to this region (which has been designated the Ovarian Cancer Cluster
Region or OCCR) [106]. In principle, this difference in phenotype between
BRCA2 mutations is attributable to an increased risk of ovarian cancer
within the OCCR and/or a decreased risk of breast cancer.
1.3.19 Population genetics ofBRCA1 and BRCA2 gene
Early linkage studies based on large families, especially those with ovarian
cancer indicated that BRCA1 contributed approximately 45% of hereditary
breast cancer e2 ] , BRCA2 adds a further 350/0, including large families
with male breast cancers [107]. More recently analyses of BRCA1 and
BRCA2 genes in many populations revealed that only 30%-600/0 of breast
cancer families are attributable to BRCAI and BRCA2 mutations.
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Szabo and King (1997) have been conducted a combined data analysis on
multiple population-based studies for comparison of frequencies of BRCAI
and BRCA2 mutations in high-risk families and in other series of patients
from most populations represented in the literature (108) (Table 1.1). They
have suggested several conclusions:
First, the proportion of high-risk families with breast or ovarian cancer
attributable to BRCAI mutations varies widely among populations.
Second, in the most populations, BRCAl and BRCA2 together explain 6%-
10% of breast and ovarian cancer unselected for family history.
Third, about 30% of high-risk families have no detected mutations in either
BRCAl or BRCA2 gene.
Fourth, in families with male breast cancer, BRCA2 mutations are more
common than BRCAI mutations, as has been apparent since BRCA2 was
mapped (Wooster et al. 1994).
Finally, in all regions other then Iceland, the frequency of BRCAI
mutations is 1.5-2.0 fold higher than the frequency ofBRCA2 mutations.
32
Chapter 1- Introduction (Literature Review)
Table 1.1: Frequency of germline mutations in BRCA 1 and BRCA2 genes
in families screened from various populations. (Adapted from Szabo et al. 1997)
No. of families or patients
with mutations/No. of
families or patients screened
Population BRCAI BRCA2 Reference(s)
A) Families with three or more cases of female breast and/or ovarian cancer:
Britain 71/339(21%) 25/290 (9%) Gayther et al. (1995 , 1996,
1997b); Xu et al. (1997)
Canada 12/30 (40%) 8/49 (16%) Simrad et al. (1994) ; Phelan ct
al. (1996)
Finland 8/100 (8%) Vehmanen et al. (1997)
France 38/160 (24%) 14/77(18%) Serova-Sinilkova et al. (1997) ;
Stoppa-lynonet et al. (1997)
Germany 9/49 (18%) Jandrig et al. (1996) ; Hamann et
al. (1997)
Holland and Belgium 71/517 (14%) Hogervorst et al. (1995) ; Peelen
et al. (1997)
Hungry 7/32 (22%) 4/32 (13%) Ramus et al. (1997)
Iceland 1/11 (9%) 7/11 (64%) Thoracius et al. (1996)
Israel 16/34 (47%) 8/34 (24%) Levy-Lahad et al. (1997)
Italy 21/73 (29%) Caligo et al. (1996); Montagna
et al. (1996); De Benedetti et al.
(1996)
Japan 2/20 (10%) Inoue et al. (1995)
Norway 3/25 (12%) Anderson et al. (1996)
Russia 15/19 (79%) Gayther et al. (1997a)
Sweden and Denmark 24/106 (23%) 12/106 (11%) Johannsson et al. (1996) ;
Hakansson et al. (1997)
United States 69/179 (39%) 24/94 (25%) Castilla et al. (1994); Friedman
et al. (1994 , 1995); Struewing et
al. (1995)
B) Families with male and female breast cancer:
United States 2/24 (8%) 12/64 (19%) Couch et al. (1996); Friedman et
al. (1997) ; Serova et al. (1997)
Hungry 0/6 (0%) 2/6 (33%) Ramus et al . (1997)
Iceland 0/10 (0%) 9/10 (90%) Thorlacius et al. (1996)
C) Breast and/or ovarian cancer patients not selected for family history:
Iceland 42/497 (8%) Johannesdottir et al. (1996)
Italy 4/49 (8%) De Benedetti et al. (1996)
Israel 23/243 (9%) 14/243 (6%) Abeliovich et al. (1997)
Japan 8/179 (4%) 2/103 (2%) Matsushima et al. (1995) ;
Katagiri et al. (1996) ; Miki et al.
(1996)
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1.3.20 The prevalence, incidence and prognosis of breast cancer
Breast cancer is the most common cancer among women, excluding skin
cancers [109, 110] (Figure 1.11) with a lifetime risk of 10% in the general
population [111]. In spite of earlier detection and better treatment, largely
due to recent technological advances it is still the second leading cause of
cancer death in women, exceeded only by lung cancer C12] . Global
common cancer incidence rate in developed and developing countries is
shown in Figure 1.12 [113].
The risk of breast cancer increases with age, with the majority of sporadic
breast cancers occurring after menopause. In addition, women who carry
BRCA1 or BRCA2 mutations have a significantly increased chance of
developing breast cancer before the age of 50 [114. 11S].
Both BRCAI and BRCA2 are considered to be responsible for a similar
proportion (40%) of inherited breast cancer [116] but the majority (81%) of
the breast-ovarian cancer families are due to BRCAI whereas BRCA2 is
found in the majority (76%) of families with male and female breast cancer
[117). Carriers of BRCAI or BRCA2 mutations from families with high
cancer risk have been estimated to have an 85% lifetime risk of developing
breast cancer [116]. In addition, BRCAI mutations' carriers have a 65%
lifetime risk of developing ovarian cancer [102].
Studies in various populations report the risk of breast cancer in women
with BRCAI or BRCA2 mutations as 56% to 87% by age 70 Cos. 118]. In
comparison, women in the general population have approximately a 10%
lifetime risk for breast cancer and a 1%-2% lifetime risk for ovarian cancer.
Penetrance estimates for breast cancer risk in women with germline
BRCAI mutations vary depending on the population used for analysis [22,
119, 120].
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The National Cancer Institute (NCI) estimates that about 1 in 50 women
will develop breast cancer by age 50 years and about one in ten women in
the United States will develop breast cancer by age 80 years C27.128].
The Western diet is associated both with earlier age at menarche and with
post-menopausal obesity, which Increases endogenous oestrogen
production and hence breast cancer risk [129]. Breast cancer incidence is
much higher in most Western countries than in many developing countries,
and this is partly (and perhaps largely) accounted for by these dietary
effects combined with later first childbirth, lower parity and shorter
breastfeeding C30, 131]. Table 1.2 shows this comparison pointing these
figures in Iran and UK.
Table 1.2: The new cases and incidence rate of female breast cancer in
Iran compared to other countries
Country New Incidence rate *
cases Crude ASR(W)
Islamic R. of Iran 3491 10.46 14.76
United Kingdom 34815 116.27 74.93
Less developed 471063 19.66 23.07
countries
More developed 579285 94.93 63.22
countries
World 1050346 34.94 35.66
1) The column marked WIth * show the incidence rate (per 10 persons) of female
breast cancer whilst another depicts the number of new cases (See chapter 7 section
7.6 Glossary).
2) Adapted from GLOBACAN 2000: Cancer Incidence, Mortality and Prevalence
Worldwide, Ver. 1.0. IARC CancerBase No.5. Lyon, IARC Press. 2001.
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1.3.20.1 The prevalence of BRCA1 and BRCA2 mutations in general
population
Mutations of BRCAI and BRCA2 are rare in the general population. A
segregation analysis of a population-based case-control study of 4730
breast cancer cases (aged 20-54 years) and 4688 matched controls (the
CASH study) estimated a prevalence of 0.0033 (0.6% heterozygote
frequency) for all high-risk dominant breast cancer-susceptibility alleles
together (27]. By combining BRCAI penetrance estimates and population-
based figures of cancer mortality in the relatives of British breast cancer
patients, an indirect estimate of the prevalence of BRCAI mutations of
0.0006 (0.120/0 heterozygote frequency) consistent with the CASH data was
obtained (117]. Precise, direct estimates of the frequencies of BRCAI and
BRCA2 mutations are difficult to obtain as they require screening of many
individuals and are hampered by the large sizes of the genes, the diversity
of mutations, and the incomplete sensitivity of current mutation screening
methods.
The true incidence of germline BRCAI mutations in the general population
remains unknown [132], but it is estimated that 1 in 200 to 1 in 400 women
may be carriers of the BRCA1 mutation [133, 134].
Some BRCAI and BRCA2 mutations occur with greater frequency in
certain ethnic groups because of the founder effect. The founder effect
occurs when a relatively small group is genetically isolated from the rest of
the population. If an individual in that isolated group carries a rare
mutation, later generations will have a higher frequency. of that mutation, as
the allele becomes dispersed throughout the group.
Three specific mutations in BRCAI and BRCA2 are more common in the
Ashkenazi Jewish population. A large-scale population study has been
conducted [135] to investigate the prevalence of specific BRCAI and
BRCA2 mutations in Ashkenazi Jewish individuals who were unselected
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for breast cancer. BRCAI mutation screening on approximately 3,000
Ashkenazi Jewish samples determined a carrier frequency of 1.09% for the
185deiAG mutation and 0.130/0 for the 5382insC mutation. BRCA2
analysis on 3,085 individuals from the same population showed a carrier
frequency of 1.520/0 for the 6174deiT mutation. This expanded population-
based study confirms that the BRCAI 185deiAG mutation and the BRCA2
6174deiT mutation constitute the two most frequent mutation alleles
predisposing to hereditary breast cancer among the Ashkenazim, and
suggests a relatively lower penetrance for the 6174deiT mutation III
BRCA2. There was no evidence for differences between them III
105penetrance [ ).
In Iceland, the single BRCA2 999del5 mutation has a heterozygote
frequency of approximately 0.50/0 [136. 137, 138]. While these results have
important implications for the management of breast cancer susceptibility
in the Ashkenazi and Icelandic populations, they are not directly relevant to
other populations. The BRCA2 mutations 982del4 in American and French,
2041insA in Dutch, Canadian and American, 3034del4 in Belgium,
Canadian, Spanish, French, Switzerland, Italian and American families
have also been reported [98. 139) .
••••••••••••••••••••••••••••••••••••••••••••••••••••••••
: Knowledge of the carrier frequency of specific mutations in every :
: population will greatly influence the counselling of those women :
: regarding breast cancer risk and genetic testing, as well as the :
: approach to mutation detection taken in the laboratory. :
~ .
1.3 .21 Breast cancer screening and prevention
Breast cancer is not a systemic disease at its inception, but is a progressive
disease and screening can arrest its development; treatment of advanced
breast cancer is often futile and disfiguring [140].
Screening reduces mortality from breast cancer largely because,
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I-Breast cancer is a progressive disease.
2-The progression of breast cancer can be halted by early detection and
treatment.
3-By halting disease progression, screening for breast cancer can prevent a
significant proportion of deaths from the disease.
4-The basic mechanism for the prevention of deaths by screening is the
reduction in the incidence rate of advanced tumours.
Recommendations for cancer screening of individuals with a BRCAI or
BRCA2 gene mutation have been made by a task force convened by the
Cancer Genetics Consortium (CGSC), an NIH-sponsored consortium of
researchers assessing the ethical, legal, and social implications of genetic
testing for cancer risk [141]. The CGSC statement emphasized that
recommendations are based on presumed benefit and may change as new
evidence becomes available; therefore, patients should be counselled
regarding the limited knowledge about strategies to reduce risk and patient
preference should be taken into account in decisions about follow-up. The
CGSC recommendations for individuals with a BRCAI or BRCA2 gene
mutation are:
• Monthly breast self-examination starting in early adulthood
• Annual or semi-annual clinical breast examination beginning at age 25-
35 years
• Annual mammography beginning at age 25-35 years
No studies have evaluated the outcome of early breast cancer screening.
The breast cancer screening recommendations are based on data from
families with cancer-predisposing BRCAI or BRCA2 mutations, which
indicate that elevated breast cancer risk begins in the late 20s or early 30s
C41] . Men with BRCAl cancer-predisposing mutations may also be at
increased risk for breast cancer, and evaluation of any breast mass or
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change is advisable; however, there are insufficient data to recommend a
formal program of surveillance [141].
1.3 .22 Risk estimation to family members
Virtually all individuals with a cancer-predisposing mutation in BRCAI or
BRCA2 have inherited it from a parent. The parent mayor may not have
had a cancer diagnosis depending upon the penetrance of the mutation, the
gender of the parent with the mutation, the age of the parent with the
mutation, and other variables. It is appropriate to offer mutation analysis to
both parents of an individual with a BRCAI or BRCA2 mutation.
Occasionally neither parent will be identified as having the BRCA1 or
BRCA2 mutation. Reasons for this include a de novo mutation in the
proband, alternate paternity or adoption.
In breast cancer, the risk to close relatives of a case, averaged across all
ages, is about twofold. Most of this familial risk is probably genetic in
origin [142). The risk is about the same for the mother, sisters or daughters
of a case, suggesting dominant rather than recessive effects. Large
population-based studies indicate that only 15-20% of overall familial risk
is attributable to mutations in BRCA1 and BRCA2 [143]. The possibilities
for the remaining 80% are some combination of a small number of
moderately strong genes, and a larger number (possibly a hundred or more)
of weaker genes [142) Figure 1.13.
The variant alleles are associated with risks of around 1.5-fold and are
predicted to account for only a few per cent of breast cancer incidence.
Collectively they account for only a very small fraction of the familial risk.
There are many almost certainly more genes to be identified, which
together will account for a much higher fraction of cancer incidence than
the genes in the inherited cancer syndromes.
41

Chapter 1- Introduction (Literature Review)
years in the Cancer and Steroid Hormone Study, [148] a higher familial risk
was reported for lobular carcinoma in situ than for other subtypes.
The tumour grade of both BRCAI and BRCA2 breast cancers was
significantly higher than that of sporadic breast cancers [145]. High grade as
an independent index of prognosis may lead to a poorer outcome [149].
However, some reports suggest a better prognosis in familial breast cancer
[146, 147, 150].
These observations may also have implications for the management of
women with a raised risk of breast cancer.
1.3 .24 Genetic testing strategies
Genetic testing for risk is now part of the standard of clinical care for
families, although its value may be controversial when the practical
benefits of the actions open to someone at risk are not clear [151].
Mutation screening can be carried out on either affected individuals, or
unaffected individuals with a very strong family history of breast/ovarian
cancer. Testing should be carried out on the following category of patients
using genomic DNA/eDNA:
• Mutation screening in affected individuals
• Mutation screening in unaffected individuals with strong family history
• Mutation screening in unaffected individuals for common mutations
found in the selected population
• Predictive testing of at risk relatives
• Confirmation of the presence of a known mutation
The type of patient accepted for mutation screening is dependent upon local
practices and funding.
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1.3.25 Mutation detection methods
The detection of inactivating mutations ill tumour suppressor genes IS
critical to their characterisation, as well as to the development of diagnostic
testing. Most approaches for mutational screening of gennline specimens
are complicated by the fact that mutations are heterozygous and that
missense mutations are difficult to interpret in the absence of information
about protein function. To date there is no one technique that is ideally
suited to a complete analysis of BRCA genes with each method carrying
both advantages and disadvantages [117].
For example, Single Strand Conformational Polymorphism (SSCP)
analysis is simple to perform and rapid but is less sensitive than other
techniques. Reproducibility can also be a problem because of the extreme
sensitivity of SSCPs to temperature and other gel conditions. (Orita et al
1989). Heteroduplex Analysis (HA) can detect small insertions and
deletions and not at the detection of single base changes. It can be useful as
an initial screen to look for common mutations (Gayther et al 1996).
Fluorescent Conformational Sensitive Gel Electrophoresis (F-CSGE) can
be used for the detection of all types of mutations by automated
heteroduplex analysis). It is reported that the sensitivity is approaching
100%. This technique will pick up polymorphic variants and variants of
unknown pathological significance as well as truncating mutations
(Ganguly et aI1998).
Unlike all other techniques, the Protein Truncation Test (PTT) detects only
those mutations, which result in premature termination of the protein
product. This technique is particularly suited to analysis of the large exons
in BRCAl and BRCAl and allows the use of genomic DNA as a test
source. The technique is relatively easy to perform and does not require
special equipment. It is very sensitive but is expensive and involves a
radioactive detection method (Roest et al 1993).
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Direct Sequencing (nS) analysis is often considered the "gold standard" for
mutation detection in terms of sensitivity, but is labour intensive when not
automated, time consuming and expensive (Sanger et aI1997).
BRCA1 and BRCA2 are relatively large genes, comprising 22 and 26
coding exons respectively. The majority of these exons are small, often less
than 100 bp in size, and there is one large exon in both BRCA1 and BRCA2
gene that comprises 61% and 45% the entire coding region respectively
(See Appendix II). These aspects alone present number challenging features
for the analysis ofmutations in the BRCA1 and BRCA2 genes.
860/0 of alterations are predicted to lead to a truncated protein product as a
result of frameshift, nonsense, splice or regulatory aberrations [104). The
remaining 14% are missense mutations of which half are located in regions
of putative functional importance, the RING finger motif near the 5' end of
the gene and sequence encoding the acidic blob at the 3' end. There appears
to be little evidence of mutation clustering with a fairly even distribution of
mutations throughout, and there are no specific alterations which occur
with a particularly high frequency, although five individual mutations
(185deIAG~ 5382insC~ 1294de140~ 4184de14~ Cys61Gly) represent
approximately one third of all those reported to date [94).
The utility of any screening test depends on three basic factors: the prior
probability of having the condition of interest, the sensitivity of the test
(the chance that a person with the condition will have a positive test result),
and the specificity of the test (the chance that a person without the
condition will have a negative test result).
For BRCA genes, one must consider the distinct possibility that a woman
diagnosed with breast cancer at a particular age or with a specific family
history harbours a mutation in BRCAI or BRCA2~ that a mutation will be
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detected using a given screening technique; and that a benign sequence
variant will be interpreted as a deleterious BRCAI mutation.
1.3.25.1 Factors affecting sensitivity of the test
There are a number of families reported in which the genetic linkage
evidence for involvement of BRCAI is very strong but for which mutations
have not been identified [152]. Although these could be due to coding
mutations missed by SSCP, similar families have been found among groups
using direct sequencing. Such families could be analysed initially for the
presence of a single transcript (indicating that on one chromosome, the
copy of BRCAI is improperly transcribed into messenger RNA) through
analysis of the polymorphisms described in the region in cDNA and
genomic DNA [39] or by a functional assay when available. The frequency
of these presumed regulatory mutations lying outside of the regions
currently being analysed (exons and intronlexon junctions) will affect the
utility of any sequence-based test for BRCAI mutations.
1.3.25.2 Factors affecting specificity of the test
In the preceding paragraphs, I have focused on factors affecting the
sensitivity of an assay for BRCAI mutations, i.e., the chance that a true,
clinically meaningful alteration in the BRCAI gene will be detected using a
particular screening method. However, one must also consider the
specificity of such an assay, i.e., the rate of false positives. In practical
terms this usually involves the proper interpretation of observed missense
mutations. How can one be certain that an observed amino acid substitution
found in a patient or relative of a patient is clinically meaningful? Missense
mutations, which are recurrent in cancer cases but absent or very rare in the
general population, are likely to be clinically meaningful; cosegregation of
the missense mutation with the disease in relatives of the proband provides
further support that the missense mutation is indeed causal [104].
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1.4 Aims
This study was set for the following purposes:
• To report initial experience in identifying germline mutations m the
BRCAI and BRCA2 breast and ovarian cancer susceptibility genes, to
assess the spectrum of such mutations, and to determine the frequency of
recurrent mutations in a cohort study from the Iranian population.
• To show the implication of the result and the management of early-onset
breast cancer within the Iranian District Health Services (DHS) [153]
• To exploit of the result as a basis for further studies on breast cancer in
Iran
• To evaluate and improve upon existing mutation detection techniques
with respect to the BRCA genes
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2 Methods and Materials
2.1 Subjects and Methods
2.1.1 Subjects (Data collection)
Two main centres for cancer research and treatment in Tehran-IRAN,
namely the Iranian Centre for Breast Cancer (ICBC) and the Cancer
Institute affiliated to the Medical Sciences of Tehran University were
chosen for a cohort study includes 104 individuals from 96 unrelated
families with either breast or ovarian cancer for screening of germline
mutations in the BRCAI and BRCA2 genes.
From the ICBC about 4000 medical records of individuals who have been
attended a clinic between 1997-1999 for routine breast examination or for
breast disease examination were reviewed. Fifty-four women from 46
unrelated families who met the criteria were selected for this study.
In the 12 months after December 1999, a consecutive series of fifty patients
from 50 unrelated families who had been diagnosed with either breast or
ovarian cancer, attending clinic at Cancer Institute for surgery who met the
criteria were also chosen for screening.
All selected women (104 individuals from 96 unrelated families) were
under the age of forty-five and were informed that their DNA samples
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would be analysed for known genes associated with susceptibility to breast
cancer; they were offered the opportunity to receive the results and asked to
sign a second consent form if they chose to learn the results (Appendix
VII).
Criteria were proposed to address the spectrum of germline mutations
associated with onset breast and ovarian cancers in this selected group.
2.1.1.1 Inclusion criteria
Different criteria have been chosen in different studies usmg pedigree
analysis and based on estimation of individual's risk for probability of
carrying germline mutation in BRCAI and/or BRCA2 genes [1,2,3,4,5,6].
Family history, age of onset (premenopausal or postmenopausal state),
male breast cancer, bilateral breast cancer, ovarian cancer, number of
affected relatives and etc were factors that considered to estimate of
developing breast cancer and lead to select the participants in these studies.
However, the ideal approach for data collection is the way, which capable
to covers most of the above factors to obtain greater chance for detection a
mutation in an individual at risk.
The present study is performed to obtain initial experience in identifying
gennline mutations in the BRCAI and BRCA2 genes in the Iranian
population. More recently a survey has been carried out in Esfahan-Iran
concerning a common age of menopause in Iranian women (Data in press).
This survey suggests that Iranian women may experience menopausal state
between the age of 35 and 45 years.
In this study, the age of 45 years was chosen based on the previous
population studied [7,8,9, 10], the cancer registry data in Iran (11] and because
it is more likely to detect germline mutation in breast cancer predisposing
genes at the premenopausal state.
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Due to time limitation as a PhD course and presence of difficulties for data
collecting in a short period, age of onset (premenopausal state) was chosen
as a main criterion in high-risk families in this selected group. Other
criteria were considered to select participants are as follow:
1. Affected women with breast cancer at the age of less than 45 years.
2. Affected woman with ovarian cancer at any age.
3. Affected women with breast cancer more than 45 years of which at least
one first degree relative has breast cancer less than 45 years.
4. Unaffected women who have at least one first degree relative with
breast cancer less than 40 years or two second degree relatives more
than 40 years.
5. The family contains a male breast cancer patient who is the first or
second degree relative.
A total of 104 samples derived from 96 unrelated families who met one of
the above criteria were collected. These samples were included six ovarian
cancer cases, two bilateral breast cancer cases and sixteen unaffected
women who met the above criteria. The reason for collection of samples
from unaffected individuals was due to presence of a strong family history
among them (Table 2.1, Figures 2.1 and 2.2, find out for more detail in
chapter 6 section 6.1.8).
Note: The participant must be a first degree relative (mother, sister,
daughter) of an affected member of a high-risk family.
66
Chapter 2- Methods and Materials
II:2
BC-42
1:3 1:4
70-Utr
111:3 111:4
42 yrs 4lyrs
II:l
III:2
44 yrs
1:2
BC-43
1:1
III:l
44 yrs
Figure 2.1: File record-146UBF
The pedigree shows a family with
affected twins. Probands 111:3 and
III:4 are seeking a genetic test. Their
sisters (twin) probands III:1 and III:
2 who has been diagnosed with
breast cancer less than 40 years.
Their mother proband 11:2 died with
breast cancer at the age of 42 years,
maternal grandmother 1:4 died from
uterine cancer at the age of 70 and
paternal grandmother 1:2 died with
breast cancer at the age of 43 years.
Figure 2.2: File record-l 04UBF
The pedigree shows a proband
IV:3 who is seeking advice. 1:1
Her two sisters IV:1 and IV:2
were diagnosed with breast
cancer at the age of 31 and 34
respectively. Her paternal grand
father and her cousin II:I and
II:2 died from colon cancer.
II:} II:2
1:2
III:l
II:3
III:2
IV:l
31 yrs
IV:2
34 yrs
IV:3
42 yrs
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Table 2.1: Age-specific distribution of female breast cancer in the present cohort study
Cases Total 15-19 20-24 25-29 30-34 35-39 40-44 >45
cases
No. 0!'o No. % No. 0!'o No. % No. 0!'o No. % No. %
Affected * 82 1 1.2 9 10.9 10 12.2 24 29.3 38 46.3(Be) - - - -
Unaffected 16 - - 2 12.5 3 18.8 1 6.3 3 18.8 5 31.3 2 12.5
Affected * 6 1 16.7 16.7 4(OV) - - - - - - - - 1 64
Total 104 1 0.96 2 1.92 12 11.53 11 10.57 28 26.93 44 42.3 6 5.76
*The affected women histologically have been confirmed with breast or ovarian cancer.
BC= Breast cancer OV= Ovarian Cancer
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2.1.2 Methods
2.1.2.1 Breast/Ovarian cancer gene predisposing scanning
In an ideal situation it would be preferable to have the capacity to screen all
exons of both genes. However, this may only be practicable for a small
cohort of patients, i.e. those at very high risk of being mutation carriers.
Also local practices and funding may prevent the full screen of both genes.
Thus, it is considered acceptable to carry out a limited screen, which targets
areas of the genes where common mutations exist, typically exons 2, 5, 11
and 20 ofBRCAI and exons 10 and II ofBRCA2.
For such a these reasons, in this study BRCAI exons II and BRCA2 exons
10 and 11 by the Protein Truncation Test (PTT) [ 12, 13, 14] and BRCAI
exons 2, 3, 5, 13 and 20 and BRCA2 exons 9, 17, 18 and 23 by the Single
Strand Conformation Polymorphism (SSCP) assay [15] and Heteroduplex
Analysis (HA) [16] were analysed by amplification from genomic DNA
with the polymerase chain reaction (PCR). Although mutations are
scattered throughout both BRCAI and BRCA2 some coding regions were
particularly chosen for several reasons: first, many putative mutations have
been reported in these regions [17] second, it has been shown that they have
a significant role in protein function (exon 2-5 -Ring finger domain [18];
exon II and exon 20 -BRCI domain) [19, 20] and third, exons 10 and 11
cover a large segment of the genes.
All indices have been analysed for germline mutation in both BRCAI and
BRCA2 genes regardless to their mutation status.
2.1.2.2 Material preparation (Genomic DNA purification)
The source material for testing varies; most laboratories extract genomic
DNA from blood samples due to its simplicity of preparation and stability,
whereas others also collect RNA from the same patient. Generally
cDNAlRNA is not used as a template for mutation screening, the
possibility remains that truncation mutations decrease mRNA stability and
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thus might decrease the detection of the mutated allele derived mRNA after
RT-PCR/PTT [21]. Therefore, in the case of breast cancer in particular,
patients are not always available to obtain fresh samples.
In addition mRNA expression level might change in different hormonal
levels (Oestrogen and Progesterone) such as during menstruation period,
pregnancy, lactation, menopausal state and etc.
In this study genomic DNA was used as a genetic material. Fresh whole
blood was collected in K-EDTA tubes and stored at -20°C until genomic
DNA extraction became feasible (as a source of material); no more than 10
days later.
Using a Wizard Genomic DNA purification kit from Promega,
Southampton, UK~ catalogue no. LA1620 and in accordance with the
manufacturer's protocols, genomic DNA was extracted from peripheral
blood lymphocytes in Department of Biotechnology at the Pasture Institute
in Tehran- Iran.
The Wizard ® Genomic DNA Purification Kit is designed for isolation of
DNA from white blood cells. It is based on a four-step process e2]. The
first step in the purification procedure lyses the cells and the nuclei. For
isolation of DNA from white blood cells, this step involves lysis of the red
blood cells in the Cell Lysis Solution, followed in second step by lysis of
the white blood cells and their nuclei in the Nuclei Lysis Solution. The
cellular proteins are then removed by a salt precipitation step (3Td step),
which precipitates the proteins but leaves the high molecular weight
genomic DNA in solution. Finally, the genomic DNA is concentrated and
desalted by isopropanol precipitation (4th step).
Wizard ® Genomic DNA Purification Kit contains:
• Cell Lysis Solution
• Nuclei Lysis Solution
• Protein Precipitation Solution
• DNA Rehydration Solution
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2.1.2.3 Protocols for genomic DNA isolation from whole blood
The purification of genomic DNA from fresh whole blood following
collection in EDTA-, heparin- and citrate-anticoagulant tubes, produced no
adverse effects upon subsequent manipulations of the DNA, including PCR
eJl. Anticoagulant blood samples may be stored at 2-8°C for up to two
months, but DNA yield is reduced with length of storage. The yield of
genomic DNA will vary depending on the quantity of white blood cells
present. The following protocol was routinely used for isolating DNA form
a 3ml sample volume:
1) Add 9.OmI of cell lysis solution to a sterile 15ml centrifuge tube.
2) Gently rock the tube of blood until thoroughly mixed; then transfer
blood to the tube containing the cell lysis solution. Invert the tube 5-6
times to mix.
3) Incubate the mixture for 10 minutes at room temperature (invert 2-3
times once during the incubation) to lyse the red blood cells. Centrifuge at
2000 xg for 10 minutes at room temperature for each 3mI sample.
4) Remove and discard as much supernatant as possible without disturbing
the visible white pellet. Approximately 50-100fll of residual liquid will
remain in the 15mI tube. If the blood sample has been frozen, repeat Steps
1-4 until the pellet is white. There may be some loss of DNA from frozen
samples.
Note: Some red blood cells or cell debris may be visible along with the
white blood cells. If the pellet appears to contain only red blood cells, add
an additional aliquot of cell lysis solution after removing the supernatant
above the cell pellet, and then repeat steps 3-4.
5) Vortex the tube vigorously until the white blood cells are resuspended
(10-15 seconds). Completely resuspend the white blood cells to obtain
efficient cell lysis.
6) Add 3mI nuclei lysis solution to the tube containing the resuspended
cells. Pipette the solution 5-6 times to lyse the white blood cells. The
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solution should become very viscous. If clumps of cells are visible after
mixing, incubate the solution at 37°C until the clumps are disrupted. If the
clumps are still visible after 1 hour, add additional nuclei lysis solution
(l.Oml for 3ml sample volume) and repeat the incubation.
7) Optional: Add RNase (15III per 3ml sample volume) to the nuclear
lysate and mix the sample by inverting the tube 2-5 times. Incubate the
mixture at 37°C for 15 minutes, and then cool to room temperature.
8) Add 1.0ml protein precipitation solution to the nuclear lysate and vortex
vigorously for 10-20 seconds. Small protein clumps may be visible after
vortexing.
9) Centrifuge each 300~1 sample at 13000-16000 x g for 3 minutes at room
temperature (centrifuge at 2000 x g for 10 minutes at room temperature for
3ml sample volumes). A dark brown protein pellet should be visible at this
stage.
10) For the 3ml sample volume, transfer the supernatant to a 15ml
centrifuge tube containing 3ml isopropanol at room temperature.
11) Gently mix the solution by inversion until the white thread-like strands
of DNA form a visible mass.
12) Centrifuge at 2000 <g for 1 minute at room temperature for 3ml
sample. The DNA will be visible as a small white pellet.
13) Decant the supernatant and add one sample volume of room
temperature 700/0 ethanol to the DNA. Gently invert the tube several times
to wash the DNA pellet and the sides of the micro centrifuge tube.
Centrifuge as in Step 12.
14) Carefully aspirate the ethanol using either a drawn Pasteur pipette or a
sequencing pipette tip. The DNA pellet is very loose at this point and care
must be used to avoid aspirating the pellet into the pipette. Invert the tube
on clean absorbent paper and air-dry the pellet for 10-15 minutes.
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15) Add 250111 DNA rehydration solution to the tube and incubate at 65°C
for I hour. Periodically mix the solution by gently tapping the tube.
Alternatively, rehydrate the DNA by incubating the solution overnight at
room temperature or at 4°C.
16) Store the DNA at 2-8°C.
\otel: If additional nuclei lysis solution was added in step 6, add a total of
l.3ml Protein Precipitation Solution for 3ml sample volume at step 8.
\ ott' 2: At Step 10, some supernatant may remain in the original tube
containing the protein pellet. Leave this residual liquid in the tube to avoid
contaminating the DNA solution with the precipitated protein.
Following extraction, the concentration of DNA from each sample was
measured using Genequant in accordance with manufacturer's
recommendations.
2.1.2.4 DNA amplification by Polymerase Chain Reaction (PCR)
DNA segments can be hugely amplified using the polymerase chain
reaction (PCR) [24. 25]. Two synthetic oligonucleotides are synthesized,
each complementary to sequences on opposite strands of the target DNA at
position just beyond the ends of segment to be amplified. The
oligonucleotides serve as replication primers, with the 3' ends oriented
towards each other and positioned to prime DNA synthesis across the
desired DNA segment.
The basic principle of PCR involves three mam steps: denaturation,
annealing and extension. In PCR experiments a negative control was
always used, to exclude the possibility of any contamination.
Consideration of the following made the experiments reproducible and
PCR product more efficiently:
• Pipeuing and DNA template
It is better to add water to the PCR tube first, followed by the other
ingredients: there was no difference in PCR yield when each other
component of the reaction was added in a different order.
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To minimize the chance of primer binding to the DNA template and to
prevent the polymerase from working (even theoretically) prior to the first
denaturing step, it is useful to keep the vials on ice while pipetting the
ingredients of the reaction.
• First peR program
The aim of a PCR reaction is to amplify a specific locus without any non-
specific by-products in high yield. Therefore, annealing should take place
at a sufficiently high temperature to allow only perfect primer-template
complementarity to occur in the reaction. For any given primer pair, the
PCR program can be selected based on the composition (GC content) of the
primers and the length of the expected PCR product. In the majority of the
cases, products expected to be amplified are relatively small (from 0.2 to 2-
3 kb). The activity of the Taq polymerase is about 2000 nucleotides/minute
at optimal temperature (72-78°C) and the extension time in the reaction can
be calculated accordingly.
As the activity of the enzyme may not be always optimal during the
reaction, an easy rule applied successfully to consider an cxtcnston III1IC (in
minutes) equal to the number of kb of the product to be amplified (lmin for
a lkb product, 2min for a 2kb product etc.). Later on, after the product(s)
become "known", extension time may be further reduced.
Some researchers use a 1-3 minutes first denaturing step before the actual
cycling starts e6, 27]. This is supposed to help denaturing the target DNA
better. In addition, a final 1m'! extension /I/IIC, of 5-10 minutes, is described
in many papers (supposedly to help finish the elongation of many or most
PCR products initiated during the last cycle).
An ounculuv: time of 45-60 seconds was sufficient for all primer pairs
tested in this work. The auncaltns; temperature was chosen based on the
melting temperature of the primer-template duplex, which can be
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calculated. It is desirable (but not absolutely necessary) for the two primers
to have a close melting temperature or Tm (say, within 5°C or so). If the
melting temperature (Tm) difference between the two primers is high, the
lower Tm can be increased by increasing the length of that primer at the 3'
end (this can also keep the size of the amplified locus constant) or the 5'
end.
For most of the primers used during my work, a dCIIOrlfl"lll).!, t irnc of 60
seconds at 94°C was sufficient to achieve satisfactory PCR yields.
• Number ofcycles.
In general, 30 cycles is sufficient for a conventional PCR reaction.
Table 2.2: Designing a first peR program
I Stage I Temperature I Time
~enaturing --~~- ..--ec;:~~l-. -~
IDenaturing I 94 ec I 30-60 sec
IAnnealing.. I 54-60 ecl 30-60 sec
IExtension I 72ecl 30-90 sec
ILaste~~~~~o~l 72 ec_J Optional
2.1.2.5 Primer design in practice
Both BRCAI and BRCA2 are large genes consisting of 24 and 27 exons
respectively. Mutations in BRCA genes are distributed throughout the
coding region C7]. BRCAI exons 2, 3, 5, 11, 13 and 20 and BRCA2 exons
9,10,11, 17, 18 and 23 were analysed by amplification from genomic DNA
with the PCR. A pair consists of at least 20 mer that was not self-
complementary or capable of forming intra molecular secondary structures,
was used in each reaction.
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The software named PRIMER DESIGNER version 2.01, Scientific and
Educational software 1990-1991 was used to calculate melting temperature
for priming, to avoid of presence of any primer dimmer and hairpin
structures in PCR products.
2.1.2.6 Oligonucleotide synthesis
Oligodeoxynucleotides used as primers for DNA amplification by PCR,
were synthesised at Dr Arthur Moir's laboratory (Biomolecular Synthesis
Service, The University of Sheffield) on an Applied Biosystem DNA/RNA
synthesiser, model 381A.
2.1.2.7 peR program
Basically, two sets of reaction components and thermocycling producer
were used for DNA amplification for SSCP and PTT methods (See
chapters 3 and 4 respectively). PCR products were used directly for SSCP
analysis but for PTT agarose gel electrophoresis is necessary to determine
yield and size of the products. Usually 100-200ng/JlI of PCR products is
sufficient for PTT detection. The presence of abnormally sized products is
indicative of splicing mutations or genetic rearrangements such as deletions
or duplications.
2.1.2.8 Horizontal agarose gel electrophoresis
PCR products were separated by agarose gel electrophoresis through 0.7%-
20/0 agarose gels run in IX TAE buffer for 25-60 minutes at 50-110 Volts.
A fourth volume of loading dye solution was added to each sample prior to
loading onto the gel. Samples were run on horizontal gel former (Biometra)
and a comb positioned. Following electrophoresis, the gels were stained for
10-15 minutes in a solution of ethidium bromide (0.5 ug/ml). peR products
were visualized by exposure of the gel to V.V.-light.
The sizes of DNA fragments were estimated by comparison to 100bp or
1000bp DNA ladder run on the same gel.
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2.1.3 Mutation detection methods
Mutation testing methods can be divided into two groups:
• Screening method:
Mutation detection methods test a DNA sample for the presence or absence
of one specific mutation; this is widely applied in diagnostic laboratories.
• Scanning method:
Mutation scanning methods screen a sample for any deviation from the
standard sequence.
Testing for known and unknown mutations in a gene posses different
problems and requires different methods. All routine diagnostic methods
such as Sequencing, PTT, SSCP, HA, DGGE, etc suffer from two
limitations. They are quite laborious and expensive for use in a diagnostic
services, which needs to produce answers quickly and within a modest
budget. They detect differences between the patient's sequence and the
published normal sequence but they do not generally distinguish between
pathogenic and enhance non-pathogenic changes.
2.1.4 Combined Single Strand Conformational Polymorphism
assay (SSCP) and Heteroduplex Analysis (HA)
SSCP [15] is the simplest and most used method ofmutation detection. PCR
is used to amplify the region of interest and the resultant DNA is separated
as single-stranded molecules by electrophoresis in a non-denaturing
polyacrylamide gel. A strand of single-stranded DNA folds differently
from another if it differs by a single base, and it is believed that mutation
induced changes of secondary structure of the DNA results in different
mobilities for the two strands. These mutations are detected as the
appearance of new bands by silver staining of bands. Separation of mutant
fragments could be increased in low pH buffer system. Abnormal pattern of
single strand DNA mobility has been detected in 88% of mutant fragments
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in range of 579-797 bp es]. SSCP and HA [16] reputedly each have
sensitivities of between 60 and 80% [16]. The main advantages of both
techniques are that they are rapid and easy to perform, relatively
inexpensive and require little specialised equipment or kits (See chapter 3
in great detail).
2.1.4.1 Polyacrylamide gel electrophoresis (PAGE)
For SSCP polyacrylamide gels were prepared as follow:
Add 2 ml lOx TBE, 0.8-4ml glycerol (2-10% concentration), 14ml 59%
acrylamide/1% bis, and 22.8ml distilled water for a final volume of 40ml to
prepare 19.5cm x 22cm x 1mm gel. Mix the gel to dissolve glycerol
entirely. Add 130JlI 20% ammonium persulfate (AMPS) and 50JlI TEMED
prior to casting the gel (Table 2.3).
Table 2.3: Formulation for polyacrylamide preparation standard gels
[19.5cm x 22cm x l mm]
Components
One gel Two gels Final
(20 wells) (40 wells) concentration
dH20 Up to 40 ml Up to 80 ml ---
Acrylamide/Bis (59:1) 14 ml 28 ml l4%(w/v)
TBE x10 2ml 4ml O.5M
Glycerol (in different %) 0.8 to 4 ml 2 to 8 ml 2-10 % (w/v)
AMPS 130 III 260 III 20% (w/v)
TEMED 50 III 100 III ---
Total volume 40ml 80 ml ---
Follow the instructions provided with the 21em x 30cm gel apparatus (from
Bio-Rad, Hertfordshire, UK) for the recommended gel casting techniques
for 1.Omm thick gels. The number of samples loaded on the gel determined
which type of comb (1.0 mm) was used.
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2.1.4.2 Running the SSCP assay
1) Denaturing the samples: Add 5f.11 of PCR product to 5f.11 loading buffer
(See Appendices table 6) and denature the strands by incubating the
samples at 99°C for 10 minutes, followed immediately by placing the
samples on ice for 20 minute.
2) Prepare two litre of 0.5x TBE electrophoresis running buffer. Assemble
the cast in apparatus (from Bio-Rad, Hertfordshire, UK) containing the gel
into the lower buffer chamber base. Add the running buffer to both lower
and upper buffer chamber.
3) All volume (luul) of denatured samples load on a 21 x 30 cm non-
denaturing 14% polyacrylamide gel [acrylamide/bis (59:1), containing 3-
10% glycerol] and run at 245 volts constant power, 12°C -16°C for 16 to 20
hours. The gel is then stained with silver and photographed.
NorE: It is important to keep the gel at proper temperature constantly so
that secondary structures of single-stranded molecule are maintained during
the run. This can be accomplished by using temperature controller, which
connected to the apparatus (from Bio-Rad, Hertfordshire, UK). It can be set
to the desired run temperature. The buffer re-circulator and stirring
mechanism insure uniform buffer temperature.
2.1.4.3 Silver staining protocol
The silver staining technique takes 1-1.5 hours but it may start to see the
results after about 30 minutes. Always stain in non-metallic containers.
Multiple gels can be stained at once (commonly four to six at a time).
1) Following electrophoresis, fix gel(s) in a solution of 10% absolute
ethanol and 0.50/0 acetic acid for 10 minutes at room temperature.
2) Stain with 0.1% silver nitrate (made from 10/0 stock) for 20 minutes at
room temperature.
3) Rinse gels once with distilled water to remove excess silver solution.
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4) Develop with a solution stock 740ml distilled water, 60ml NaOH (from
5M NaOH stock), 3ml formaldehyde 0.0480/0 for 20 minutes at room
temperature.
5) Fix stain with a solution of 0.75% NaC03 (made from 7.50/0 stock) for
10 minutes at room temperature (See also Appendix VI, Table 6).
2.1.5 Protein Truncation Test (PTT)
PTT is a mutation detection method based upon the in vitro transcription
and translation of PCR amplified sequences. It specifically detects
frameshift or nonsense mutations, which lead to the termination of mRNA
translation and subsequently protein truncation [12, 13, 14]. This sort of
analysis has been successfully applied to a number of clinical conditions
including hereditary breast and ovarian cancer.
In the BRCAI gene, missense mutations are seldom found, and are
generally thought to be non-pathogenic. For such a gene, the PTT has
several advantages. It conveniently ignores the non-pathogenic silent or
missense base substitutions and reveals the approximate location of any
mutation (See chapter 4 in great detail).
2.1.5.1 Principle of the Protein Truncation Test
PTT analysis detects premature stop codons in a single reaction by
amplifying DNA fragments of the coding region using a special primer,
which carries at the 5' end a T7 promoter followed by eukaryotic translation
initiator sequence, transcribing the fragments into mRNA, and translating
the mRNA into radiolabeled polypeptides [12, 13, 14]. Products from the
transcription/translation reaction can be analysed by Sodium Dodecyl
Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) e9] followed
by autoradiography.
SDS-PAGE is a discontinuous system that has a non-restrictive large pore
stacking gel that is layered on top of a resolving gel. Each of these gels was
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made with a different buffer, the tank buffers was also have a different
composition from that present in the gel.
The sample to be fractionated is denatured and coated with detergent by
heating in the presence of SDS and a reducing agent. The SDS coating
gives the protein a high net negative charge that is loaded on a
polyacrylamide gel and high voltage (125 volts) is applied, causing the
protein components to migrate toward the positive electrode (anode). Since
all of the proteins have a net negative charge that is proportion to their size,
the proteins are separated solely on the basis of their molecular mass- a
result of the sieving effect of the gel matrix. The molecular mass of a
protein can be estimated using SDS-PAGE by comparing the gel mobilities
of a band with protein standards. Sharp banding of the protein component
is achieved by using a discontinuous gel system, having stacking and
separating gel layers differ in either salt concentration or pH or both [30).
Following gel electrophoresis, gel bands may be visualized by
autoradiography (31). If the product is full length, no truncating mutation is
present in the amplified sequence. In samples where premature termination
has occurred the protein product will be smaller than that generated from
the non-mutant sequence. Assessment of the size difference between these
two products allows the position of the putative mutation to be determined,
No te: The key feature of PTT is a specifically designed, tailed, sense
forward primer used in the PCR amplification step (See section 2.1.8
Outline of PTT method). This primer contains four specific regions. A T7
promoter sequence at the 5'-end directs the production of RNA, using the
corresponding phage RNA Polymerase. The promoter sequence is
separated from a eukaryotic translation initiation sequence (Kozak
sequence) by a spacer sequence of 3-6bp e2• 33). The 3'-end contains the
target gene sequence (approximately 17-20bp) in-frame with the ATG
codon from the Kozak sequence.
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2.1.5.2 Agarose gel electrophoresis
After PCR amplification, agarose gel electrophoresis is necessary to
determine yield (quantity and quality) and size of the products. Size
alterations indicate the existence of small deletions/duplications or the
presence of mutations affecting splicing.
2.1.5.3 In-vitro synthesis of RNA
The next step in PTT is the in-vitro transcription/translation reaction [34J.
Promega 1M developed a system called TNT® Coupled Reticulocyte Lysate
Systems offers an alternative for eukaryotic in-vitro translations: a single
tube, coupled transcription/translation system. In most cases, the TNT®
Lysate reactions produce protein in a 90 minutes reaction. In comparisons
of [35S] incorporation, the TNr® Lysate reactions incorporate significantly
more radiolabel than do standard in-vitro translation reactions. This system
then improved and named TNT® Quick Coupled Transcription/Translation
Systems, which further simplifies the process by combining the RNA
Polymerase, nucleotides, salts and recombinant RNasin® Ribonuclease
Inhibitor with the reticulocyte lysate to form a single TNT® Quick Master
Mix.
The latest generation of TNT® kit called TNT® T7 Quick for PCR DNA
(Promega, Southampton, UK; catalogue no. L5540) designed for optimum
expression of PCR templates ranging from 350-5000bp. For most PCR
templates, the TNT® T7 Quick for PCR DNA reactions produce up to 5
times more protein [35J. The PCR products may be added directly to the
TNT® T7 Quick for peR DNA reaction without purification.
To use the TNT® T7 Quick for PCR DNA system, a PCR fragment
containing a T7 promoter is added to the TNT® T7 PCR Quick Master Mix
and incubated for 60-90 minutes at 30°C. The synthesized proteins then
can be analyzed by SDS-PAGE followed by autoradiography or
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phosphorimaging [36] (See Appendix XI for Technical Manual # TM 235,
Promega corporation).
2.1.5.4 Protein detection
The most commonly used procedure for the detection of newly synthesized
proteins is incorporation of radiolabeled amino acids during synthesis,
using esS] methionine, esS] and cysteine. TNT® T7 Quick for PCR DNA
System is, at present, only available for [3SS] methionine. [3SS] Methionine
prevents the background labelling of a rabbit reticulocyte lysate 42kDa
protein, which can occur using other labels [37].
2.1.5.5 SDS-Polyacrylamide gel preparation
For separation of the translation products, appropriate SDS-PAGE
conditions must be chosen for simultaneous detection of nearly full-length
products as well as small products. Usually a 6°,/0 and 12% polyacrylamide
gel is used for PTT products of up to 60-75kDa. In this study full-length
artificial protein of BRCAI and BRCA2 exon 11, 126kDa and 183kDa
respectively, were detected using 6% to 12% polyacrylamide gel.
2.1.5.6 SDS-PAGE analysis and visualisation by autoradiography
After electrophoresis, the SDS-PAGE gels are typically treated with
solutions to prevent cracking during drying. After drying the gels, generally
24 hours exposure to X-ray film results in a clear signal [13.32]. The extent
of esS] incorporation may be estimated by passing a radioactive Geiger
counter over the surface of a dried gel before autoradiography.
In general, analysis of the translation products should lead to strong signals
or bands for the desired translation products, occasionally accompanied by
several smaller, weaker non-specific bands. These lower abundance
products are often derived from internal translation initiation sites (AUG)
and, in exceptional cases, might obscure the analysis and/or detection of
[38truncated fragments ].
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Abnormal, short protein products indicate the presence of truncation
mutations. Whether or not both truncated and wild type translation products
are detected in the same sample depends upon the disease. In X-linked
syndromes (e.g. Duchenne Muscular Dystrophy), the analysis of male
patients is simplified by the presence of only one allele, which either
contains a mutation or does not.
To assess the capacity of a new Promega transcription/translation system
(TNT® T7 Quick for PCR DNA) all positive cases and few normal cases for
BRCA2 exon 11, were analysed by the PTT method in duplicate. The
presence of truncating mutations is typically analysed using two
overlapping segments; the first segment covers 2799bp and the second
overlapping covers 2620bp. The second screening, the entire BRCA2 exon
11 sequence was screened in one experiment that consists of 4959 base
pairs (see chapter 4, Table 4.3, Figure 4.2) gave no detectable differences.
2.1.6 SDS-PAGE in practice
• Using 2 x Mini-Protean system (Bio-Rad, Hertfordshire, UK, catalogue
no.165-3301) make thin minigels (7cm x 10cm) in 0.75 mm diameter with
10 well combs.
• The amount of reagents indicated in Table 2.4 and 2.5 are sufficient for
the preparation of one 7 x 10 em gel, 0.5-1.00 mm thick.
• Add the ammonium persulfate (AMPS) and TEMED immediately prior
to pouring the gels, as these reagents promote the polymerisation of
acrylamide.
• Pour the resolving gel mix into assembled gel plates, leaving sufficient
space at the top for the stacking gel to be added later. Gently overlay the
gel mixture with 0.1% SDS or N-butanol and allow the gel to polymerise
for at least 15-30 minutes. After polymerisation, remove the SDS or N-
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butanol and rinse the surface of the resolving gel with water to remove any
unpolymerised acrylamide and blot with Postlip papers to dry.
• Fill the remaining space with the stacking gel solution and insert the
comb immediately. After the stacking gel has polymerised, remove the
comb and rinse the wells with water to remove unpolymerized acrylamide.
At least I em of stacking gel should be present between the bottom of the
loading wells and the resolving gel.
• Assemble the plates according to manufacturer's instruction.
• Fill the apparatus with SDS-PAGE running buffer Ix (See Table 2.7).
• Load sample on the SDS-Polyacrylamide gel.
2.1.7 Assembling of the PTT reaction components
1) Sample preparation
Before begin: To reduce the chance of RNase contamination, gloves should
be worn when setting up experiment, and microcentrifuge tubes and pipet
tips should be RNase-free.
* Aliquot all [3SS] into 51J.1 aliquots (sufficient for 20 reactions) and keep
frozen at -70°C
* Make Master Mix of distilled water (1.3 1J.l) and esS] (0.2 1J.l) per reaction
in a O. 51J.1 microcentrifuge tubes
* Add IOO-200ng/lJ.l of PCR products to the Master Mix microcentrifuge
tubes (containing ofwater and [3SS]) up to 3 IJ.l.
*Remove the TNT ill T7 PCR Quick Master Mix from storage at -70°C.
Immediately place the Master Mix on ice and rapidly thaw by hand
warming and place on ice.
Note: Except for the actual translation incubation, all handling of the
Lysate mix should be done at 4°C. Any unused Master Mix should be
frozen as soon as possible after thawing to minimise loss of translational
activity. Do not freeze/thaw the Lysate mix more than two times.
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* Add 10 ul of TNT ® T7 PCR Quick Master Mix to Master Mix
microcentrifuge tubes
IGreat care must be taken to not introduce air hubbies into the mix.]
2) Incubate the sample at 30°C for 90 minutes.
3) Add 112.5-117Jllloading sample buffer (45JlI per 5J.lI translated mix) to
the sample and boil it for 5-10 minutes. Cool it on ice.
4) Load sample (25J.l1-30J.ll) on 6% and 12 % SDS-Polyacrylamide gel
5) Apply high voltage (125 volts) for 60-75 minutes. Run until blue dye
goes down to the bottom or just off.
6) Fix SDS-Polyacrylamide gel in 7% acetic acid for an hour with shaking.
7) Keep SDS-Polyacrylamide gel in a solution consist of 3% glycerol, 20%
methanol for an hour (to prevent gel cracking when dried) with shaking.
8) Dry down for one hour at 80°C by auto dryer.
9) Visualize by autoradiography for 24 hours (Depend on CSS]
incorporation in protein product).
10) Developed the film using Kodak developer for 1-3 minutes until bands
comes out, rinse with tap water and fix by Kodak fixing solution for 1-3
minutes, rinse with tap water and leave it to be air died.
All this procedure must be perfonn under safety condition (observing
radioactive protection protocol).
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2.1.8 Outline ofPTT method
1) Coding sequence without introns (large exons in genomic DNA) is PCR
amplified. The essential feature of PIT is a specifically designed tailed
sense (forward) primer. This contains four different regions:
• At it's 5'·end a T7 RNA-polymerase promoter sequence, which
facilitates the in-vitro production of RNA. Usually, additional
nucleotides are present upstream of the T7 promoter. Even the addition
of a single G nucleotide upstream of the promoter increases the
. . al ffi . [39]transcnption e lClency .
• A 5-7 base pairs spacer that separates T7 promoter from a consensus
Kozak sequence, facilitating the initiation of protein synthesisj'"].
• A eukaryotic translation initiation sequence (Kozak sequence) that
includes a ATG start codon, facilitating the initiation of protein
synthesis[12. 14].
• The 3' region contains a gene specific sequence designed so that the
sequence amplified reads in-frame from the ATG. At the 3' end of the
target, the primer can include a stop codon if the amplified sequence
does not contain the native stop codon e1] .
5
'.GGATCC TAATACGACTCACTATAGGG AACAG CCACCATGG GAGAACAACTGTCTACAAACT.3'
Spacer T7promoter Spacer Kozak sequence
Including ATG
Target sequence
*Large deletions, duplications and splicing mutations may be detected by
agarose gel electrophoresis at this stage.
**10 this study, no translation termination codon incorporates in the reverse
pnmer.
2) After amplification, the PCR product is added to a coupled in-vitro
transcription-translationsystem.
3) For detection a labelled amino acid is included, which is usually
methionine. The label can be a radionucleotide such -as--fS.Sl-which -is
visualised by autoradiography.
4) The polypeptides produced are separated by size using SDS-PAGE. If
the product is only full length, no truncating mutation is present.
Truncating mutations result in shorter products, the size of which gives the
approximate position of the mutation.
5) The area of the gene where the truncating mutation is occurred is then
sequenced to identify the alteration of the gene precisely.
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2.1.9 Advantages of PTT
PTT has clear advantages over other screemng methods when large
portions of the mutations are due to small genetic changes, causing
. . (4 38)truncation mutations . .
1) An advantage of PTT over conventional assays is that the length of the
truncated protein pinpoints the position of the mutation, thereby facilitating
its confirmation by sequence analysis. Difficulties can be expected in the
case of in-frame deletions comprising 4kDa or less, for example those due
to exon skipping, caused by splice site mutations. In such events, the
truncated protein is only slightly smaller than the wild-type product and
thus difficult to detect by SDS-PAGE. Fortunately, such mutations are
accompanied by smaller RT-PCR products, which can be easily detected by
. 12 13 38)agarose gel analysis ( · . .
2) PTT ignores missense mutations; thus polymorphisms detected by other
methods (e.g. SSCP/HA) do not have to be eliminated by sequencing [12.
15).
3) PTT allows the analysis of large stretches of coding sequence (up to 5kb
genomic DNA) (12), for instance the entire BRCAI or BRCA2 exon II
sequence can be analysed in one experiment. This significantly reduces
workload. However, if large areas are analysed the resolution of the SDS-
PAGE decreases. Solution: use a couple of different percentages of
polyacrylamide gel 4%-200/0 to cover the large range of proteins.
Alternatively the area to be analysed can be amplified in overlapping
sections. To prevent mutations near the 51-end of each section being missed
(polypeptide produced is so small it falls off the gel), the overlaps must be
200-300 bp. Thus, a mutation present at the end of one section should be
detected twice, once at the end of one section and again at the beginning of
the following section.
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4) Detects truncating mutations i.e. disease causing and not missense
mutations, which often represent non-disease related sequence variation [12,
13] .
2.1.10 Disadvantages of PTT
1) Insensitive to mutations immediately upstream and downstream of
peR primer sites.
The boundaries of the translated fragments represent the most critical
regions for PTT analysis and are primarily determined by the resolution of
SDS-PAGE analysis. Early (N-terminal) mutations-close to the 5' end- may
result in products, which have too little, or no label incorporated, or their
electrophoretic migration might fall outside of the resolution range. Late
(C-tenninal) mutations -close to the 3' end- might result in a size
difference, which is not resolved near the top of the gel. Finally, mutations
at translation initiation and termination sites represent a special case. Here,
an internal control of the overlapping segment is not available; special
attention (e.g., sequence analysis or SSCP) is required to reveal these
. [38)mutations .
2) PTT may be limited to amplification of the mutated allele, which may
lead to failure to detect very small in-frame deletions/insertions or missense
mutations. Amplification failure can have several explanations including a
mutation of the primer binding site (an altered or deleted sequence), large
insertions, translocations and inversions which go beyond amplifiable
lengths, or duplications when one or both primer binding sites lie within the
duplicated segment. Mutations that affect the amount of RNA produced or
which render the mutated mRNA unstable may also not be detected e8) .
3) Not applicable to all genes: dependent on the proportion of mutations
that are truncating: E.g. APC, BRCAI, BRCA2 and Dystrophin all have
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approximately 90-95% truncating mutations. In addition, restricted to
truncating mutations.
4) Radioactive detection method. [35S] Methionine commonly used to make
radiolabel newly synthesized proteins, which can then visualised by
autoradiography.
5) Cannot detect missense mutations. Basically PTT may detect either
frameshift or nonsense mutations (truncating mutation) that lead to
generate stop codon. However, some missense mutations may cause a
disease but does not generate stop codon lead to detect by PTT (See chapter
4 Figure 4.6).
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Table 2.4: Resolving gels for SDS-PAGE
Components
Gel Gel Gel Gel Gel
4% 6% 10% 12% 200/0
40% bis:acryl (29: 1) 0.5 rol 0.75 ml 1.25 ml 1.5 ml 2.5 ml
1.5 M Tris (pH=8.8) 1.25ml 1.25 ml 1.25 ml 1.25 ml 1.25 ml
10% (w/v) SDS 50Jll 50 ul 50 ul 50 ul 50 Jll
20% (w/v) AMPS 25Jll 25 ul 25 ul 25 ul 25 Jll(fresh)
TEMED 4/-11 4 Jll 4 Jl1 4 Jl1 4 /-11
Distilled water 3.17ml 2.92 ml 2.42 ml 2.17 ml 1.17 ml
Total volume = 5ml for one gel
Table 2.5: 5% Stacking gels for SDS-PAGE
Components Two gel Four gels
40 % bis:acryl (29: 1) 0.638 m1 1.276 ml
1 M Tris (pH-6.8) 0.625 ml 1.250 ml
100/0 (w/v) SDS 50 /-11 100 /-11
200/0 (w/v) AMPS (fresh) 25 III 50 ul
TEMED 4 /-11 8 /-11
Water 3.66 ml 7.32 ml
* Total volume= 5ml for two gel
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Table 2.6: Formulation for 2x SDS-PAGE sample buffer
Components Concentration vol/ml
Tris-base (pH=6.8) 1M 0.5
Glycerol --- 0.8
SDS 10% (w/v) 1.6
2-Mercaptoethanol --- 0.4
Bromophenol blue Saturated 0.1
Water --- 4.5
* Total volume 8ml
* Store working solution at 4°C.
Table 2.7: Formulation for Ix SDS-PAGE running buffer
Components Concentration gllitre
Tris-base (pH=8.6) 2.5mM 6
Glycine 190mM 28.8
SDS 0.1% (w/v) 2
* Dissolve above ingredients in 800 ml distilled water.
*Adjust pH to 8.3
* Adjust volume to 1 litre with distilled water.
* Store at room temperature.
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2.1.11 Meta-peR technique
Meta-PCR is a method for creating chimaeric DNA molecules and
increasing the productivity of mutation scanning techniques e7]. Many
mutation-scanning techniques are capable of locating mutations in DNA
fragments much larger than the average exon. Meta-PCR that can
maximize the length of sequence scanned by these techniques, improving
their productivity and realizing their full potential. Meta-PCR is a simple,
versatile, and powerful method for generating chimaeric DNA molecules.
Currently, up to five PCR amplifiable fragments can be combined to form a
single linear amplimer e7] . The Meta-PCR reaction is self-assembling and
takes place in two coupled stages carried out in a single reaction vessel.
The order of fragments is reproducible and determined by primer design
(See chapter 5 in great detail).
2.1.12 Direct nucleotide sequencing
Direct nucleotide sequencing is the most reliable technique in detecting
variant DNA sequence. Sanger and colleagues invented a technique in
1977, which is an enzymatic method and involves DNA synthesis by a
primer dependent DNA polymerase from a ssDNA template [40]. This
method consist of three stages:
1. Annealing a short oligonucleotide (primer) to a DNA template;
complementary to a region adjacent to the sequence of interest.
2. The Primer/template duplex is as a substrate for chain extension where
dNTPs and radioactively labelled dATPs are incorporated into the
extended DNA strand.
3. The reaction is terminated by adding dideoxynucleotides to the extended
DNA strands in the four separate reactions
These reactions produce a series of DNA fragments, after separation of the
four sets of reactions in adjacent slots by electrophoresis on a long
denaturing polyacrylamide gels, that can then be visualised by
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autoradiography. This method characterises the location and nature of the
sequence change and is therefore the final step of any detection method.
Recently, a new sequencing technique has been developed and applied
widely named cycle sequencing. However, a new protocol based on cycle
sequencing and fluorescence detection technology has been developed [41].
Fluorescent-labelled dideoxy terminators are sets of different fluorescent
dyes that are covalent coupled to each of the four dideoxynuc1eotide
triphosphate (ddNTPs). Typically this method is using as automated ABI
DNA sequencer; used relatively this technique is the best method for
mutation detection although it is expensive.
2.1.12.1 Disadvantages of direct nucleotide sequencing (OS)
The sensitivity of OS reaches to 98% [42] however failure to detect the
entire exon deletions, or error in RNA transcripts processing outside to the
coding regions (exonic part of the genes) has been reported. The proportion
of BRCAI and BRCA2 genes mutations wrongly attributable to such
inefficiencies is unknown, but it has been estimated at to 5%-15% [43].
In this study each sequence variant was re-amplified from the original
genomic DNA to minimise the possibility of errors. Amplified DNA was
sequenced using BIG DYE dideoxy-terminator chemistry (Pre-Sequencing
Kit, Amersham Life Science) as described in the manufacturer's protocol
on an automated ABI 373A DNA sequencer in Dr A. Moir's laboratory.
Each fragment was sequenced in both directions with the original PCR
pnmers.
2.1.12.2 BIG DYE sequencing protocol
1. Add 1.5f.l1 exonuclease and 7.51J.1 PCR product to a O.5ml eppendorf.
Spin, and then incubate at 30°C for 15 minutes follow at 80°C for 15
minutes)
2. Add 1.5f.l1 alkaline phosphatase. Spin and repeat incubation as step one.
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3. Make up the following master mix:
4J..lI Ready React
4J..l1 halftenn
3.2J..l1 Primer (EITHER forward or reverse at cone. of lpmol/ul)
4.8J..lI distilled water
4J..lI Prepared template
i.e. a separate master mix is required for forward and reverse of same PCR
product.
4.Spin, and then amplify at 94°C for 30 sec, at 50°C for 15 sec and
extending at 60°C for 4 min for 25 cycles on an Applied Biosystems DNA
thermal cycler, Applera Europe BV, Cheshire, UK.
PCR product then precipitates and washes as described below;
2.1.12.3 Sodium acetate precipitation
1. Add 50J..lI 95% ethanol and 2JlI 3M Sodium Acetate (pH4.6) to a 0.5J..lI
eppendorf.
(NB. 3M sodium acetate = 4.92g in 20ml distilled water) (Rmm = 82.03)
2. Add all sequencing products, Vortex and stand at room temperature for
at least 15 minutes (preferably 30 minutes or more). (NB.30mins works
fine.)
3.Centrifuge at 13,OOOrpm, 16°C, for 20 minutes.
IMPORTANT: Proceed to the next step immediately. If not possible, then
spin the tubes for 2 minutes more immediately before performing the next
step.
4. Carefully aspirate the supernatant.
Il\1PORTANT: The supernatant must be removed completely, as
unincorporated dye terminators are dissolved in them. The more residual
supernatant left in the tubes, the more unincorporated dye terminators will
remain in the samples.
5. Add 250J..L175% Ethanol.
6. Centrifuge for 5 minutes, 13,OOOrpm, 16°C.
7. Remove supernatant carefully as in step 4.
8. Repeat steps 4-7
9. Open lids and air dry.
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2.1.13 Features of the 'ideal' mutation screening method
Breast cancer is now considered as a health problem worldwide. Most
countries are now offering a diagnostic and predictive genetic test to the
high-risk families as a public or private health services. Due to
complexities of BRCA genes analysis, new techniques are rapidly
emerging to overcome these difficulties. The ideal method should have
features, which can then be readily reproduced by molecular genetics
laboratories. Some of these features are mentioned below:
• Able to scan kilo base lengths
• 1000/0 detection rate
• No false positives or negatives
• Single step
• No complex equipment or facilities
• No harmful reagents
• No electrophoresis
• High throughput
• Low elapsed and bench time
• Mutation identification
• Low cost
It is important to note that no currently available technique can guarantee
the identification of all cancer-predisposing mutations in for example the
BRCAI or BRCAl genes. [6)
2.2 Materials and general equipments
A detailed list of materials, equipments and suppliers used in this study can
be found in Appendix IX, X unless otherwise indicated all other chemicals
were from BDH. The preparation of stock reagents and buffers is described
in Appendix VIII. The distilled water referred to as dH20 in the text was
prepared commercially.
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Chapter 3
3 Combined Single Strand Conformation
Polymorphism assay (SSCP) and Heteroduplex
Analysis (HA)
3.1 Introduction
SSCP is widely regarded as the simplest and most commonly used method
of mutation detection. The PCR is used to amplify the region of interest
from genomic DNA and the resultant widely regarded on products are
separated as single-stranded molecules by electrophoresis in a non-
denaturing polyacrylamide gel C]. Different single-stranded DNA
sequences fold differently from each other even when two sequences differ
by a single base; it is believed that mutation induced changes of secondary
structure of the DNA confer different electrophoretic properties upon the
two strands. These differences that arise owing to mutation can be detected
by the appearance of new species following electrophoresis and detection
by silver staining ofbands (Figure 3.1).
The secondary structure of single-stranded DNA changes under different
physical conditions e.g. temperature and ionic environment. Hence the
sensitivity ofSSCP depends on these (and possible other) conditions.
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Whilst some empirical rules have emerged for the choice of separation
conditions for sequence variants in particular sequence contexts, it is
impossible to predict whether a certain mutation can be detected under
given conditions, especially when the mutation falls within a new sequence
context. The success of mutation detection in PCR-SSCP is generally very
high; more than 80% of mutation can be detected in a single run when
fragments are shorter than 300bp[2). As sensitivity is not 100%, the absence
of a new band does not prove that there is no mutation in the analysed
molecule.
The sensitivity of PCR-SSCP decreases with increasing fragment length,
less than 300bp being the optimum. For mutation detection in longer
fragments (exons >300bp and whole cDNAs) overlapping short primer sets
can be used, or long PCR products digested with appropriate restriction
enzymes prior to SSCP.
3.2 The principle of Single Strand Conformational
Polymorphism assay
For SSCP, wild type and test samples are typically amplified by PCR from
genomic DNA, denaturation at 99°C and rapid cooling is followed by
electrophoresis on a non-denaturing polyacrylamide gel that allows the
single strand molecules to form secondary structure, which affects their rate
of migration, products can be detected by silver staining. Some of each
product may reanneal to give double-stranded DNA, which typically runs
faster through the gel than single-stranded DNA. Since each strand takes up
a different structure, two bands are seen in wild-type DNA. A homozygous
mutation produces two bands in a different position than the wild type
amplicon and a heterozygote will produce four bands (two wild type, two
mutant). The sample is then sequenced to determine the specific location
and nature of the mutation.
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3.2.3 Heteroduplex Analysis (HA)
A Heteroduplex is a double-stranded DNA molecule in which the two
DNA strands show imperfect base complementarity. When dsDNA is
denatured, the two strands separate; upon renaturation, complementary
DNA strands reanneal and form a homoduplex. However, when there is a
mutation in one of the strands then a heteroduplex is formed. The
electrophoretic mobility of heteroduplexes in polyacrylamide gels is
usually less than that of the corresponding homoduplex, and these two
species can often be readily distinguished e' 4] (Figure 3.2). This concept of
heteroduplex formation also forms the basis of mutation screening when
the normal (probe) and patient's DNA is mixed, denatured and annealed.
Most, but not all of these methods, rely on detecting mismatched bases
formed when complementary strands of a mutation and the wild type allele
are allowed to hybridise to form a heteroduplex. This is likely to occur
naturally when DNA sample from an individual who is heterozygous for a
particular genotype is denatured then cooled to allow mutant strands to
base pair with complementary strands from the wild type allele. In
fragments of less than 200 bp insertions, deletions, and most single base
substitutions can be detected using this approach. Heteroduplex analysis is
mostly used combined with single strand conformational polymorphism
assay (SSCP) on a single gel to improve sensitivity [1] (Figure 3.2).
Several mutations in a gene can also be combined to form a multiplex
heteroduplex analysis. Such a method has been successfully reported in
early-onset breast cancer [5].
• Advantages of HA
Advantages and disadvantages ofRA similar to those for SSCP:
1) The SSCP and Heteroduplex Analysis techniques are each estimated to
have sensitivities between 60 and 80% in detecting single-base-pair
substitutions and the combined mutation detection rate should be higher [6].
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2) The size limit for the DNA fragment is higher than SSCP (up to 800bps)
[7).
In view of the nature of this experiment described in this chapter, I have
included details of the methodology as they pertain SSCP, in order to
clarify the results and their interpretation.
3.3 SSCP in practice
Both BRCAI and BRCA2 are large genes containing 24 and 27 exons
respectively (See Appendix II and table I). In both genes the first exon is
non-coding and exon 4 consists of a repetitive sequence of the Alu family
that is omitted from most transcripts.
In this study 104 samples for germline mutations in the BRCAI gene exons
2, 3, 5, 13,20 and BRCA2 gene exons 9,17, 18,23 were analysed by
SSCP/HA assay based on PCR-amplified genomic DNA.
In order to improve the SSCP analysis, BRCA2 exon 18 was amplified in
two segments.
To avoid any missed frameshift mutations that might be present close to the
N-terminal (early) and C-terminal (late) coding region of BRCAI and
BRCA2 gene exon II, these regions were screened by SSCP/HA. The
entire coding sequences of exon 11 in both BRCAI and BECA2 gene was
also analysed by Protein Truncation Test (See chapter four for more detail).
3.3.1 Primer design
Table 3.1 and 3.2 show the sequences of primers used in this work for the
amplification of the above BRCAI and BRCA2 genes. In all cases splice
junctions were included in the analysis.
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Table 3.1: Details of primers used for amplification and screening of the BRCAI gene by SSCPIHA
Exon Forward primer Reverse primer Ani. Temp
Product
Used (OC) length (bp)
2 5'- aaa eet tee aaa tet taa a -3' 5'- gte ttt tet tee eta gta tgt -3' 54 302
3 5'- aae gaa ett gag gee tta tg -3' 5'- ttg gat ttt teg tte tea ett -3' 54 308
5 5'- ete tta agg gea gtt gtg ag -3' 5'- atg gtt tta tag gaa ege tat g -3' 56 278
11- 5'end 5'-tte agt ttl tga gta eet tgt tat t -3' 5'-eta tea tta eat gtt tee tta ett e-3' 55 362
11- 3'end * 5'-eat tga aga ata get taa atg aet g- 3' 5'- aet ggg gea aae aea aaa aee t- 3' 57 343
11- 3'end * 5'- aag aaa tta gag tee tea gaa -3' 5'- aea eaa aaa eet ggt tee aat - 3' 53 501
13 5'- aat gga aag ett ete aaa gta -3' 5'- atg ttg gag eta ggt eet tae -3' 55 320
20 5'- ata tga egt gte tge tee ae -3' 5'- agt ctt aea aaa tga age gg -3' 56 259
*C-tenninal (3'end) of BRCAI exon 11 was analysed using conventional PCR-SSCP assay and digested PCR-SSCP with BamHI with
different sizes 343bp and 501 bp respectively.
(Annealing temperature=AnI. Temp)
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Table 3.2: Details of primers used for amplification and screening of the BRCA2 gene by SSCPIHA
Exon Forward primer Reverse primer Ani. Temp ProductUsed (OC) length (bp)
9 5'- eta gtg att tta aae tat aat ttt tg -3' 5'- etg tag tte aae taa aea gag g -3' 55 168
11- 5f end 5'-ggt act tta att ttg tea ett tgt gt-3' 5'- gta tte cae ttt tga atg ttg tae -3' 56 373
11- 3'end 5'- gta tta gga ace aaa gte tea e -3' 5f-tag tga ttg gea aea ega aag g -3' 57 385
17 5'- eag aga ata gtt gta gtt gtt gaa -3' 5'-aga aae ett aae cat act ge -3' 55 304
18 partl 5'- eag tgg aat tet aga gte aea e -3' 5'- gee act ttt tgg gta tet ge -3' 57 229
18 part2 5'- gea gat ace eaa aaa gtg ge -3' 5'- gae tga ttt tta eea aga gtg e -3' 57 234
23 5'- cae tte tte cat tge ate ttt etc -3' 5'- gag att eea taa act aae aag cae -3' 57 265
(Annealing temperature=Anl. Temp)
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3.3.2 peR amplification protocol
The DNA region to be screened was amplified by PCR, using DNA from
the three samples described above as templates. After optimising
conditions (dilutions of DNA template, primer, Mg2+ concentrations and
PCR thermocycling settings), the PCR components prepared (Table 3.3).
Table 3.3: Modification of standard PCR components for
optimum SSCP templates
Components Volume Final
concentration
1) distilled water (pH 7.0) Up to 20J.lL
2) lOx PCR Buffer* 2.0J.lL
3) MgCI2+ (25mM) 1.4-1.6J.lI 1.7-2mM
4) dNTPs (2.5 mM each nucleotide) 1.5J.lL 200J.lM
5) primer mix (5pM/J.lL each primer) IJ.lL 0.25pM/J.lL
6) genomic DNA template (50-100ng) I.OJ.lL
7) Red Hot Taq DNA polymerase (2-5 Unit) 1.0J.lL
* 21.!l of lOx PCR Reaction Bufferconsistof: 750mMTris-HCI (pH 8.8 at 25°C),
200mM(NH4hS04 and 0.1 %(v/v) Tween20
3.3.3 Thermocycling procedure
The DNA template was denatured with one cycle at 94°C for 2 minutes.
Denaturing at 94°C for 30 sec, annealing at 55°C -60°C for I minutes and
extending 72°C for I minute for 30 cycles. A final extension at 72°C for 5
minutes was performed. Annealing temperatures were varied according to
predicted primer-template melting temperature.
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3.3.4 Interpretation of results
The interpretation of the results of an SSCP/HA gel requires experience,
which therefore require that controls of known mutations be used in each
analysis. Some double-stranded DNA often reforms after the denaturation
step, which will produce bands closer to the bottom of the gel. It is helpful
to include an undenatured sample to help in identifying these bands. Those
heteroduplexes molecules formed when a mutant and wild type strand
anneal, can also predict a sequence alteration. These heteroduplexes
migrate just above the double-stranded DNA. While heteroduplexes are
most prominent in the case of insertion or deletion, they can sometimes be
observed with point mutations [8].
Since the exact migration properties of single strand conformers can vary
from gel to gel, it is useful to include all available control samples at least
once on each gel. While it is expected that the two strands will migrate
differently, this is not always the case. Similarly, in a heterozygote, not all
four strands are always resolved. It is important to note that a mutant
sample should give a clearly different pattern from a wild type sample. In
addition, a heterozygote should display approximately equal intensity in all
four bands. The final proof of the alteration ultimately comes from
nucleotide sequencing (Figures 3.3-3.7).
3.3.5 Modifications of SSCP/HA detection
The condition of the SSCP gel can be varied to produce gels in which the
samples form alternative conformations. The number of possible
conformations is so large that there is no theoretical basis for choosing
conditions. Clearly, the more conditions run, the greater and the potential
sensitivity can be obtained.
The variables that have been employed for each amplicon for analysing of
both BRCAI and BRCA2 genes are listed in Table 3.4 and 3.5
respectively.
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Table 3.4: SSCP gel-running conditions for each BRCAI amplicon*
Exon/ Polyacrylamide/ Temperature Glycerol Running
Amplicon cross linker (59: 1) (OC) concentration time/hours
2 14% 12 3% 15
3 140/0 12 3% 16
5 140/0 12 3% 14
11- 5'end 140/0 15 1% 17
11- 3'end 140/0 14 5% 20
13 14% 12 2% 16
20 14% 12 3% 16
*SeeTable 3.1 for the amphcons Sizes
Table 3.5: SSCP gel-running conditions for each BRCA2 amplicon*
Exon/ Polyacrylamide/ Temperature Glycerol Running
Amplicon cross linker (59: 1) (OC) concentration time/hours
9 140/0 12 3% 16
11- 5' end 14% 15 2% 17
11- 3'end 140/0 12 3% 20
17 14% 12 5% 18
18 partl 140/0 12 3% 16
18 part2 14% 12 5% 15
23 14% 25 5% 16
*See Table 3.2 for the amphcons Sizes
Note: The sameconstant power(245 volts) was applied for all conditions above.
The type and the position of the alteration within a sequence context of
amplicon have a significant influence on the conformation of single-
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stranded molecule. In addition, each of above variables can alter the
conformation of single-stranded molecule. Gels with higher percentage of
acrylamide and lower cross-linking can detect more mutations [5]. It is not
possible to predict how a given change in conditions will affect the
mobility of a specific fragment (Figure 3.12).
3.4 Results
• Mutant, sequence variant, and polymorphism results
Six distinct sequence variants were detected by analysing 104 samples for
germline mutations in the BRCAI gene exons 2, 3, 5, 13 and 20 and
BRCA2 gene exons 9, 17, 18 and 23 by amplification from genomic DNA
with PCR. Two of these were frameshift (putative mutations), three
missense (unknown significant changes) and one sequence variant included
a 12bp duplication [BRCAI, IVS20+48] (Table 3.5 and Figures 3.3 -3.13).
A common polymorphism in BRCA2 [IVSI6-14T>C] was detected in
affected and unaffected individuals (Figures 3.9 -3.11). Seventy-eight
samples of British affected women were analysed within the BRCA2
intron-exon 17 boundary, fifty-nine individuals carried this polymorphism
(Figure 3.11).
All these alterations were characterised by direct sequencing. DNA
sequences obtained from affected patients' carriers and normal individuals
in conjunction with the sequence data in public databases for BRCAI and
BRCA2 genes [GenBank Accession numbers: U14680, L78833, U43746
and Z74739] were compared and identified the nucleotides variation.
• Ambiguous results
For SSCP, in some cases different mobilities were detected in two strands
but direct sequencing revealed the presence of a normal sequence. This can
be a result of low sensitivity of SSCP method and/or inefficient generation
ofPCR products (Figure 3.12 - 3.15).
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Table 3.6: Germline mutations detected by SSCP in the BRCAI and BRCA2 genes
Mutation and Tumour Stop codon Coding Scanning Family Age atGene/Exon nucleotide type occurred at effect method history diagnosis
change
BRCAl- 185-186de1AG IDC 39TGA Frameshift SSCP 2BC-IPS 37Exon2
BRCAl- 181-182insT IDC 40TGA Frameshift SSCP 1-0V 41Exon2
BRCA2- IVSI6-14T>C Close to SSCP n.a. n.a.n.a.
----
splice siteExon 17t IVSI6- 6T>G
BRCA2- 8345A>G IDC ---- Missense SSCP Negative 38Exon 18 (N2706S)
BRCAl- IVS20+48 dup IDC ---- Polymorphism SSCP 2BC<42 27t tExon 20 gtattccactcc
BRCA2- 9266C>T IDC ---- Missense SSCP Negative 31Exon 23 T3013I
ttThis patient also harbour a frameshift mutation in BRCA2 exon 11.
tThis is close to splice site variant were detected in 81 out of 104 individuals (61 heterozygous and 20 homozygous).
BC= Breast Cancer OV= Ovarian Cancer PS= Prostate Cancer n.a.= not applicable
IDC= Invasive Ductal Carcinoma
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Figure 3.7: Depicted two sequence variants in an individual.
1) A one variant was observed in BRCA2 intron-exon 17 boundary
[IVSI6-14 T>C] (Homozygous).
Figure 3.7 (d) lane 2-4 show normal pattern and lane 1 depict the normal
patterns of single strand DNA mobility and homoduplex pattern of same
sample seen on polyacrylamide gel.
Direct sequencing identified a single base pair substitution T>C at IVS16-
14 in this sample (Figure 3.7 a).
2) A single base pair substitution was detected in BReA2 exon 18.
Figure 3.7 (e) lanes 2, 3 reveal normal pattern and lane 1 depict the
abnormal patterns of single strand DNA mobility seen on polyacrylamide
gel. Direct sequencing characterised A>G substitution at 8345 nucleotide.
(Figure 3.7 b, c). Substitution of Asparagine to Serine (both are uncharged
polar amino acid) on BRCA2 gene expression is more unlikely to be
effective.
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Figure 3.8: PAGE image of sequence variants of Homozygous and heterozygous of BRCA2 exon 17
detected by SSCPIHA
HOiDO Hetero 'VT
1 2 3 4 5 6 7 8 9 10
Figure 3.8: Lanes 1-10 (top row) show normal pattern of single strand DNA electrophoretic mobility and bottom row depict
different pattern of double strand DNA mobility from three different genotypes (lanes 1, 4, 5) within the defmed DNA
region seen on polyacrylamide gel.
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Figure 3.9: PAGE images (a, b, c) of Heteroduplex Analysis (HA) of sequence variants
. in BRCA2 [IVS 16-14 T>C] in Iranian affected women with breast cancer
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Single base pair changes between the different genotypes are evident.
The designations are as follows: Lanes Wt, TT (homozygote n; .Lanes Ht, TC (heterozygote C); Lane Ho,CC (homozygote C).
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Figure 3.14 (a) lanes 1-3 show normal pattern and lane 4 revealed the
abnormal pattern of single strand mobility seen on polyacrylamide gel.
Direct sequencing verified a normal sequence pattern for sample (lane)
four.
Figure 3.14 (b) all four samples show normal pattern of the heteroduplex
mobility. Sample four was analysed three times by SSCP and direct
sequencing and every time gave the same results in both methods.
Figure 3.15: The electropherograms verified the entire normal sequence of
the BRCA2 exon 18 (second part =235bp) for ample four in figure 3.14 (a).
Both directions (forward and reverse sequences) have shown the normal
sequences pattern the specific DNA fragment.
Wild type sequence ofBRCA2 exon 18 (second part =235 bp)
1 gcagataccc aaaaagtggc cattattgaa cttacagatg
41 ggtggtatgc tgttaaggcc cagttagatc ctcccctctt
81 agctgtctta aagaatggca gactgacagt tggtcagaag
121 attattcttc atggagcaga actggtgggc tctcctgatg
161 cctgtacacc tcttgaagcc ccagaatctc ttatgttaaa
201 ggtaaattaa tttgcactct tggtaaaaat cagtc
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3.5 The combined SSCP/HA and restriction digestion method
To evaluate the sensitivity of the PTT, restriction digestion with BamBI
(recognition site = GGATCC) was applied to test one hundred samples for
gennline mutation in the BRCAI exon 11-3' end (50Ibp).
Genomic DNA was amplified using a primer pairs and convention PCR
program (Table 3.1).
PCR products were digested in total volume of 30Jll (distilled water-Loul,
PCR products= 10JlI, Buffer 10x= 3ul, Restriction enzyme-s 5U) and
incubated at 37°C for 4-6 hours.
5JlI of the digested products and 5JlI of SSCP loading buffer were
incubated at 99°C for 10 minutes, followed immediately by placing the
samples on ice for 10 minute. All 10Jll was then loaded on a PAGE 14%
with glycerol 10% (Figure 3.16 a and b). The rest of assay was performed
as a conventional SSCP method (See also chapter 2).
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Note 1: Figure 3.16 (a) shows the normal pattern of ssDNA mobility in
lane 7 and other similar lanes that differ with abnormal pattern of ssDNA
mobility in lanes 2, 3, 8, 10, 13 and 17 on polyacrylamide gel.
Lane 4 seems to be the result of an inefficient PCR products and lane 5
reveals a highly abnormal pattern of ssDNA mobility.
PCR products of samples in lanes 5, 7, 8 were characterised by direct
sequencing, which revealed a wild type DNA sequence.
Note 2: Figure 3.16 (b) lane 2 shows an abnormal pattern of single strand
DNA mobility compared with lanes 1, 3,4, 8, 9, 10 and 11.
Lanes 5 and 6 seem to be inefficient PCR products and lane 12 reveal
abnormal pattern of single strand DNA mobility.
PCR products of samples 2, 5, 6 and 12 were characterised by direct
sequencing, which revealed a wild type DNA sequence.
Figure 3.17(1-7): The electropherograms verified the entire normal
sequences of the BRCAI exon lI-3'end. Restriction digestion also did not
reveal any changes in the specific DNA fragment in one hundred samples
that have already been analysed by PTT.
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3.6 Discussion
A total of 104 samples were investigated for gennline mutations in BRCA I
gene exons 2, 3, 5, 13 and 20 and BRCA2 gene exons 9,17, 18 and 23 by
PCR-amplification from genomic DNA used SSCP/HA methods.
Due to a lack of published data on BRCA gene mutations from Iranian
population at the beginning of the study, there were no known positive
control samples (mutant sample) to accompany the SSCP analysis.
Therefore, according to the present mutation databases at the BIC, and
owing to the high frequency of alterations and their significant protein
functions in some of those regions (exon 2 and 20 of the BRCAI), I
assumed that above regions of BRCA genes might be good starting point
for screening. However, further study is required to screen the entire
sequences of both BRCAI and BRCA2 genes that lead to investigate
mutational spectrum in this selected population.
Six distinct sequence variants were identified, two frameshift (putative
mutations-one novel), two missense changes" of unknown significance and
two polymorphisms (one intronic 12bp duplication [BRCAI, IVS20+48]*
and another close to splice site [BRCA2, IVSI6-14T>C]**).
t Two missense mutations in BRCA2 gene were detected once in this set
of 104 samples tested. One in the exon 18 (N2706S) resulting from A>G
substitution at 8345 nucleotide that lead to exchange Asparagine to Serine
(both are uncharged polar amino acid) and another within the exon 23
(TI301l) changing one base pair C>T at 9266 nucleotide which substitute
Threonine (uncharged polar) to Isoleucine (non polar) amino acid. It is
more unlikely these variants to be deleterious mutation. Further
investigation (family study) among members of Iranian breast cancer
families tested and control group is required to determine whether these
particular mutations segregate with cancer in family members.
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* Effect of the intronic variant [IVS20+48] l2bp duplication gtattccactcc
.. . I [9 10 11 12 13 14] h .on BRCAI expression IS controversia ' , , " owever; It seems to
be a polymorphism. This variant has also reported in a study at the
university of Nottingham [15].
**This common polymorphism [BRCA2, IVS16-l4T>C] was detected in
affected and unaffected individuals, 81 out of 104 (61 heterozygous and 20
homozygous). Interestingly no abnormal patterns were observed in single
strand DNA mobility and all these variants were identified by heteroduplex
patterns alone. Apart from this polymorphism, no other sequence variants
were detected in unaffected individuals.
To address if this polymorphism [BRCA2, IVSI6-I4T>C] is a marker in
Iranian women, 78 samples of British affected women with breast cancer
were also analysed by SSCP/HA. Fifty-nine patients had this
polymorphism.
Although only SIX sequence variants have been detected by SSCP/HA
methods in 104 probands tested. Some circumstances may have contributed
to this outcome: first, I have only analysed common regions for mutations
in both BRCAI and BRCA2 genes, not the entire genes; second, only
coding regions have been screened for variations, mutations in the
promoter, and changes deeper within the introns would have been missed;
third, SSCP is not sufficiently sensitive to detect all sequence variants.
No sequence variant was detected at the 5' and 3' ends of exon 11 m
BRCAI or BRCA2 by SSCP/HA analysis, suggesting that there was no
loss of sensitivity in analysing such large fragments by PTT.
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3.7 Comment
My experience to date suggests that the SSCA/HA strategy, which I have
used, is efficient and relatively sensitive. Any fragment should be subjected
to analysis by both SSCPIHA simultaneously because some variants might
not be detected by either SSCP or HA individually. Initially, the use of
SSCA/HA demonstrated the variants to be detected as double-stranded
heteroduplex mobility shifts, often in the absence of variation in the single-
strand conformation pattern. (See figures 3.8-3.11, which depicted only
heteroduplex pattern mobility of BRCA2 gene at IVSI6-14). Indeed the
high frequency of frameshift alterations in the BReA genes leads them to
rapid detection via Heteroduplex Analysis. Although the SSCP assay was
sensitive at detecting point mutations, the high frequency of apparent
polymorphisms in the BRCAI is proving problematic in trying to identify
disease related alterations. On a number of occasions SSCP variants have
been sequenced to reveal putative missense mutations, which have been
either previously or subsequently established as rare polymorphisms. There
are also several common polymorphisms that, although distinguishable as
such, may in fact mask the presence of other sequence alterations of
potentially greater significance.
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Chapter 4
4 Protein Truncation Test (PTT)
4.1 Introduction
An increasing number of disease genes have been identified in which the
majority of mutations result in premature termination of translation C].
Standard techniques to detect minor changes in DNA [e.g., SSCP analysis,
heteroduplex analysis and DGGE (Denaturing Gradient Gel
Electrophoresis) analysis] reveal all sequence changes, including those that
are not pathogenic (polymorphisms) or are of questionable pathogenicity
(missense mutations). A rapid and efficient test is the Protein Truncation
Test (PIT) [ 2, 3] which was originally designed as a tool to detect
mutations that lead to premature translation termination in the Dystrophin
gene [4]. The coding region of a gene is screened for the presence of
translation terminating mutations using de novo protein synthesis from an
amplified copy. It is also known as the in-vitro protein synthesis (IVPS)
assay [5].
PTT is a mutation detection method based upon the in-vitro transcription
and translation of typically PCR amplified sequences. It specifically
detects frameshift, splice or nonsense mutations, which lead to the
termination of mRNA translation and subsequent protein truncation [6].
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4.2 Method
The Protein Truncation Test procedure is outlined in chapter two section
2.1.8 and shown schematically in Figure 2.4.
In summary, the coding region of a gene is screened for the presence of
translation terminating mutations using de novo protein synthesis from an
amplified DNA template. The procedure includes three important steps. The
first step involves the isolation of genomic DNA and amplification of the
target gene coding sequences using PCR or, alternatively, isolation of RNA
and amplification of the target sequence using Reverse Transcription PCR
(RT-PCR). The resulting PCR products are then used as a template for the
in-vitro synthesis of RNA, which is subsequently translated into protein. The
final step is the SDS-PAGE analysis of the synthesized protein. The shorter
protein products of mutated alleles are easily distinguished from the full-
length protein products of normal alleles.
4.2.1 DNA isolation
Generally cDNAIRNA is not used as a template for mutation scanning,
mainly due to technical difficulties and its susceptibility to degradation.
However, in hereditary breast cancer cases in particular, patients are not
always available to obtain fresh sample. To date, most laboratories use
genomic DNA as a source of material for genetic testing. In this study
genomic DNA was extracted from fresh whole blood and used as a template
for further analysis (See chapter two for more detail).
4.2.2 Primer pairs design and amplification of the target gene
coding sequences
Several factors are important to design primer pairs for the PTT.
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• The ATG-initiation codon in the tailed sense forward primer must be in-
frame with the coding sequence. If the AUG is not in-frame, translation will
start at the first internal translation initiation site and an unexpected, shorter
translation product will be produced.
• If a disease gene contains several kilo bases (kb) of coding sequence, it is
necessary to amplify several 2-4 kb fragments. The choice of primers
ultimately determines the sensitivity obtained; they should be designed with
care. If possible, the tailed forward primer of the first segment should be
located upstream of the natural translation initiation site; otherwise,
mutations affecting this site will not be detected [3]. A reverse primer should
not be selected near the end of a region where a large open reading frame is
present in one or both of the alternative reading frames; in such cases a
frameshift mutation to an alternative reading frame will not cause a
truncation and it would thus be missed [3] .
• To ensure that truncation mutations in the 5'- or 3'-end of a fragment are
not missed, flanking segments should have an overlap of 350-500bp if
possible [6].
• It is important to place the forward primer in a region where the sequence
contains a codon for the labelled amino acid to be incorporated if possible
(e.g., cysteine and methionine are infrequently encoded amino acids while
leucine and lysine are more common).
4.2.3 Sensitivity of the PTT
In comparison with other mutation detection techniques, the sensitivity of
PTT is good with detection of mutated alleles when present at 5-10% cases.
This technique may be use to identify a disease causing gene. At a point
where only segments of the sequence of a candidate gene is known, tailed
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pnmers can already be designed to scan patient samples for truncating
mutations.
4.2.4 False negative of results
Failure to amplify the mutated allele or failure to detect very small
deletion/insertions or missense mutations can lead to a false negative result
ofPTT eL these might be due to:
I.Mutations in the primer-binding site
2.Very small in-frame deletions/insertions because the mobility shifts are too
small to detect. These problems can be overcome by the use of different
percentage gels and overlapping primer sets.
3.Germline/somatic mosaism
4.Large insertions, translocations and inversions, which enlarge the region
under analysis beyond amplifiable length.
4.2.5 False positive of results
Upon translation, a range of undesired background translation products may
produce, usually derived from secondary sites of translation initiation (See
Figure 4.3, b). Although these products could disguise truncated products, in
general the translation pattern is fairly constant and changes are easy to
detect.
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4.2.6 Applications of PTT
Initially, PTT was developed for detecting mutations in the large dystrophin
gene (4] responsible for Duchenne Muscular Dystrophy. Subsequently,
additional genes have been identified which contain nonsense and frameshift
mutations corresponding to a major fraction of patients exhibiting either the
disease or carrier state of the disease. PTT is now widely used to identify
and characterize these mutations (Tab Ie 4.1). Clinically important tumour
suppressor genes such as those involved in breast cancer BReAI (6],
BRCAl (7] and colon cancer APC gene (3. 5] are ideally studied through the
use of PTT. These genes contain one or two large exons, within which a
majority of the known truncation mutations lie, thus a DNA-based
diagnostic protocol can be used. Other disease characteristics make PTT the
method of choice for mutation analysis. In diseases where the majority of
cases are caused by a single mutation or a small number of specific
mutations, PTT may present an attractive method with which to reveal the
remaining mutations. For example, in Cystic Fibrosis one mutant type
(6F508) comprises 700/0 of disease mutations; of the remaining 300/0 of
mutations, half cause premature termination of translation.
PTT has been very successfully used for mutation detection in the APC gene
e· S] where 95% of the mutations in APC are translation terminating (Exon
15 is 8.5 Kb long and can be analysed in 3 - 4 overlapping fragments),
BRCAI gene (6] and Dystrophin gene e· 3] where the frequency of missense
mutations is low.
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Table 4.1: Applications of PTT in human molecular genetics
I
Disease 0/. TruncatingFM t ti •• Gene Referencesu a Ions
I Familial Adenomatous Polyposis I 95% I APC I 3, 5
IHereditary desmoid disease I 100% I APC I 8
IAtaxia telangiectasia I 90% I ATM I 9
Hereditary breast and I 900/0 I BRCAll 6
ovarian cancer
I 90% I BRCA21 7
, Cystic Fibrosis I 15% I CFTR j 10
IDuchenne Muscular Dystrophy I 950/0 I DMD I 2,4
IFanconi anaemia
J
80% I FAA 1 11
IHunter Syndrome -----, -50% I IDS I 12
Hereditary non-polyposis I -80% I hMsm/ 13
colorectal cancer
I -70% I hMLH11 14
INeurofibromatosis type 1 I 50% I NFl I 15
INeurofibromatosis type 2 I 65% I NF2 I 16
IPolycystic Kidney Disease I 95% I PKDl I 17
**The percentage oftruncating mutations reported which should be detectable using
PIT.
In view of the nature of this experiment described in this chapter, I have
included details of the methodology as they pertain PTT, in order to clarify
the results and their interpretation.
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4.3 PTT in practice
PTT is applied most frequently for mutation detection in hereditary breast
cancer. Most, in some cases all, mutations reported in BRCAI and BRCA2
gene particularly in exonl Icause premature translation termination [1. 18. 19],
are readily detectable by PTT, and make it a very sensitive and efficient tool
for mutation detection.
BRCAI and BRCA2 are relatively large genes; consist of 22 and 26 coding
regions respectively. Both have a large exon (exon I I) that comprises 6I%
and 45% the entire BRCAI and BRCA2 coding region respectively (See
Appendix II).
Using Wizard Genomic DNA purification kit (Promega, Southampton, UK;
catalogue no. LA1620) in accordance with the manufacturer's protocols,
genomic DNA was extracted from peripheral blood lymphocytes. Modified
primers, containing a T7 promoter and a perfect Kozak consensus sequence
were used to generate PCR products from exon I I ofBRCAI and BRCA2
suitable for PTT. Each pair of primers amplified 3446bp and 4959bp for
BRCAI exon II and BRCA2 exon I I respectively (Table 4.3, 4.4 and
Figure 4.1 a, b). This approach considerably reduces the workload involved
in scanning large multi-exon genes.
To avoid any missed frameshift mutations that might be present close to the
5' and 3' end of exon I I in both BRCAI and BRCA2 genes, four sets of
primer pairs were also used to screen these regions using SSCP method
(Table 4.3 and 4.4 and also see chapter three section 3.3 for more detail).
PCR was performed using genomic DNA containing 50-IOOng genomic
DNA, IJlI 5pM of each primer (forward and reverse), 2JlI of2.5mM mixture
dNTPs, 2.5JlI of each 5x PCR Buffer A [300mM Tris-S04, (pH 9.1 at
25°C), 90rnM(NH4)2 S04 and 5mM MgS04] and Buffer B [300mM Tris-
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S04,(pH 9.1 at 25°C), 90mM(NH4)2 S04 and IOmM MgS04] , l~l
ELONGASE® Enzyme Mix (Invitrogen, Paisley, UK) in accordance with
manufacturer's recommendations, and distilled water was added to a fmal
volume of 25ul, For amplification, each sample was denatured at 94°C for 1
min and followed by 31 cycles ofPCR (at 94°C for 25 sec, at 56°C for lmin
and at 68°C for 4 min on an Applied Biosystems DNA thermal cycler,
Applera Europe BV, Cheshire, UK) were followed by an incubation at 68°C
for 10 min. The PCR products were subsequently analysed on a 0.7%
agarose gel and used for PTT. Usually IOO-200ng/JlI of PCR products is
sufficient for PTT detection.
Note: In this study full-length artificial protein ofBRCAI and BRCA2 exon
11, ~126kDa and ~183kDa respectively, were analysed. The boundaries of
the translated fragments represent the most critical regions for PTT analysis:
5'-end mutations result in products which might be too small to allow
detection (no or little label incorporated, electrophoretic migration outside
the resolution range), 3'-end mutations might result in a size difference
which is not resolved near the top of the gel. These regions (5' and 3' end) of
exon 11 in both genes were screened separately by SSCP assay to identify
any potential reduction in PTT sensitivity of using such large fragments.
168
Chapter 4- PTT Method, Results and Discussion
Table 4.2: Modifications of standard peR components for
optimum PTT templates
Components Volume Final
concentration
1) Distilled Water (pH 7.0) Up to 25JlL
2) 5x PCR Buffer A, B (each)
60mM Tris-S04(pH 9.1), 18mM 2.5JlL
(NH4 )2S04, with MgS04between 1-2 mM
4) dNTPs mix (2.5 mM each 2JlL 200JlM
nucleotide)
5) Primer mix (5JlMIL each primer) 2JlL oApM/JlI
6) Genomic DNA template (100ng) 1.0JlL
7) ELONGASE@ Enzyme Mix (5 Unit) 1.0JlL
The PCR products of the whole of exon 11 of BRCA1 and BRCA2 genes
were screened in a single reaction using a coupled transcription-translation
system, TNT® T7 Quick for PCR DNA kit (from Promega, Southampton,
UK; catalogue no.L5540) in accordance with manufacturer's protocols.
The 100-200ng/JlI of above PCR products were used directly (without
purification) as templates in coupled transcription-translation reactions
with 2J.lCi of esS] labelled methionine (lCN PHARMACEUTICALS,
HANTS, UK catalogue no.015l001H) and incubated for 90 minutes at
30°C. The samples were diluted in sample buffer (45J.lI per SJ.lI translated
mix), boiled for ten minutes and analysed by SDS-PAGE (6% to 15%
acrylamide) [discontinuous and denaturing sodium dodecyl sulfate -
polyacrylamide gel 7cm x IOem] on a 2 x Mini-Protean (Bio-Rad,
Hertfordshire, UK, catalogue no.16S-330l). The de novo proteins were
separated and visualised by autoradiography after the gel had been dried
(See chapter two section 2.1.7 for more detail).
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Figure 4.1: Amplification of the BRCA1 and BRCA2 exon 11
a) PCR products monitored on 0.7% agarose, confirming the integrity of
the primer syntheses, intensity of PCR products and the compatibility of
the primer pairs.
In both figures a and b:
Lanes 1 and 2 are PCR products of BRCA2 exon 11 =4994 bp
Lanes 3 and 4 are PCR products of BRCA2 exon 11 part 1=2834 bp
Lanes 5 and 6 are PCR products of BRCA2 exon 11 part 2=2657 bp
Lanes 7 and 8 are PCR products of BRCA 1 exon 11 =3482 bp
* P R products that used as a template for PTT includes T7 promoter sequences, which
flanking upstream of DNA specific segment, this added 35bp to the normal amplified
DNA segment.
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b) Again PCR products monitored on 0.7% agarose, for 16 hours at 45
volts to reveal size, quantity and quality of PCR products. Ladder I kb run
along side to confirm the fragments sizes.
As Figures 4.1 a, b show, that under different running conditions, no
dimmers were formed; the quality and the quantity of each of the peR
products were suitable for use in PTT procedures.
This approach may reduce cost and time for screening of these significant
regions of BRCA genes in genetics laboratories. Therefore using similar
annealing temperature (Table 4.3 and 4.4) to amplify both exon 11 of
BRCA1 and BRCA2 allows amplify more samples at the same time.
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SDS-PAGE analysis of the entire exon 11 of BRCAl gene revealed the
capability of the PTT to detect mutations within ~5kb coding sequences in a
single reaction using a coupled transcription - translation system, TNT® T7
Quick for PCR DNA kit from Promega, Southamton, UK.
Figure 4.2, a and b (lane 1,2) shows the normal pattern ofBRCA2 exon 11-
full length protein (l83kDa) and lanes 3-5 depict three different sizes of
truncated proteins, which were identified on both 6% and 12% SDS-PAGE.
Arrows show the size and position of the normal and those truncated
proteins.
Lane 4 shows the translation products of a mutation that occurs close to the
3' end of exon 11 and produces a large truncated protein, which migrates
close to the top of the gel.
Lane 5 shows a small truncated protein that resulting from a mutation that
occurs close to the 5' end of exon 11 and migrates close to the bottom of the
gel.
In each lane, several additional protein bands can be seen. These signals are
probably generated by secondary translation initiation at internal ATG
codons in the amplified segment.
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Note: Figure 4.4 (b) lanes 1-8 and 10 show the normal pattern of entire
translated protein ofBRCAl exon 1l(3429bp ~ 127kDa) and lane 9 depicts
the truncated protein (l551bp ~ 57kDa), which run faster than normal one
on the SDS-PAGE.
Direct sequencing revealed (in both directions figure 4.4, a and c) a mutation
in sample lane 9 and characterised two base pair deletion (AA) in BRCAI
gene exon 11 at nucleotides 2336 and 2337 that leads to a TAA (stop
codon) at codon 741 on complete BRCAlcDNA.
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Note: Figure 4.5,b shows an image of SDS-PAGE (6% acrylamide) that
reveal the pattern of a normal and the truncated protein of BRCA2 exon 11
segment one.
A one base pair (A) insertion between nucleotides 3979 and 3980 (on
BRCA2 cDNA) leads to a TAA (stop codon) at codon 1246 and made a
truncated protein (l904-7IkDa) that seen on lane 8. Arrows in lane 8 show
different positions of the truncated protein.
Lanes 1-5 and 7 show normal pattern of the full-length translated protein of
BRCA2 exon 11 segment one (2799bp-11 IkDa).
A negative control reaction containing no added template was used to allow
measurement of any background incorporation (lane 6).
Direct sequencing revealed (in both directions) a mutation in this sample
(lane 6) and characterised a one base pair (A) insertion. Figures 4.5,a and c
show this alteration.
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Note: The well separated ~17kDa protein on SDS-PAGE 15% revealed the
capacity of PTT and SDS-PAGE for small amplicons used for in-vitro
coupled transcription-translation reactions.
Although these samples were found normal, the analysing of short PCR
products by PTT might have an advantage when combined with the Meta-
PCR technique in which short Meta-PCR products are assembled (See
chapter 6 for more detail).
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4.5 Multiplex PTT
New variations on exiting mutation detection techniques are rapidly
emerging to reduce the cost of genetic testing while maintaining specificity
and sensitivity. The PTT is one of the common methods used in genetic
laboratories to analyse breast cancer predisposing genes. There are different
approaches for the analysing of exon 10 and 11 of the BRCA genes. Some
analyse exon 11 in two segments in separate reactions and others screen in
three or four segments.
In this study different approaches were applied to scan exon 11 of the
BRCA genes and to investigate the advantages and disadvantages of each
method. Finally, I made significant improvements to the method called
Multiplex PTT that leads to a reduction in the time and cost (by up to 50%)
for analysing most (exon 11) of the BRCAI and BRCA2 genes.
Basically, the assay is similar to the conventional PTT. Some modifications
were performed to achieve stronger signals and through an increase in the
yield of de novo protein.
It was anticipated that at least two problems might be encountered: The first,
synthesis of more amounts of artificial protein and the second is obtaining
the clear separation and visualisation.
Using two big PCR products (mixture of PCR products of exon 11 of the
both BRCAI and BRCA2 gene - 8.5kb in total) in a coupled transcription-
translation reaction at the same time may reduce in-vitro protein yields.
In this study small amounts of TNT® T7 Quick for PCR DNA Mater Mix
(from Promega, Southampton, UK; catalogue no. L5540) were used for
coupled transcription-translation reaction (114 of the manufacturer's
recommended), see chapter two section 2.1.7 and appendix XI for more
details. This reduction in the concentration of reaction components did not
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compromise product yield. This means that the cost of the test has been
previously reduced, exploiting multiplex PTT assay might reduce the test
expenses even further.
Gradient SDS-PAGE (40/0-20% acrylamide) has been shown to achieve
better resolution. Additional amounts (0.5111) of T7 RNA polymerase may
lead to more de novo proteins production. Increasing the incubation time (90
minutes in 30°C) did not effect on yield.
In order to ensure correct interpretation of the results, a batch of samples
including normal, and negative control should be analysed alongside of
samples tested which lead to simplify the comparison of mobility patterns of
normal and truncated proteins.
In this experiment the de novo protein were separated on SDS-PAGE (60/0
acrylamide), transferred to nitrocellulose and visualised by autoradiography
(Figures 4.9 and 4.10a, b).
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Figure 4.9: Lanes 1-4 and 9,10 depicted normal pattern of mixed full length
of translated proteins ofBRCAI (lane 1 bottom arrow) and BRCA2 exon 11
(lane 1 top arrow).*
Lanes 5 and 6 shown previously ascertained truncated protein of BRCA2
exon 11 (arrow) with background of full length of protein of BRCA1 exon
11.
Lanes 7 and 8 shown previously ascertained truncated protein of BRCA1
exon 11 (arrow) with background of full length of protein of BRCA2 exon
11.
*In this experiment PCR products from the entire length of exon I10f both
BRCAI and BRCA2 gene, ~3.5kb and ~5kb respectively were used as
templates for coupled transcription and translation in single reaction.
Note: Any given suspected samples should be targeted for conventional PTT
to avoid misinterpretation of abnormal patterns. With more experience one
become familiar with the normal pattern of in-vitro synthesized protein
resulting from the co-translation from specific PCR products and
discrimination of abnormal patterns is readily observed.
The following SDS-PAGE images show the patterns of the normal and
previously ascertained truncated protein of different sizes. These additional
images were only produced to show the capacity of multiplex PTT in
application of various sizes of PCR products.
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Figure 4~10,a: SDS-PAGE image of the Multiplex PTT
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Figure 4.1 O,a
Templates in lane 1: Mixture of a wild type protein of BRCA2 exon 11
segment one (2799bp~IIIkDa-bottom arrow) and wild type protein of the
BRCA2 exon 11 full-length protein (4959bp~183kDa-top arrow).
Templates in lane 2: Mixture of a truncated protein of BRCA2 exon 11
segment one (1904bp~7IkDa-bottom arrow) and wild type of the BRCAl
exon 11 full-length protein (4959bp~183kDa-top arrow).
Templates in lane 3: Mixture of a truncated protein of BRCA2 exon 11
segment one (l904b~7IkDa- arrow) and a truncated protein of the BRCA2
exon 11 (1881bp~69kDa- disguising).
Templates in lane 4: Mixture of a truncated protein of BRCA2 exon 11
segment one (l904bp~71kDa-top arrow) and a truncated protein of the
BRCAI exon 11 (l55Ibp~57kDa- bottom arrow).
Templates in lane 5: Mixture of a wild type protein of the BRCA2 exon 11
full-length protein (4959bp~183kDa-top arrow) and a truncated protein of
the BRCAI exon 11 (l55Ibp~57kDa- bottom arrow).
Templates in lane 6: A wild type protein of BRCA2 exon 11 segment one
(2799bp~IIlkDa), poor protein product.
Templates in lane 7: A truncated protein of BRCA2 exon 11 segment one
(I904bp~71kDa- arrow)
Templates in lane 8: A wild type protein of the BRCA2 exon 11 full-length
protein (4959bp~183kDa).
Templates in lane 9: A truncated protein of the BRCA2 exon 11(l88Ibp~
69kDa).
Templates in lane 10: A wild type of Luciferase protein (T7 Control DNA)
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I
Figure 4.10,b: SDS-PAGE image of the Multiplex PTT
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Figure 4.1 O,b
Templates in lane I: Mixture of a wild type protein of BRCA2 exon II
segment one (2799bp~lllkDa-bottom arrow) and wild type protein of the
BRCAI exon 11 full-length protein (3429bp~127kDa-top arrow).
Templates in lane 2: Mixture of a truncated protein of BRCA2 exon II
segment one (1904bp~71kDa-bottom arrow) and wild type protein of the
BRCAI exon II full-length protein (3429bp~127kDa-top arrow).
Templates in lane 3: Mixture of a wild type protein of BRCA2 exon 11
segment one (2799b~lllkDa-top arrow) and a truncated protein of the
BRCAI exon 11 (l55Ibp~57kDa- bottom arrow).
Templates in lane 4: Mixture of a truncated protein of the BRCA2 exon
11(l88Ibp~69kDa-arrow) and wild type protein of the BRCAI exon II full-
length protein (3429bp~127kDa-unregonisable because of poor protein
producing).
Templates in lane 5: Mixture of a wild type protein of the BRCA2 exon II
full-length protein (4959bp~ I83Da) and wild type protein of the BRCAI
exon 11 full-length protein (3429bp~I27kDa). Both protein product are poor
and unrecognisable.
Templates in lane 6: Mixture of a truncated protein of the BRCA2 exon
11(l88Ibp~69kDa-top arrow) and a truncated protein of the BRCAI exon
II (l55Ibp~57kDa-bottom arrow).
Templates in lane 7:A negative control reaction containing no added
template was used to allow measurement of any background incorporation.
Templates in lane 8: A wild type of Luciferase protein (T7 Control DNA)
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4.6 Discussion
PTT is one of the most commonly used methods in genetics laboratory
worldwide. The specificity of the test is 100% and the sensitivity although
not yet defined but in a systematic study seems to approach 90%-95%,
because of insensitivity of the method in detection of mutation at close to the
5' and 3' end of the DNA specific of interest.
1) To date only PTT kit from Promega 1M, Southampton, UK is available, it
can produce polypeptide chain from up to 5kb artificial transcript eo).
In this study to assess the capability of the PTT and the utility of the TNT®
T7 Quick for PCR DNA kit (from Promega TM, Southampton, UK) in
producing of a range of artificial protein and to observe the clarity of those
visualisation by autoradiography, different DNA specific fragments from
range of -470bp to -5kb in sizes (Figure 4.2 - 4.7) were tested.
I have observed no significant effect of the length of the PCR products on
the efficiency of the translation/transcription reaction, however, with
increasing the size of the translated products, gel resolution will diminish the
minimum truncation event that will be detectable. It is strongly recommend
that, at this DNA fragment size (around 5kb), the 5' and 3' end of the region
of interest should be analyse by another mutation detection technique to
avoid missing any mutation due to insensitivity of the test.
However, in my experience, translation/transcription of PCR products up to
4-5kb is not difficult, best results are obtained when transcription/
translation amplification fragments of up to 2kb from genomic DNA are
analysed by PTT.
2) I found Multiplex-PTT to be a very cost effective approach for the
analysis of large fragments such as BRCA genes exon 11 and might be
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applicable in genetic laboratories to reduce expenses and time of genetic
tests.
Although, reticulocyte lysate (PTT kit from Promega TM, Southampton, UK)
contains the cellular components necessary for protein synthesis (tRNA,
ribosomes, amino acids, translational factors, further optimisation for mRNA
translation by adding an energy-generating system consisting of
phosphocreatine kinase and phosphocreatine, a mixture of tRNAs to expand
the range of mRNAs, potassium acetate and magnesium acetate) but it has
not been reported with the same promoters in the same reaction multiple
proteins can be expressed [21].
3) For the BRCAI exon 11, the first translation site (ATG) appears at codon
74 (nucleotides 222) and the second one is at codon 308 (nucleotides 924)
when a mutation occurred upstream to the codon 74, the synthesized
polypeptide is very small and/or no radioactive signal from newly
synthesized polypeptide can be detected. Therefore, when a mutation occurs
upstream of the codon 308 there are only two ATG sites in the PCR
products (one in the forward primer- Kozak sequence, see chapter 2 section
2.1.8 - and the next one is at the codon 74) to facilitate radiolabelling; the
chance to detect a mutation is still low. But in the middle and towards to the
end of this segment there are sufficient ATGs to enable radiolabelling, thus
there is still a little chance to miss a mutation close to the 3' end.
For the BRCA2 exon 11, the first translation site (ATG) appears at the
codon 148 (nucleotides 444) when a mutation occurred upstream to the that,
only one ATG site in the PCR products is remain (Kozak sequence) to
produce signal, so that the band close to the bottom of the gel may appear
very faint and can be easily missed.
200
Chapter 4- PTT Method, Results and Discussion
However, using cysteine (TCT) labelling may overcome these problems due
to enough number sites ofTCT throughout the BRCAI and BRCAl exon 11
to make signals. Therefore, it has been strongly recommended by
PromegaTM to use [35S] Methionine because it prevents the background
labelling of a rabbit reticulocyte lysate 42kDa protein, which can occur
using other labels [22].
In addition, designing a forward primer (Kozak sequence) includes more
than one ATG site may useful to enhance [35S] Methionine incorporation
and lead to better visualisation by autoradiography where mutation occur
close to 5' end.
Note:
1) Among twenty amino acids only Methionine and Cysteine have sulfhydryl
group to be radiolabeled.
H
I
H.,N-C-CO()H
.. I
CH2
I
CH2I
,
CH3
(a) Methionine
II
I
11 \- ( -('()( lii
.. I
CH2
I
<.,·H..
(b) Cysteine
2) The above codon numbers is accounted based on BRCA genes exon 11
notcDNA.
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Chapter 5
5 Meta-peR technique
5.1 Introduction
Conventional methods used to clone nucleotide sequences encoding open
reading frames or to detect gene mutations' rely on either the preparation of
cDNA or the isolation of each exon of a gene individually from genomic
DNA (2].
For genes that have several exons, often spread over large distances in
genomic DNA, preparation of cDNA or fragments of each exon can be a
tedious process. In some cases, original tissue is not available; leaving
genomic DNA as the source of genetic material as the most convenient
choice for most laboratories due to the simplicity of its preparation and its
intrinsic stability.
Yet working with genomic DNA leaves the exon as the unit of analysis for
mutation scanning. Because the average higher eukaryote exon is only
140bp in size eJ the sheer number of tests involved scanning for the
complete of genes for point mutations means that the more sensitive,
labour-intensive methods impose severe constraints on throughput.
A variety of scanning methods are available to identify unknown point
mutations. The choice of technique being determined by several competing
factors, two of the most important factors is the sensitivity of the method
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and the complexity of the procedure. Some widely used mutation detection
methods such as SSCP/HA are technically simple but are only capable of
scanning small DNA fragments and even than with variable sensitivity [1, 4,
5]. Other mutation-scanning techniques like PTT are capable of locating
mutations in DNA fragments much larger than the average exon [6].
There has been an increasing demand for rapid and accurate methods for
scanning of point mutations in large multi-exon genes. Recently a method
called Lexon has been described (Tuohy and Groden, 1998) for the
production of in-frame concatamers of PCR products of APC gene exons 3-
9A for downstream analysis in the Protein Truncation Test [7]. Following a
new technique named Meta-PCR have been developed by Wallace et al
(1999) for creating chimaeric DNA molecules using a modified PCR
reaction for downstream analysis by direct nucleotide sequencing [8].
Meta-PCR is a simple and very convenient method for linking small DNA
fragments from large multi-exon genes that can maximize the length of
sequence scanned by downstream techniques. Through Meta-PCR small
PCR amplicons are assembled into a single large chimaeric DNA molecule
in two coupled stages carried out in a single reaction vessel. The order of
fragments is predetermined by primer design. Currently, up to five PCR
amplifiable fragments can be combined to form a single linear amplicon [8].
In this study BRCA genes were chosen as the target to evaluate feasibility
of the Meta-PCR technique. RNA as a source of genetic material is not
suitable for analysing and scanning of each exon of BRCAI and BRCA2
genes individually is an onerous task (Table 5,1)~ this technique might
circumvent these problems using genomic DNA.
Three distinct sets of BRCA gene fragments were selected to assemble with
different approach for downstream analysis. The first set consisted of
BRCAI exons 2, 20 and the BRCA2 exon 18 and their subsequent analysis
by Protein Truncation Test (See chapter 4 for great detail) e' 6, 9, 10], the
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second set comprised BRCAI exons 2, 20,23 and 24 and their subsequent
analysis by direct sequencing and the last one contained six significant
coding regions from the BRCA genes, the 5' and 3' termini of exon 11 from
both BRCAI and BRCA2 gene, exons 2 and 20 from BRCAI, which most
likely to harbour a mutation. Downstream analysis of Meta-PCR products
by Protein Truncation Test was used rather than direct sequencing because
the total assembled above fragments size (~2.8kb) is sufficiently big to
ignore analysing by the latter approach.
5.2 Principle of Meta-PCR
The Meta-PCR process involves two coupled steps: the main phases of the
primm) Meta-Pt.R reaction are illustrated in Figures 5.1 A and B.
During this phase, genomic DNA is amplified with limiting quantities of
primers (Tables 5.2, 5.3 and 5.4). In the initial cycles, the reaction behaves
like a simple multiplex PCR. However, as the amplimers begin to increase
in concentration, there are insufficient amount of each primer to
hybridise to and re-extend the entire single-stranded DNA. This
"encourages hybridisation to occur between the linker segments of the
linker primers" (now incorporated into the peR products) forming two
types of intermediate (Fig. 5.IA). One of these intermediates (intermediate
I in Fig. 5.IA) is capable of being extended by Taq polymerase, leading to
a fusion product comprising the two fragments. As progressively more
extendable intermediates form, longer fragments accumulate, until at some
point, probably late in the primary Meta-PCR reaction, the full-length
product arises (Fig.5.IB). Reamplification of a small aliquot of the primary
Meta-PCR in a secondary reaction (secondarv Meta-PtR) with an excess
of internal nested primers reamplifies the full-length product with high
specificity, producing sufficient product for downstream analysis (Fig.
5.IB).
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Table 5.1: BRCA 1 and BRCA2 coding regions sizes
BRCA1 exons sizes/bp BRCA2 exons sizes/bp
Exon 2 (exon size=99) Exon 2 (exon size=106)
Exon 3 (exon size=54) Exon 3 (exon size= 249)
xon 5 (exon size=78) Exon 4 (exon size=109)
Exon 6 (exon size=89) Exon 5 (exon size= 51)
Exon 7 (exon size= 140) Exon 6 (exon size= 41)
Exon 8 (exon size= l 08) Exon 7 (exon size= 115)
Exon 9 (exon size=46) Exon 8 (exon size= 50)
Exon 10 (exon size=77) Exon 9 (exon size= 112)
.. xon 11 (exon size=3426) Exon 10 (exon size= 111 6)
Exon 12 (exon size=89) Exon 11 (exon size= 4931)
Exon 13 (exon size=172 Exon 12 (exon size= 99)
Exon 14 (exon size= 127) Exon 13 (exon size= 73)
Exon 15 (exon size=191) Exon 14 (exon size= 428)
Exon 16 (exon size=3 11) Exon 15 (exon size= 182)
xon 17 (exon size=88) Exon 16 (exon size= 188)
Exon 18 (exon size=7 1) Exon 17 (exon size= 171)
Exon 19 (exon size=41) Exon 18 (exon size= 355)
Exon 20 (exon size=84) Exon 19 (exon size= 156)
Exon 21 (exon size=55) Exon 20 (exon size= 145)
Exon 22 (exon size=74) Exon 21 (exon size= 122)
Exon 23 (exon size=61) Exon 22 (exon size= 199)
Exon 24 (exon size=325) Exon 23 (exon size= 164)
Exon 24 (exon size= 139)
Exon 25 (exon size= 305)
Exon 26 (exon size= 147)
Exon 27 (exon size= 609)
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5.3 Meta-peR in practice
In order to evaluate the capability of the Meta-PCR technique for
overcoming difficulties of analysis of complex genetic disorders, the
combination of PTT or direct sequencing methods was approached as a
downstream analysis. Different approaches have a significant influence on
primer design and maximising the length of sequence scanned.
For PTT analysis, special care has to be taken to ensure that the primers
designed maintain open reading frame, this leads to some inflexibility in
primer designing.
For direct sequencing approach, many parts of the target genes (Intron
and/or exon) can be selected, allow flexibility in the positioning of the
primer, and make it relatively easy to determine the most suitable annealing
temperatures (Tm) which is critical for the assembly of DNA fragments.
5.3.1 General considerations for primer design
The genomic specific segments were selected to have closely equivalent Tm
values for the positioning of the primers. The complementary 5' termini, or
linker segments of the Meta-PCR primers, were designed typically with
approximately 500/0 GC content, avoiding any internal secondary structure,
and to have Tm values that exceeded those of the genomic specific
segments to favour self-assembly. A supplementary unmatched adenine
residue was inserted between the genomic and 5' linker segments of the
self-assembling primers to accommodate the 3' adenine overhangs added
by Taq polymerase to the nascent DNA strand.
It should be noted that adding a supplementary unmatched adenine
(A) residue at the sense sequence causes an insertion of a
supplementary thymine (T) residue at the 3' end in the antisense DNA
fragments assembled into peR products. This must be accounted for
where maintenance of an open reading frame is desired.
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All primers were checked to avoid homology to Alu repeat sequences using
the BLAST analysis program available at:
http://www.ncbi.nlm.gov/cgi-bin/BLAST/nph-blast
5.3.2 Advantages of Meta-PCR technique
1) The Lexon method has weakness relative to Meta-PCR technique; it
does not accommodate an additional 3' adenine overhang by Taq
polymerase in the primer design. Failure to do this leaves only a subset of
overlap intermediate being extendable by Taq polymerase, since Taq lacks
a 3'~ 5' exonuclease activity, and is thus incapable of resolving
mismatched 3' terminal bases. This leads to insufficient overlap extension
and results in a low yield of the spliced product. Meta-PCR intercalates the
junction between the genomic-specific primer segments and linker-specific
primer segments with an additional unmatched adenine residue. The sole
purpose of the extra adenine is to facilitate extension of intermediates that
form between fragments that have undergone the 3' adenine addition. This
gives efficient overlap extension and high yield of the desired product [8].
2) The linker specific primer segments in Meta-PCR are designed with
higher Tm values than the genomic specific segments, unlike those used in
the Lexon method. This encourages the formation of overlap intermediates,
further improving the yield and specificity of the fmal desired product [8].
3) Meta-PCR also improves upon the Lexon method. The Lexon method
involve a primary amplification step where the component fragments are
amplified in separate reaction vessels with non-limiting primer
concentrations. This primary reaction is then combined multiple fragments
in the secondary reactions to create the recombinant products. In contrast,
the primary amplification step of Meta-Pf'R is a multiplex reaction with
limiting concentrations of primers. Direct coupling of primary and
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secondary PCR reactions give Meta-PCR considerable time and cost saving
over the Lexon method.
In view of the nature of this experiment described in this chapter, I have
included details of the methodology as they pertain Meta-PCR, in order to
clarify the results and their interpretation.
5.3.3 Meta-peR amplification
Genomic DNA was used as a template for amplification. Primers were
synthesized on a 0.2J.lM scale and were purified by high-performance
liquid chromatography (HPLC) at Oswel Ltd (Southampton-UK) for direct
sequencing approach and on a 0.05J.lM scale which were provided as high-
purity and salt free (HPSF) by MWG (Milton Keynes-UK) for PTT
analysis. Meta-PCR amplification was performed in two stages. The
primary reactions were performed in 20111 volumes using 100ng of genomic
DNA, l ul of each primer (40nMIL) (Table 5.2, 5.3 and 5.4), 2f..ll of mixture
of dNTP (5mM), 2111 Buffer B xlO [20mM Tris-HCl (pH 8.0 at 25°C),
100mM KCl, O.lmM EDTA, ImM DTT, 50% glycerol, 0.5% Tween® 20
and 0.50/0 Nonidet®-P40], 3111 Mg25mM, Ifll Taq DNA polymerase
(Promega, Southampton, UK; catalogue no. M1665) in accordance with
manufacturer's recommendations, and distilled water was added to a final
volume of 20f..l1.
For amplification, each sample was denatured at 94°C for 3 minute and
followed by 30 cycles of PCR (at 94°C for 1minute, at 60°C-65°C for 1
minute and extending at 72°C for 2 minutes on an Applied Biosystems
DNA thermal cycler, Applera Europe BV, Cheshire, UK) were followed by
a final synthesis 72°C for 10 minutes.
The secondary Meta-PCR were performed in separate 20f..ll volumes using
3-5f..ll of the primary PCR product, 2111 of each internal (nested) primer
(5f..lM1L), 2f..ll of mixture of dNTP (2.5mM), 2111 Buffer B xlO [20mM Tris-
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HCl (pH 8.0 at 25°C), 100mM KCl, O.lmM EDTA, ImM DTT, 50%
glycerol, 0.50/0 Tween® 20 and 0.5% Nonidet®-P40], 2111 Mg25mM, 1111
Taq DNA polymerase (Promega, Southampton, UK; catalogue no. M1665)
in accordance with manufacturer's recommendations, and distilled water
was added to a final volume of 20Jll.
The thermal cycling conditions were identical to those used for the primary
amplification. On completion of the secondary PCR, a 3ul portion of the
PCR products were checked on a 0.7%-1.2% agarose gel to confirm the
presence of the expected fragments sizes.
The above formula was applied for Meta-PCR amplification in both PTT
and direct sequencing approaches.
5.4 Downstream analysis of Meta-Pf'R products by Protein
Truncation Test
In this study Meta-PCR technique was applied to assemble BRCA2 exon
18 and BRCAI exons 2 and 20 and was followed by downstream PTT
analysis. The BRCAI exons 2 and 20 are hot spot regions that are known to
harbour particularly deleterious mutations. In order to avoid missing any
mutation in these two exons, the above three exons were assembled in the
following order of preferences: 18, 20 and 2. However, the order of
fragments is reproducible and can be predetermined by primer design.
5.4.1 Primer design
For maintenance of the open reading frame demanded that the exon-to-
exon connections constitute an integral number of codons, and that in-
frame stop codons within the intron sequence be mutated to sense codons.
This scheme facilitates mini-gene construction in translation based
mutation detection methods, such as PTT.
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In order to maintain assembled fragments of the BRCA2 exon2, BRCAI
exon20 and 2 in an open reading frame format, three site directed mutation
were introduced, as follow:
I) For the first fragment, the BRCA2 exon 18, the sequence of aat taa ttl
gca ctc ttg gta aaa at was changed to the sequence of aat tac ttt gca ctc ttg
gta aaa at
2) For the second fragment, the BRCAI exon 20, the sequence of cc tca agt
tga caa aaa tct ca was changed to the sequence of cc tca agt tgt caa aaa tct
ca
3) For the third fragment, the BRCAI exon 2, the sequence of tgg faa gtc
agc aca aga gtg tat was changed to the sequence of tgg tat gtc agc aca aga
gtg tat
These site direct mutations were introduced to the above sequences 1 to 3
relative to the relevant primers named ExI8R-L4F, Ex20R-LIF, Ex2R (int)
respectively (See also table 5.2 and section 5.4.2).
Two linker specific primer segments (each 24bp) were used to produce a
chimaeric DNA molecule for above three specific gene fragments (Table
5.2).
Note: Adding a supplementary unmatched adenine (A) residue at the
sense sequence leads to insertion of a supplementary thymine (T)
residue at the 3' end in the antisense sequence of the DNA fragments
assembled in the PCR products. It is important to ensure that the PCR
products are in frame for PTT analysis
Two nested primers including an internal forward primer (comprising a T7
promoter and a perfect Kozak consensus sequence to facilitate coupled
transcription-translation) and a conventional reverse primer were designed
to produce sufficient product for PTT analysis and to facilitate priming a
few residues upstream and downstream of the external primers (Table 5.2).
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5.5 Downstream analysis of Meta-Pf'R products by direct
.
sequencing
In this approach the strategy was modified by increasing the number of
segments to be linked, which are the BRCAI exons 2, 20, 23 and 24 and
using optimised linker specific primer segments (designed shorter in size
from 24bp to 13bp).
Once again due to the significance of exons 2 and 20 in BRCAI protein
function and in order to avoid missing any mutation in these two exons, the
above four exons were assembled in the following order of preferences: 23
20,2 and 24.
5.5.1 Primer design
Three linker fragments (each 13bp) were used to produce a chimaeric DNA
molecule from the above four specific gene fragments (Table 5.3).
These linkers are much shorter (~50%) and richer in GC content than those
used for the PTT approach. This new design significantly promotes the
formation of overlap intermediates, further improving the yield and
specificity of the final desired product (See section 5.5.2).
Two nested primers were designed to produce sufficient product for direct
sequencing analysis and prime few residues upstream and downstream of
external primers (Table 5.3).
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5.5.3.3 Recovery of secondary Meta-PCR products following agarose gel
electrophoresis
The secondary Meta-PCR products were recovered from agarose gel slices
using a Jetsorb" gel extraction kit (Genomed Inc.) according to the
manufacturer's instruction. A total of 60-80ng of recovered Meta-PCR
products was sequenced in both orientation using internal nested primers
with BigDye terminator cycle sequencing kits (Applied Biosystems). The
manufacturer's protocols were followed with the exception that the
annealing temperature for the cycle sequencing reaction was increased
from 50°C to 55°C to reflect the high Tm of internal primers.
5.5.3.4 Determination of the nucleotide sequence of wild type Meta-PCR
products
Direct sequencing confirmed that Meta-PCR products comprised the
expected exons in the correct orientation.
Figures 5.7a-i and 5.8a-j depict the full length of wild type Meta-PCR
products sequenced from both termini in single reaction. No degradation of
sequence was observed across the transitions from one component to the
next.
Figures 5.9. - 5.11 show the nucleotide sequences (Forward and reverse
direction) from wild type Meta-Pf'R products using several samples to
confirm reproducibility of the Meta-PCR reaction by direct sequencing
analysis and to show linkers junction areas more clearly.
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5.5.3.5 Detection of three previously ascertained heterozygous BRCAI
mutations from Meta-PCR products
To test the suitability of the Meta-PCR products for downstream
application such as direct sequencing, Meta-PCR products from three
previously determined heterozygous BRCAI mutations in exon 2 and exon
20, were directly sequenced to confirm that the genotype present in
genomic DNA was correctly represent in the Meta-PCR products. The
three mutant heterozygotes were BRCA1; 181-182 insT, 185 delAG and a
l2bp duplication [BRCA1, IVS20+48]. These were clearly visible in the
heterozygotes in figures 5.12 - 5.14.
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Figure 5.13: Forward electropherogram show the nucleotide sequence of
the mutant heterozygote of BRCAI exon2 (185-186 delAG) within the
assembled the BRCAI exon20 to exon2 by Meta-PCR technique. Arrow
depicts the location of [AG] deletion and frameshift sequence consequently
(See chapter 3 figure 3.5 for the same mutant heterozygote sequence
pattern without assembled sequences).
Figure 5.14: Forward electropherogram show the nucleotide sequence of
the mutant heterozygote of BRCAI, IVS20+48 [12bp duplication
gtattccactcc] within the assembled the BRCAI exon20 to exon2 by Meta-
PCR technique. Down brackets depict the location of l2bp duplication
gtattccactcc and frameshift sequence consequently occurred. (See chapter 3
Figure 3.4 for the same mutant heterozygote sequence pattern without
assembled sequences).
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5.6 Do the size and/or the segment numbers matter?
In the two previous trials, it was shown that three and four segments could
be assembled with different approaches (sections 5.4 and 5.5 respectively).
Here, I am trying to answer to the significant question with respect to
Meta-PCR. "What is the size limit for gene assembly?"
To date, up to five PCR amplifiable fragments can be combined to form a
single linear amplicon [8]. I attempted to assemble six key coding regions
from the BRCA genes, the 5' and 3' termini of exon 11 from both BRCAI
and BRCA2 genes and exons 2 and 20 from BRCAI.
Downstream analysis of Meta-PCR products by Protein Truncation Test
was used rather than direct nucleotide sequencing because the total
assembled above fragments size (~2.8kb) is sufficiently big to ignore
analysing by the latter approach.
5.6.1 Primer design
The various complete combinations of linker specific primer segments and
genomic specific fragments were designed as shown in Table 5.4.
Five linker specific primer segments (each 13-14bp) were used to produce
a chimaeric DNA molecule for above six specific gene fragments (Table
5.4). Also, one site directed mutation was introduced into BRCAI exon 2
segment, in which the sequence of taa gtc agc aca aga gtg tat was changed
to the tat gtc agc aca aga gtg tat to maintain an open reading frame in the
final assembled sequences (See section 5.6.2).
To obtain the best results in PTT and SDS-PAGE separation the order of
the fragments was determined preferentially.
Two nested primers including an internal forward primer (comprising a T7
promoter and a perfect Kozak consensus sequence to facilitate coupled
transcription-translation) and a conventional reverse primer were designed
to produce sufficient product for PTT analysis and to facilitate priming a
few residues upstream and downstream of the external primers (Table 5.4).
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2179 aaa gaa gea aaa tgt aat aag gaa aaa eta eag
K E A K C N K E K L Q
2212 tta ttt att ace eea gaa get gat tet etg tea
L F I T P E A D S L S
2245 tge etg eag gaa gga eag tgt gaa aat gat eea
C L Q E G Q c E N D P
2278 aaa age aaa aaa gtt tea gat ata aaa gaa gag
K S K K V S D I K E E
2311 gte ttg get gea gea tgt cae eea gta eaa cat
V L A A A C H P V Q H
2344 tea aaa gtg gaa tae agt gat act gae ttt eaa
S K V E Y S D T D F Q
2377 tee eag aaa agt ett tta tat gat cat gaa aat
S Q K S L L Y D H E N
2410 gee age act ett att tta act eet act tee aag
A S T L I L T P T S K
2443 gat gtt etg tea aae eta gte atg att tet aga
D V L S N L V M I S R
2476 gge aaa gaa tea tae aaa atg tea gae aag etc
G K E S y K M S D K L
2509 aaa ggt aae aat tat gaa tet gat gtt gaa tta
K G N N Y E S D V E L
2542 ace aaa aat att eee atg gaa aag aat eaa gat
T K N I P M E K N Q D
2575 gta tgt get tta aat gaa aat tat aaa aae gtt
V C A L N E N Y K N V
2608 gag etg ttg eea eet gaa aaa tae atg aga gta
E L L P P E K Y M R V
2641 gea tea eet tea aga aag gta eaa tte aae eaa
A S P S R K V Q F N Q
2674 aae aea aat eta aga gta ate eaa aaa aat eaa
N T N L R V I Q K N Q
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Figure 5.17: SDS-PAGE images of assembled from BRCAI and
BRCA2 exon 11 (5' and 3' ends) and BRCAI exons 20 and 2
a) 1 2 3 4 6 7
b) 1 2 3 5
t t
6
c)
1 2 3 4 5 6 7 8 9
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5.7 Discussion
Many disease susceptibility genes are large and consist of many exons
throughout which point mutations are scattered almost randomly. BRCA
genes fall into this category. The large numbers of exons necessitate large
numbers of individual tests, slowing down the screening process. It is in
facilitating the screening of large multi-exons genes that Meta-PCR is
likely to be most useful. The advantages to diagnostic laboratories already
using techniques like CSGE or PTT of coupling Meta-PCR to their
mutation scanning method are clearly demonstrated in this chapter.
Meta-PCR could be used to permit simultaneous scanning of disparate
mutational hot spots (in the case of BRCAI gene exons 2 and 20 are
notable) thereby allowing a rapid, targeted mutation scanning strategy.
Breast cancers display heterogeneity that can be caused by mutation in the
known cancer predisposing BRCAI and/or BRCA2 genes. Meta-PCR
could be used to combine exons from the different genes for simultaneous
screening. This could be particularly useful for diseases with mutational hot
spots in more than one gene such as BRCA genes.
I have applied Meta-PCR method to improve the overall efficiency of
scanning these genes by assembling the more "significant" coding regions
and analysing them in a single reaction either by PTT and/or by direct
sequencing. These methods were chosen because of their high sensitivity
and specificity (each method possesses advantages and disadvantages).
For the PTT approach it was possible to assemble exons 18 of the BRCA2
gene and the exons 2 and 20 of the BRAI gene successfully. Primer design
is the most important criterion for success in this approach. It is critical to
ensure the assembled sequences are in frame at the end of the assembly
stage. The greatest advantage of this approach compared with direct
sequencing is that the length of sequence can be increased up to 5kb for
downstream analysis such as PTT.
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With the direct sequencing approach, using shorter linker specific primer
with higher GC content caused a further improvement in product yield.
Primer design is much easier than for the PTT approach, but the length of
sequence can be maximized up to 700bp - 800bp with approximate to the
length of readily obtained nucleotide sequence.
Both these approaches worked successfully, suggesting that it may be
possible to assemble the entire of coding regions of BRCAI and BRCA2
genes in a multi-step procedure.
By these experiments it become clear that Meta-Pf'R is a simple, versatile
and powerful method for creating chimaeric DNA molecules for the
analysis of multi exon genes using a combination of PTT and/or direct
sequencmg.
In the latest trial (assembling of six segments) insufficient Meta-PCR
products lead to poor de novo protein production that might be resulted
from several reasons: first, increasing the number of segments; second,
differences in fragments sizes; third, a large size of assembled fragment;
and fourth, induction a site direct mutagenesis.
However, assembling of more segments may require further PCR
optimisation. Therefore, purification of Meta-PCR products by dHPLC
may produce better results to compare with agarose gel.
Finally, success in the product is critically depend on, designing the linker
specific primer with ~ 50% GC content, suitable position for primer (Gene
selection area) with no internal secondary structure, adding adenine residue
between genomic and 5' linker segment, making closely equivalent Tm
values in both linker segments and genomic specific segments, checking all
primers for homology to Alu repeat sequences and the purity of synthesized
primers are the most significant parameters, which should not be
overlooked.
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Chapter 6
"We know that there are keys we can tum to lower risk
if we have advanced notice," Jeffrey Weitzel Oct 2001.
6 Genetic counselling and breast cancer prevention
6.1 Genetic counselling
Genetic counseling is the process of providing individuals and families
with information on the nature, inheritance, and implications of genetic
disorders to help them make informed medical and personal decisions.
Achieving a family history is used in estimating breast cancer risk; it is
appropriate to obtain a history of all cancers in biological relatives,
especially breast and ovarian cancers. For each cancer, the age of onset,
laterality, mode of treatment, and any possible related prior environmental
exposures should be noted, if possible. Medical records, including
pathology reports, are useful to confirm the history of cancer in the patient
and relatives. The following aspects of the family history can be used to
identify average-risk, moderate-risk, and high-risk individuals:
• Number of affected relatives
• Ratio of affected to unaffected relatives
• Age at cancer diagnosis
• Presence of bilateral/ multifocal breast cancer
• Presence of ovarian cancer
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• Case(s) of male breast cancer
• The ethnicity of the family
The initial pedigree might provide invaluable information about hereditary
breast cancer in a specific family. However, updating data on each follow
up, may add relevant information. Accurate pedigree can play a valuable
role in risk assessment for all probands in a family [1l.
6.1.1 Pedigree analysis pitfalls
A clinician may be faced with certain problem in pedigree analysing and
accurate risk assessment that cause delays or at least interfere with
counselling of the consultand properly. These difficulties are:
I. Incomplete penetrance and variable expressivity of the gene
2. Small families and limited number of women at risk
3. Paternal transmission of disease
4. Death of key relatives before the age of development of breast cancer
5. Adopted individual with breast or ovarian cancer
6. Lack of entire family history due to immigration or other non
communication reasons within the families
7. Inconsistency in the family history in following up and poor recall
8. Establishment of false family history of autosomal dominant
transmission of breast cancer predisposing gene
6.1.2 Problems in identifying patients at risk of hereditary breast
cancer
Identification of women at high risk of hereditary breast cancer begins by
taking an accurate family history el. At particular risk are women with a
family history of early-onset breast cancer, a family history of bilateral
breast cancer, those with several affected family members and a family
history of other malignancies at an early age. However, a family history of
breast cancer may not be a reliable indicator of those who are likely to
carry a gennline mutation of a breast cancer susceptibility gene.
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Approximately 6%-19% of individuals with breast cancer have an affected
relative, but this does not reliably identify women who are likely to be
carriers of germline alterations [3] . In large families a positive family
history may reflect the high incidence of sporadic disease, and in small
families the absence of family history does not rule out the presence of a
genetic mutation [3]. BRCAI mutations may also be transmitted through
male relatives in a family with no male or female breast cancers being
manifest [4]. Other individuals may exhibit de novo germline mutations and
consequently have no family history of breast cancer [4]. Identification of
BRCAI carriers by family history may also be obscured by incomplete
penetrance of this gene. Lifetime disease penetrance of BRCAI is believed
to be 88 per cent [5). Carriers of BRCAI may not be identified in the
remaining cases, as they will not develop disease, thereby obscuring the
pattern of inheritance.
6.1.3 Genetic risk assessment
Mutations in the BRCAI and BRCA2 genes are inherited in an autosomal
dominant manner. It IS necessary to identify the specific cancer-
predisposing mutation In an affected family member before molecular
genetic testing of either the BRCAI or BRCA2 gene can be used in genetic
counselling and testing of a symptomatic at risk family members. Offspring
of individuals with a BRCAI or BRCA2 mutation have a 50% chance of
inheriting the mutant gene [6). Prenatal testing is possible for foetuses at
50% risk; however, requests for prenatal diagnosis of adult-onset diseases
require careful genetic counselling.
Women who are at increased risk of breast cancer should preferentially
attend a 'high-risk' clinic where facilities for accurate risk estimation,
genetic counselling and testing exist.
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6.1.4 Stratification of fami lies at the risk of breast cancer
Pharaoh et al (1998) have classified families at risk of breast cancer into
three categories (7] . Members of families in the high risk group are
postulated to have a 20% or more chance for development of breast cancer
due to highly penetrant BRCA1 gene. Moderate risk group has chance to
develop breast cancer less than three times to the general population .
Table 6.1 : The criteria for breast cancer risk stratification
(Pharoah et al. 1998)
k-lil!h risk.l!roup I
1. Families with 4 or more breast /ovarian cancer relatives on the
same side of the family affected at any age.
2. Families with three affected breast cancer (only) relatives average
age of diagnosis <40.
3. Families with three breast /ovarian cancer relatives, average age
of breast cancer <60.
4. Families with a member affected of both breast and ovanan
cancer.
1l\1odcratc risk !!rOUD .I
1. Families with a first degree female relative with breast cancer
diagnosed <40 years or first degree male relative with breast
cancer diagnosed at any age, or a first degree paternal female
relative with breast cancer diagnosed <60 years, or
2. With two first or second degree relative with breast cancer
diagnosed <60 years on the same side of the family, or
3. With three first degree relatives with breast cancer at any age on
the same side of the families , or
4. With a first degree relative with bilatera l breast cancer diagnosed
<60 years.
I Lown-sk!!roun I
1. Women with a family history of breast cancer not fulfilling the
above two sets of criteria.
276
Chapter 6- Genetic counselling and Breast Cancer prevention
6.1.5 Estimation of an individual's risk of developing breast
cancer
The risk of an individual to develop breast cancer depends on the
individual's family history and non-genetic risk factors. If the family
history suggests autosomal dominant inheritance of breast or ovarian
cancer risk, consideration is given to the use of BRCAI and/or BRCA2
mutation analysis to evaluate risk status [8, 9, 10]. Such testing should only be
considered after pre-test education and obtaining informed consent.
Methods to estimate an individual's risk for developing breast cancer have
been developed, and studies to estimate the probability that an individual
has a BRCAIIBRCA2 cancer-predisposing mutation have been performed.
Both the risk of developing breast cancer and the probability of having a
BRCAIIBRCA2 cancer-predisposing mutation depends to some extent on
the family history of breast and/or ovarian cancer and by the age of onset
[11, 12, 13].
For instance, the risk of breast cancer for a woman with one first degree
relative affected with ovarian cancer is about 50% versus for a woman
without family history of breast or ovarian cancer, whilst the risk of female
breast cancer with a relative of a male breast cancer patient may increase
approximately by twofold. Mutation screening test may be offered to the
families with small nwnber of breast or ovarian cancer, with at least one
case of ovarian cancer, bilateral breast cancer or a case of breast cancer
diagnosed before age of 40 (14].
Two approaches, one based on mathematical modelling and the second on
genetic testing, are widely used to estimate an individual's risk of
developing breast cancer in order to provide information for affected
women at risk.
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6.1.6 Mathematical models
6.1.6.1 The Clause model
The Claus model uses empiric data from the Cancer and Steroid Hormone
Study and assumes that inherited risk is attributable to an autosomal
dominant gene mutation with high penetrance [11, 13]. The risk estimate is
based on a woman's current age and the number of first and second-degree
relatives with breast cancer and their age of diagnosis. The Claus model
provides the best available estimate of risk based on family history of
breast cancer. The Claus model does not take into consideration any other
factors known to increase breast cancer risk.
Risk assessment models are not suitable for families with distinct major
gene mutation such as mutations in BRCAI or BRCA2 genes. Members of
such families need comprehensive genetic counselling and pedigree
analysis. The risk assessment should be base on their relationship within
the family and the prior probability of carrying the same mutant gene.
6.1.6.2 The Gail model
The Gail model e5] projects individualized probabilities of developing
breast cancer using some of the known non-genetic risk factors as well as
limited family history information. It is based on the major predictors of
risk identified in the Breast Cancer Detection Demonstration Project study:
current age, age at menarche, age at first live birth, number of previous
breast biopsies, presence of atypical hyperplasia, and number of first
degree relatives (mother or sister) with breast cancer [15]. The Gail model
does not consider second-degree relatives, paternal relatives, or ages of
diagnosis of breast cancer. It provides a useful estimate of risk for women
without a family history of breast cancer, but would be expected to
overestimate risk in women whose mothers or sisters had breast cancer
diagnosed at an elderly age and underestimate risk for women who have
second and third degree relatives with early breast cancer.
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The Gail model is the basis for the Breast Cancer Risk Assessment Tool, a
computer program that is available from the National Cancer Institute
(NCI).
6.1.7 Probability of having a BRCAI/BRCA2 mutation
6.1 .7.1 Probability based on personal history of breast cancer
Several studies have looked at the probability of detecting a BRCAI
mutation among women with a personal history of breast cancer,
unselected for family history. In a population-based sample of women in
western Washington State diagnosed with early-onset breast cancer, 6% of
women diagnosed with breast cancer before age 35 years had a BRCAI
mutation, and 7% of women diagnosed before age 45 years and with at
least one first-degree relative with breast cancer had a BRCAI mutation
[16).
6.1.7.2 Probability based on family history
Initial studies estimated that 50% of families with inherited breast cancer
[17) and approximately 750/0 of families with inherited breast and ovarian
cancer had a BRCAI mutation C8) . From initial studies, BRCA2 mutations
were estimated to occur in approximately 15-30% of families with
inherited breast cancer [17) and an unknown proportion of families with
inherited breast and ovarian cancer [18). Subsequent clinical studies have
identified cancer-predisposing mutations less frequently. These differences
may reflect the criteria used to define a high-risk family and the sensitivity
of molecular methods currently available, i.e., even families linked to
BRCA1 or BRCA2 may not be found to have an identifiable mutation.
Subsequent studies have further attempted to determine the probability of a
cancer-predisposing mutation among families with multiple cases of breast
and/or ovarian cancer. In a multi-centre study, women were referred for
BRCAI and BRCA2 mutation analysis if they had been diagnosed with
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breast cancer before the age of 50 years or ovarian cancer at any age and
also had at least one first or second-degree relative with either diagnosis.
Among this selected group, the likelihood of the proband having a BRCAI
or BRCA2 cancer-predisposing mutation was over 50% if she had breast
cancer diagnosed before age 50 years and three or more of the following:
bilateral breast cancer or ovarian cancer, a diagnosis of breast cancer before
age 40 years, a relative with breast cancer diagnosed before age 50 years,
or a relative with ovarian cancer [19].
6.1.8 Probability of developing breast cancerby age for the
several present participants
In this study, due to insufficient participants' pedigree information, risk
calculation of developing breast cancer using different models was not
applicable. However, CancerGene (BRCApro) software version 3.3.2 was
used to calculate the probability of developing breast cancer (BC) for the
several unaffected participants who have strong family history of breast or
ovarian cancer (see pedigree 6.1-6.5).
The CancerGene web address is:
http://www.swmes.edu/home-pages/cancergene/
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1:1
Pedigree 6.1: File record-l04UBF
The pedigree shows a proband
IV:3 who is seeking advice.
Her two sisters IV: 1 and IV: 2
1:2
IV:3
42 yrs
III:2
IV:2
34 yrs
11:3
111:1
IV:1
31 yrs
11:211:1
were diagnosed with breast
cancer at the age of 31 and 34
respectively.
Her paternal grand father and
her cousin II: 1 and 11:2 died
from colon cancer. The figure
below depicts the probability
of development breast cancer
by ages for probands IV: 3.
Remaining Risk
P104UBF
104
50
40
:40
%
20
Claus Family History Model
The Claus ta1Jk used in tAis caU:IlJatjon is:~
tirst-tkg1Yl8Nkuives
29 39 49 59 69 79
IE 62 14B 265 37J 433
Probability of Developing Breast Cancer by A.ae
Age
46
51
56
61
66
71
76
%
4.67
10.01
16.37
22.48
28.24
33.12
36.71
10
As above diagram shows this proband (IV:3) has about 39% per cent risk
of developing breast cancer by age of 79.
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Pedigree 6.2: File record-120UBF
The pedigree shows a proband 111:3
who is seeking advice.
Her mother 11:2 and aunt 11:3 both have
1:1 1:2
II:3
OVCa
II:2
OVCa
11:1
111:1 111:2 111:3
BC at 36 Be at 53 43yrs
been diagnosed with ovarian cancer.
Her two sisters III: 1 and 111:2 was
diagnosed with breast cancer at the age
of 36 and 53 respectively.
The figure below depicts the
probability of development breast
cancer by ages for probands 111:3.
Remaining Risk
P120UBF
120
50
40
30
%
20
Claus Family History Model
The C/o,us tabk used ill this CalcUlatioll is: .&!.
(j1St-degree 1'elames
29 39 49 59 69 79
1.6 5fJ 13.4 239 33.1 399
Probability of Developine; Breast Cancel' by Age
Age
48
53
58
63
68
73
78
0",
4.27
9.73
15.48
20.92
26.29
30.08
33.48
10
• I
~ n ~ ~ ~ n n ~ ~
Age
As above diagram shows this proband (111:3) has about 34% per cent risk
of developing breast cancer by age of 79.
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Pedigree 6.3: File record-134UBF
The pedigree shows a proband 11:3
who is seeking advice.
Her two sisters II:1 and II:2 were
1:1 1:2
11:1 11:2 11:3
make pedigree analysis informative. BC a.t 34 BC a.t 47 37 yrs
The figure below depicts the probability of development breast cancer by
ages for probands II:3.
diagnosed with breast cancer at the
age of34 and 47 respectively.
No more information was available to
Remaininc Risk
P134UBF
134
50
40
30
%
20
Claus Family History Model
The Cltms U1JJl8 used in this caleulation is: Two
fjl'St-d8gree relatives
29 39 49 59 69 79
1D 5D 13.4 23.9 33.7 39.9
Probability of Deveiopinc Breast Cancer by Age
Age
42
47
.52
57
62
67
72
77
%
3.3
7.39
12.34
17.86
23.15
28.3
32.31
35.57
10
As above diagram shows this proband (II:3) has about 37% per cent risk of
developing breast cancer by age of79.
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111:4
41yrs
1:4
70-Utr
11:2
BC-42
1:3
111:3
42 yrs
111:2
44 yrs
1:2
BC-43
1:1
111:1
44 yrs
Pedigree 6.4: File record-146UBF
The pedigree shows a family with
affected twins. Probands III: 3 and
III: 4 are seeking a genetic test. Their
sisters (twin) probands III: 1 and III:
2 who has been diagnosed with
breast cancer at the age of <40. Their
mother proband II: 2 died with breast
cancer at the age of 42 years,
maternal grandmother I: 4 died from
uterine cancer at the age of 70 and
paternal grandmother I: 2 died with
breast cancer at the age of 43 years.
Remaininl Risk
P146UBF
146
50
40
10
%
20
Claus Family History Model
The Claus table used in tAis calculaUon is:~
lirst-tlef(1'INJ ",Jatnes
29 39 49 59 69 79
I fj s.s 13.4 239 33.7 399
Probability of Developine Breast Cancer by Ale
Age
47
52
57
62
67
72
77
%
4.24
9.35
15.06
20.53
25.85
30
33.37
As above diagram shows these probands (III:3 or III:4) has about 35% per
cent risk of developing breast cancer by age of 79.
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11:3
BC at 30
1:2
Be at 90
1:1
11:2
Bila.tera.1 BC at 46
Pedigree 6.5: File record-150UBF
The pedigree shows a proband
III:1 who is seeking advice.
Her mother 11:2 and her aunt both
were diagnosed with breast
cancer at the age of 46 and 30
respectively. Her maternal grand
mother 1:2 died from breast 11:1
cancer at age of90.
The figure below depicts the
probability of development breast
cancer by ages for probands 111:3.
Remaining Risk
P150UBF
150
so
40
30
%
20
Claus Family History Model
The Ckms toJ18"sed in this caJc"latlon is: Mother
and maJ8maJ.second-degree reltW't'e
29 39 49 59 69 19
1.1 5.1 13.1 24.5 34.4 40.1
Probability of Developing Breast Cancel"by Ate
Age
35
40
45
50
55
60
65
70
75
%
2.04
4.49
8.58
12.95
18.47
23.89
28.95
33.64
36.85
As above diagram shows this proband (111:1) has about 40% per cent risk
of developing breast cancer by age of 79.
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6.1.9 Cancer risks associated with mutations in BRCAI and
BRCA2 genes
The penetrance of BRCAI or BRCA2 mutations- or likelihood of cancer
when a cancer-predisposing mutation is present - is the most significant
clinical aspect of BRCAI and BRCA2 mutations. The penetrance is
uncertain and probably variable depending on the population used for
analysis (20. 21, 22). The reasons for differences in penetrance observed
between studies could be methodological (pedigree-based studies by
definition contain many affected individuals), stochastic (due to the play of
chance within families and populations), biological (due to modifying
genes in families with many cases of breast and!or ovarian cancer), or
environmental (due to diet, smoking, and lifestyle).
The accumulated evidence indicates that some individuals with cancer-
predisposing mutations survive to an elderly age without developing
cancer. Among those who develop cancer, the age of onset, as well as the
type of cancer, varies. No clear explanation exists for the observation that
some individuals with a cancer-predisposing mutation may have multiple
primary cancers before age 50 years, while others with the same cancer-
predisposing mutation may not develop cancer until after age 70 years e3,
24). These uncertainties are important to consider in pre-test counselling.
Germline mutations in BRCAI have been identified in 15-20% of women
with a family history of breast cancer and 60-800/0 of women with a family
history of both breast and ovarian cancer [25. 26). Female mutation carriers
have a lifetime breast cancer risk of 60-80% eo, 21), although penetrance
estimates as low as 36% have been reported in a series of Jewish breast
cancer cases selected regardless to family history e2l.
The median age of diagnosis in mutation carriers is 42 years, more
than 20 years earlier than the median for unselected women in the US and
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Western Europe e7] . Lifetime ovarian cancer risks are estimated at 20-
400/0, but, unlike breast cancer, age-specific penetrance is not heavily
skewed toward early onset disease es, 29].
The lifetime breast cancer risk for carriers of BRCA2 mutations also is
estimated to be 60-850/0, and the lifetime ovarian cancer risk is estimated to
be 10-200/0. However, unlike the situation with BRCA1, men with
germline mutations in BRCA2 have an estimated 6% lifetime risk of breast
cancer, representing a 100-fold increase over the male population risk.
6.1.9.1 The cumulative risks of breast cancer conferred by BRCA1
mutations
The initial studies of the penetrance of mutations in the BRCA1 gene
involved BRCAI mutation-positive families ascertained by the presence of
multiple individuals (usually four or more) affected with breast cancer or
ovarian cancer at any age. The cancer risks seen in these families are high
and may over-estimate the risk within all families with BRCA1 mutations.
The estimates of the cumulative risk of breast cancer for women with a
BRCA1 mutation from these high-risk families are summarized in Table
6.2 eo].
Table 6.2: Cumulative risk by age of breast cancer in women from
families with BRCA1 mutations
I Age (Years) I Cumulative Risk
I 30 yrs I 3.2%
I 40yrs I 19.1%
I 50 yrs I 50.8%
I 60yrs I 54.2%
I 70 yrs I 85%
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Male breast cancer is rarely associated with a BRCAI mutation; however,
several families with male breast cancer have shown linkage to the BRCA 1
locus el].
6.1.9.2 The cumulative risks of breast cancer conferred by BRCA2
mutations
Women with BRCA2 mutations appear to have a breast cancer risk similar
to that of women with BRCA1 mutations [31, 32, 33]. Current risk estimates
are based on observations from high-risk families participating in research
studies. The average age at which cancer occurs in women with BRCA2
mutations may be later than for women with BRCAI mutations el , 34]. The
estimates of the cumulative risk of breast cancer for women with a BRCA2
mutation from high-risk families are summarized in Table 6.3.
Male breast cancer has been observed in families with BRCA2 mutations,
including some families with multiple cases of male breast cancer and no
cases of female breast cancer es,36, 37].
Table 6.3: Cumulative risk by age of breast cancer in women from
families with BRCA2 mutations
I
Age (Years) I
Cumulative Risk
I 30 yrs I 4.60/0
I
40yrs I 12%
I
50yrs I 46%
1
60yrs I 610/0
I 70 yrs I 860/0
6.1.9.3 The risks of ovarian cancer conferred by BRCA1 and BRCA2
mutations
Although ovarian cancer represents only 40/0 of women's cancers, it causes
more deaths than any other cancer of the female reproductive system. fS].
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Overall, women have a 1/55 (almost 20/0) chance of developing ovarian
cancer by age 70 [39). However, if a woman carries a BRCAl mutation, the
risk of ovarian cancer is substantially increased: by age 70, the reported
risk of the disease in BRCA1-mutation carriers ranges from 16% to 44%
(40.41),
For BRCA2, family-based studies have estimated a risk of 27% by age 70,
which is lower than risks obtained by comparable analyses for BRCAl (31].
Although a lower ovarian cancer risk for BRCA2 is not supported by the
population-based studies of Ashkenazim, there is evidence that the
prevalent BRCA2 6l74deiT mutation in this population is associated with a
higher risk of ovarian cancer than other BRCA2 mutations (42).
6.1.9.4 The risks of second cancers conferred by BRCA1 and BRCA2
mutations
Even for women who have already had breast cancer, genetic susceptibility
testing may be of value. Women with breast cancer who carry BRCA
mutations are at high risk of second cancers, which may arise in the ovary
or as second breast tumours. For example, if a woman carries a BRCAl
mutation and has had breast cancer, her risk of developing a second breast
cancer has been estimated to be as high as 640/0 by age 70 (40).
Similar figures are not available for BRCA2, but mutations in this gene are
presumed to similarly increase the risk of a second breast cancer.
Women with breast cancer and germline BRCA mutations also are at
increased risk of developing ovarian cancer [42). The risk of these second
cancers may be a reason for considering BRCAI and BRCA2 testing in
women who are diagnosed with breast cancer and whose family history
indicates hereditary breast and ovarian cancer.
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6.1.9.5 The risks of other cancers conferred by BReAl and BRCA2
mutations
Several other cancers are believed to form part of the BRCAI and BRCA2
phenotype. Because so few cases are observed, risk estimates are imprecise
but are clearly much lower than for female breast cancer and ovarian
cancer. Increased risk for prostate and colon cancer have also been
reported, with relative risks of 4.1 and 3.3, respectively [32, 43, 44]. An
increased risk of prostate cancer was reported among carriers who
harbouring 185delAG or 5382insC in BRCAI gene [45].
Mutations in BRCA2 confer an elevated risk of male breast cancer, prostate
cancer, pancreatic cancer, ocular melanoma, thyroid cancer, leukemia, and
gall-bladder cancer [46].
6.1.10 Genetic testing
Following consultation (family history and pedigree analysis), genetic
testing might be offered to the high-risk individuals who seeking advice
individually and to their relatives at risk. In general, families may offered
DNA testing if their breast and/or ovarian cancer incidence suggested a
>10% prior probability of being due to BRCAI mutation [47].
Molecular genetic testing for BRCAI and BRCA2 cancer-predisposing
mutations is now offered both as a clinical service and within research
protocols. The specific DNA-based testing techniques performed by
various laboratories may include: Protein Truncation Testing (PTT), Single
Stranded Conformational Polymorphism (SSCP), complete direct
sequencing, Conformation Sensitive Gel Electrophoresis (CSGE) [48], or a
combination of these and/or other techniques. It is important to note that no
currently available technique can guarantee the identification of all cancer-
predisposing mutations in the BRCAI or BRCA2 genes [31].
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6.1.10.1 Benefits of genetic testing
Since early detection of breast cancer is one of the most significant factors
in determining survival, it becomes extremely important to identify those
. k (13 49] G . . hwomen who are at greater ns ' . enenc testmg can elp a pre-
symptomatic individual from high-risk families to reveal herlhis carrier
status and relieve stress in an uncertain condition. In carriers it may help to
choose an early preventive strategy prior to development of any related
cancer. In affected individual it may effect on treatment strategy.
6.1.10.2 Testing strategy in a family
It is strongly recommended that the genetic test be offered to an affected
individual prior to offering it to at-risk unaffected family members. Testing
an affected individual is the most effective way of determining if a BRCAI
or BRCA2 mutation is causative of breast cancer within a family. After a
cancer-predisposing mutation has been identified in an affected family
member, BRCAI or BRCA2 mutational analysis is more informative for
unaffected relatives.
6.1.10J Pre-test education and counselling
The importance of providing education and obtaining informed consent
prior to performing testing for cancer-predisposing gene mutations has
. al (50 51 52]been emphasized by sever expert groups .. .
Pre-test education for patients includes discussion of the following
suggested components:
• The patient's motivation for requesting testing and preconceived beliefs
about the test
• The patient's perceptions ofhislher risk of developing cancer
• The patient's readiness for testing and optimal timing for testing
• Alternatives to testing, such as DNA banking
• Inability of genetic testing to detect the presence or absence of cancer
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• The patient's and family's support systems, and possible need for
additional psychological support
• The patient's need for privacy and autonomy
• The possible effects of positive, negative, or uninformative test
6.1.10.4 Sensitivity of the test
The sensitivity of tests for detecting BRCAI or BRCAl mutations IS
dependent on the method used for DNA analysis and a prior risk of the
person tested to have a mutation in either gene based on the person's cancer
history, family history, and ethnic background.
6.1.10.5 Interpretation of positive test results for mutations of
uncertain clinical significance
When full gene sequencing is the method used for testing, mutations of
uncertain clinical significance may be identified, such as previously
undescribed missense mutations that are not predicted to result in a loss of
protein function. Such alterations present a dilemma for physicians who are
making patient management decisions. Three methods are available to
determine the clinical significance of these mutations: I) family studies to
determine whether the mutation segregates with cancer in family members
(which is the most practical and clinically useful method); 2) allele
frequency analysis to determine whether the allele has a higher frequency
in cancer patients than in the general population; and 3) protein function
assays to measure the effect of the mutation on the protein [53).
6.1.10.6 Interpretation of negative test results
When a BRCAI or BRCAl mutation cannot be identified in an affected
individual from a family with an increased risk of an inherited
predisposition to breast cancer, negative results are uninformative, and the
possibility of a false negative test must be considered [50]; thus, the affected
individual may still have an inherited cancer-predisposing mutation in the
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BRCAI or BRCA2 gene. She may also have a mutation in some other gene
that predisposes to breast cancer.
If the affected family member has no identifiable BRCAI or BRCA2
mutation or is unavailable for testing, all negative BRCAI and BRCA2 test
results in other family members must be considered uninformative.
An at-risk relative who does not have the BRCAI or BRCA2 mutation
identified in an affected family member is considered to have a true
negative result. It is appropriate to advise the individual that a negative
result does not reduce her cancer risk below that of the general population.
Furthermore, if that person is from a high-risk ethnic group, e.g., of
Ashkenazi Jewish descent, it may be prudent to test for all the cancer-
predisposing mutations known to be common in that population, even if a
single cancer-predisposing mutation has already been identified in an
affected family member.
6.1.11 Patient decision making
Patient decision making about genetic testing and how to use such
information is not a simple process. Even when a positive result (i.e., a
deleterious mutation) is identified, the associated cancer risks cannot be
precisely quantified and the efficacy of management options is still very
uncertain. When a negative result is obtained, it could be good news or
completely ambiguous and raise more questions than it answers.
Addressing this issue is especially important because a significant
proportion of high-risk families do not harbour deleterious mutations in
BRCAI or BRCA2 (31). Thus even though interpretation of BRCAl/2
results is relatively straightforward in many circumstances, complex cases
are not infrequently encountered in the clinical setting. In such instances,
alternative explanations for test results need to be considered, additional
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• Mammograms can detect cancer up to two years before a lump can be
felt by a manual exam.
• Mammography and breast self-exam guidelines could reduce deaths
from breast cancer in women over age 50 by as much as 35 per cent,
and in women in their 40s by 17 per cent.
• Regular screening mammograms every one to two years if you are age
40 or over.
• Education for monthly breast self-examination.
Mammography in younger women is less accurate. It usually reveals only
dense breast tissue that may mask an underlying tumour.
Mammography is more accurate in women over 50 whose glandular breast
tissue has become atrophic. As women age, glandular tissue disappears,
becomes atrophic and is replaced by fat.
In UK, the national breast-screening programme offers mammographic
screening every three years for women between the ages 50 and 64. The
compound data analysis proved that regular mammography might decline
mortality rate of breast cancer by 30%-40% result in early detection [49.56,
57]. However, Fletcher et al (1993) reported that there was no benefit of
mammography for women under the age 50 years. In contrast, the
American Cancer society, recommended mammography for women at the
age of 40-49 years [58]. Extending screening to cover women aged 40-49
years remains controversial, since the cost effectiveness of this plan is
almost five times that in older women [59). As about 5% of women who
screened reveal abnormal mammogram, 100/0-20% of which proved to had
cancer. In total, it is not agreeable to offer mammography to all women
with positive family history ofbreast cancer.
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6.2.3 Prophylactic surgery
Inherited mutations in the BRCAl and BRCAl genes predispose women to
both breast and ovarian cancers, often at young ages. Furthermore, women
with breast cancer who carry a BRCAl or BRCAl mutation develop
second contralateral breast cancers and ovarian cancers at higher rates than
do women with breast cancer who lack a germline BRCAl/2 mutation. For
young women with breast cancer and high-penetrance BRCAl/2 mutations,
the lifetime probability of developing a contralateral breast cancer may be
as high as 650/0, and the probability of developing ovarian cancer may
exceed 400/0 [28.31). In comparison, young women with breast cancer who
lack these mutations face approximate lifetime risks of 10% for
contralateral breast cancer and 2% for ovarian cancer [60. 61. 62].
While intensified screening may identify cancers at a favourable stage, it
cannot prevent them. Therefore, women with BRCAl/2 mutation-
associated breast cancer may consider prevention strategies such as
tamoxifen, prophylactic contralateral mastectomy (PCM), or prophylactic
oophorectomy (PO) to reduce their risk for second cancers. Although the
efficacy of these approaches for BRCAl/2 mutation carriers is not certain,
interim estimates can be extrapolated from studies of women at high risk
for breast and ovarian malignancy. These data suggest that PCM may
reduce breast cancer risk by 90% [63], PO may substantially reduce ovarian
cancer risk [64], and 5 years of tamoxifen use may decrease contralateral
breast cancer risk by 47% [65].
However, complete prevention of breast cancer seems to be a difficult task,
as development of carcinoma in the residual breast tissue after prophylactic
mastectomy has been widely reported.
There is insufficient evidence for or against prophylactic oophorectomy as
a measure for reducing ovarian cancer risk among BRCA mutation carriers.
Women with BRCAl mutations should be counselled that this is an option
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available to them. The uncertainty of current methods for detecting early
ovarian cancer, and the high mortality rate associated with this cancer, has
been cited as reasons to consider prophylactic oophorectomy [66).
In conclusion, neither prophylactic mastectomy nor prophylactic
oophorectomy provides complete protection against the subsequent
development of malignant disease and so ongoing surveillance is still
required. Obviously, women should be extensively counselled about the
matters before any prophylactic surgery [67).
6.2.4 Chemoprevention
The option of chemoprevention of breast cancer in gene carriers has been
proposed as an alternative to prophylactic surgery. Potential primary
prevention medications, such as tamoxifen [68) and raloxifene [69), reduce
breast cancer risk. For women who have already had one primary breast
cancer, the risk of a second primary tumour in the contralateral breast is
reduced by as much as 40-47 per cent by adjuvant tamoxifen [65. 70].
6.2.5 Lifes~le factors
Numerous studies have identified potentially modifiable non-genetic risk
factors for breast and ovarian cancer, including reproductive factors, high
levels of dietary fat, high alcohol consumption, low antioxidant vitamin
intake, excessive radiation exposure and decreased physical activity [71).
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7 District Health System in LR. Iran
7.1 Introduction
The Islamic Republic of Iran with an area of 1,648,000 sq. Ian has located
in the Middle East area. Tajikistan, Turkmenistan, Azerbaijan and Armenia
border it in the north, Afghanistan and Pakistan in the east, and Turkey and
Iraq in the west. It has access to the Caspian Sea in the north and the
Persian Gulf and the Oman Sea in the south, place Iran in very important
geopolitical area among other Asian countries (Figure 7.1).
More than half of the country is covered by mountains, one-quarter by
deserts and less than one-quarter in under cultivation. The country is
divided into 30 provinces, 260 districts and more than 66000 villages.
Tehran is a growing capital city with a population of7.5 million.
According to the latest census, conducted in 1996, the population of Iran
is about 62 million of which 62% are settled in urban areas and 380/0 in
rural communities. 42% of the population are under 15 years old and
about 4% are above 65 years old or more [1].
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"The Health House" is the most peripheral rural facility in the "Health
Network", covering an average of 1500 population. Usually a male and a
female named Behvarz are selected from among the young and interested
natives and are trained in a "Behvarz Training Centre", which is
supervised by the "District Health Centre". The training course in this
boarding school lasts two years. The main duty of Behvarz is the
provision of PHC services to a well-defined rural population. Behvarzes,
in collaboration with the Community and the other Public Sectors, identify
the target population including mothers, children, students, workers, and
eligible females for Family Planning Programmes and then provide them
the PHC services. In case of necessity, Behvarzes meet the first needs of
the patients and refer them to the "Rural Health Centre". The "Rural
Health Centre" is a village-based facility, covering approximately six
"Health Houses". It is staffed by a physician, several health technicians
and administrative personnel, who work under the physician's leadership.
The "Rural Health Centre" accepts referral patients from "Health
Houses" and provide them with more specified services. At present nearly
16000 "Health Houses" and 2600 "Rural Health Centres" provide about
900/0 of rural inhabitants with PHC services. The private sector is not
active in the rural areas.
"Health Post" and "Urban Health Centre" provide the urban
population with the PHC and out patient services. There are about 360
"Health Posts" and 1800 "Urban Health Centres". Each centre covers a
population of 12500. "Women Health Volunteers" (WHVs) by providing
the urban population with PHC services activate the role of "Health
Posts" and "Urban Health Centres". The private sector is also very active
in providing the urban community with the out patient services. Therefore
100% of urban inhabitants have access to PHC services.
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"District Health Centre" and "Provincial Health Centre" are
responsible for the management of the related units in district and
provincial level respectively.
Education and research departments in the university use the Health Unit
and community for the purposes of medical education and health
researchers.
7.2.1 Primary Health Care and "Community Participation"
By initiating the "Women Health Volunteers" (WHVs) project in Tehran
in 1990, the most significant form of "Urban Community Participation" in
PHC activities has been manifested. It was attempted to motivate the
women from the target communities to activate the role of the Health
Centres in providing PHC services to the population of those urban
communities.
Each WHV is in charge of 50 households and has regular contacted with
the "Urban Health Post" or "Urban Health Centre". The training modules
for WHVs, prepared by the Government with support of UNICEF, provide
them with proper knowledge to present identified services to their under
coverage households.
At the present time, there are 40000 WHVs in the urban areas covering 9
million inhabitants (25% of urban population) el.
7.2.2 Primary Health Care and "University"
In 1986, the management of the "University of Medical Sciences"
integrated with those of "Health Providing Units". This integration presents
the knowledge and the experiences of health system managers, health
personnel and academician to the other health sectors.
Diagram 7.1 shows a referral pathway system within DHS governs by the
University of Medical Sciences.
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7.3 History of cancer registration in Iran
Cancer registration activity dates back to 1968 when the first cancer
registration program was launched as a collaborative research agreement
between the International Agency on Cancer Research (IARC) and the
Institute for Health Studies affiliated to the Tehran University School of
Public Health Tehran-Iran, in order to study the high incidence rate of
oesophageal cancer in the province of Mazandaran-Iran [4]. Activity ceased
in early 1980 and then in 1991, the registry started again to collect data on
cancer cases referred to local cancer treatment facilities. In 1993, the
Cancer Institute affiliated to Tehran University of Medical Sciences with a
grant from Ministry of Health and medical Education initiated a cancer
registry program, to assist public health authorities in different regions of
the country to establish regional population based cancer registries [5].
At the present time three registries cover defined populations; 1) Tehran
metropolitan area cancer registry which covers a population of 6,000,000
people residing in 22 municipal districts of Tehran municipality, 2)
Mazanderan registry which covers a population of 2,600,000 residing in
Mazanderan province, and 3) Fars registry that covers a population of
3,100,000 residing in Fars province [6].
7.4 Current knowledge of the prevalence and incidence rate
of breast cancer in Iran
While breast cancer is one of the biggest health problems worldwide, the
prevalence and the incidence may differ from country to country. However,
the incidence of breast cancer is much higher in developed countries than
in less developed countries (Table 7.2) [']. Oesophageal cancer is the most
common cancer in Iran whereas breast cancer is the most common cancer
in the world [6] (Tables 7.2-7.6). One of the most important factors, which
might have influence on this, is the number of unregistered cases of breast
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cancer m the less developed countries. However, breast cancer is a
multifactorial disease and results from genetic and environmental
influences.
The prevalence and incidence rate of breast cancer in Iran have been
reported by different sources, Centre for Disease Control (CDC)-Iranian
Ministry of Health [8], the Cancer Institute affiliated to Tehran University
of Medical Sciences, Tehran-Iran) [6] and the IARC [9] but it does not
necessarily reflect the current picture of the breast cancer in Iran. Indeed,
there are some differences between these reports (Table 7.1).
The !ARC data for cancer in Iran were estimated using the approximate
incidence of cancer at all sites, from cancer registries in the same region,
together with some old data - 20 years old - on the frequency of cancers at
different sites, from hospitals in Tehran and elsewhere.
Recent relative frequency data show that breast cancer constitutes 20% of
cancers among Iranian women [5, 10, 11). Breast cancer has a uniform
geographic distribution in Iran, a higher incidence is seen where
urbanization has grown faster [6). A preliminary study has shown no
significant differences in trend of age-specific incidences among Iranian
women with breast cancer in compare with UK [6, 12) (Figure 7.2 and Table
7.2).
Infiltrating ductal carcmoma IS the most frequent (more than 60%)
histological type in Iran [5, 10, 11). A preliminary analysis of survival data
1023 cases of primary breast cancer referred to the Tehran Cancer Institute
from 1990 has shown a median survival time of 75 months and five years
survival rate of more than 60% [13).
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Table 7.1 The new cases and incidence rate of female breast
cancer in Iran from different sources of data
New Incidence rate *Source
cases Crude ASR(W)
Iranian Ministry of Health 928 3.14(CDC)- 1996 ---
Local researcher -2000 2943 8.0 12.3
IARC-2001 3491 10.46 14.76
\51) The column marked WIth • show the incidence rate (per 10 persons) of
female breast cancer whilst another depicts the number ofnew cases.
2) Adapted from GLOBACAN 2000: Cancer Incidence, Mortality and
Prevalence Worldwide, Ver. 1.0. IARC CancerBase No.5. Lyon, IARC
Press. 2001.
Table 7.1 shows the different figures for the incidence rate of breast cancer
from different sources. CDC has been noted (1996); breast cancer
incidence is achieved among 11025 new cases of cancer, which were
estimated from 1/5 of expected data. However, these numbers have been
estimated in different periods. It seems more studies are required to
produce accurate estimates.
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Table 7.2 A distribution of estimated age-specific incidence rates of female breast cancer compared in
Iran and UK
Age-specific distribution Near
Country o- s- lO- IS- 20- 25- 30- 35- 40- 45- 50- 60- 65- 70- 75- 80- +80
Incidence rate 1r
Iran* 0 0 0 0 1 4 17 14 22 35 34 41 41 29 23 • •
UK~ 0 0 0 0 2 12 26 59 105 164 272 283 264 264 314 314 405
~ For cancer, the incidence rate is usually expressed as an annual rate per 100,000 persons at risk.
* Age-specific distribution incidence rate from ref. 7
.There are no data available for this period ofage.
~ Adapted from UK National Statistics web site at http://www.statistics.gov.uk/ (based on data from 1999, reviewed in
March 2002)
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Table 7.3: The new cases and incidence rate of four common female cancers in Iran compared to other countries
New Incidence New Incidence New Incidence New Incidence
cases rate * cases rate * cases rate * cases rate *
Region 0
~ :> :> :> :>In Cervix0 o c.n n c.n o c.n Stomach n c.n"go 2 ~ Breast 2 ~ uteri 2 ~ 2 ~~ ft ~ ft ~ ft ~ Q.. ~~
Islamic R. of Iran 4451 13.34 21.19 3491 10.46 14.76 2059 6.17 8.98 1312 3.94 6.27
UnitedKingdom 2800 9.35 4.25 34815 116.27 74.93 3537 11.81 9.34 3579 11.9 65.5
Less developed countries 117092 4.89 6.16 471063 19.66 23.07 379153 15.83 18.73 192850 8.05 9.97
More developed countries 16253 2.66 1.34 579285 94.93 63.22 91451 14.99 11.35 125029 20.49 10.96
World 133342 4.44 4.45 1050346 34.94 35.66 470606 15.66 16.12 317883 10.58 10.38
1) The columns marked with • show the incidence or mortality rate (per 10;> persons) of different types of cancers whilst others depict the number of
new cases.
2) Adapted from GLOBACAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Ver. 1.0. , IARC Cancer Base NO.5. , Lyon, IARC
Press. 2001.
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Table 7.3: Shows the incidence rate of four common female cancers in
order of incidence preferences in Iran and other countries. The oesophageal
cancer is the most common female malignancy in Iran (it is even much
higher if it is account for both sexes) whilst in UK the incidence of breast
cancer is twelve fold higher than oesophageal cancer (crude rate=II6.27 vs
9.35 respectively).
However, in general, breast cancer is the most common malignancy
worldwide (See also chapter 1 Figure 1.11).
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Tables 7.4 - 7.6 compare the incidence and the mortality rate of six
common female cancers in Iran, UK and world.
The oesophageal cancer is the most common female malignancy in Iran;
the incidence and mortality rates reach to 1.3 and 2.5 fold respectively than
breast cancer.
In UK the incidence rate of breast cancer 12 fold higher than oesophageal
cancer (crude rate=116.27 vs 9.35) and its mortality rate rise to 5.5 fold,
whilst colorectal cancer is the second common cancer in British female.
The incidence rate of breast cancer is 2.4 fold higher than colorectal cancer
and their mortality rates are relatively equal worldwide. Therefore,
oesophageal cancer is not a common malignancy.
324


Chapter 7-National Health System in I.R. of Iran
Table 7.7 and figure 7.3 reveal the incidence and the mortality rate of
female breast cancer in Iran and other countries compared. UK has the
highest and Iran has the lowest incidence and mortality rates of breast
cancer among these regions even when those compare with more develop
or less develop countries respectively.
Whether development status influences the incidence and/or mortality rate
of breast cancer in these regions is clearly an area for investigation.
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As can be seen in Table 7.8 and Figure 7.4, UK has the highest incidence
and the mortality rate (crude rates) of female malignancy in the regions
compared. Since in most other countries of the developing world, Iran
possess a conspicuously "young" population, with over 42% of the
population under the age of 15 with about 40/0 above 65 years old or more,
these rates have been estimated to be lower in Iran than in other regions,
although these figures seem to be dominated by age distribution (Age
pyramid) in these regions.
7.5 Breast cancer policy
Taking all these figures together, what is the most appropriate health
policy for breast cancer screening in Iran?
In the first step, any given country should make a decision individually
based on their own criteria such as female age distribution, socio-
economic circumstances, culture and religion, priority of public health
services including common cancers and common diseases, geographical
situation, resources (personnel, finance, logistics, knowledge, etc),
availability of technology and finally political conditions.
The government plays a basic leadership role in such national
programmes and their support is an absolute necessity. Community
leaders/organisations, media (TV, newspapers), schools and universities
should also be encouraged to participate.
An understanding of the prevalence and incidence rate of breast cancer is
a critical point. In order to obtain an accurate picture of the prevalence and
incidence rate of breast cancer in Iran, cancer registration as part of a
national health programme should be carry out more vigorously.
It would be necessary for three main groups to participate in such a cancer
registry: Behvarz (in rural areas), Women Health Volunteers (in urban
areas) and physicians (General Practitioner, Gynaecologist, General
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Surgeon, Oncologist and Pathologist) throughout the country. Other
people such as health technicians and nurse-specialists might also
participate indirectly. I believe that registration data could lead to the
establishment of an appropriate strategy for cancer screening at the lower
cost and lead to a reduction in the mortality and the morbidity of the
breast cancer in the long term.
At the present time, Iran possesses numbers of knowledgeable and
dedicated physicians and excellent District Health System. Based on the
latest official information, about 10732 General Practitioner (GP), 1060
Gynaecologist, 967 General Surgeon are working in the public health
services (Ministry of Health) throughout the Iran those might participate
in a breast cancer screening programme, services and treatment by any
means (14). Equal numbers of these groups of physicians work for the
private sector; however, the private sector might not be interested to
participate in cancer studies. With such this picture the Ministry of Health
should govern all cancer studies particularly a breast cancer screening
programme. It seems with close collaboration of twelve main universities
(Three in Capital, Mashhad, Esfahan, Shiraz, Tabriz, Ahvaz, Yazd,
Kermanshah, Bandar-e-Abbas, Zahedan) located across the Iran (See
figure 7.1) a cancer campaign, initially by cancer registry, can be
deployed effectively in Iran.
It should be noted that, the population of Iran (62 million in 1996) is
expected to increase rapidly, 42% of the population are less than 15 years
old and only 40/0 are older than 65 years old. The Annual Growth Rate
(AGR) was 1.4 in 1996 [1), which will result in around 17 million Iranian
women being placed at risk of breast cancer. If one assumes that a
woman's lifetime risk for breast cancer is 10 per cent on average, then
around one and half (1.5) million Iranian women will develop breast
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cancer In their lifetime. Although Oesophageal cancer is the most
common cancer in Iran, breast cancer is sufficiently common to be
considered as a main health problem for women.
The distribution of estimated age-specific incidence rates of breast cancer
among Iranian women is almost similar to UK, up to the age of 70 years,
[6. 12) however, it is increased markedly over the age of 70 for UK and
decreased sharply among Iranian women. This might be dominated by
pyramidal age distribution and/or unregistered cases of Iranian women.
Unregistered cases could be resulted in non-attending of elderly patients
in clinic due to social, physical and cultural difficulties particularly in
rural areas.
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7.6 Glossary:
European and World standard population by age:
An age-standardised rate (ASR) is a summary measure of a rate that a
population would have if it had a standard age structure. Standardisation is
necessary when comparing several populations that differ with respect to
age, because age has such a powerful influence on the risk of cancer. The
most frequently used standard populations are the world and the European
standard populations. The calculated incidence or mortality rate is then
called the World age standardised or European age standardised incidence
or mortality rate. They are expressed as a rate per 100000 (Table 7.9).
Cumulative Rate:
Cumulative incidence is the probability or risk of individuals getting the
disease during a specified period. For cancer, it is expressed as the number
of newborn children (out of 100, or 1000) who would be expected to
develop a particular cancer before the age of 65 (or 70, or 75) if they had
the rates of cancer currently observed. Like the age-standardized rate, it
permits comparisons between populations of different age structures.
Population at risk:
The part of a population that is susceptible to have a specific cancer. It is
defined on the basis of demographic data, such as place of residence, sex,
age group, etc.
Crude Rate:
Data on incidence or mortality are often presented as rates. For a specific
tumour and population, a crude rate is calculated simply by dividing the
number of new cancers or cancer deaths observed during a given time
period by the corresponding number of people in the population at risk. For
cancer, the result is usually expressed as an annual rate per 100,000 persons
at risk.
Prevalence:
The prevalence of cancer is the number of cancer cases in a given
population at a specified point in time. It depends on the incidence and on
the duration of the disease, that is, on survival.
Incidence:
The incidence is the number of new cancer cases arising in a given period
in a specified population. Cancer registries collect this information
routinely.
333
Chapter 7-National Health System in I.R. of Iran
Mortality:
The mortality is the number of cancer deaths occurring in a given period in
a specified population.
Table 7.9: European and World standard population by age
(After Doll et al., 1966)
Age group European standard World standardpopulation population
0-4 8000 12000
5-9 7000 10000
10-14 7000 9000
15-19 7000 9000
20-24 7000 8000
25-29 7000 8000
30-34 7000 6000
35-39 7000 6000
40-44 7000 6000
45-49 7000 6000
50-54 7000 5000
55-59 6000 4000
60-64 5000 4000
65-69 4000 3000
70-74 3000 2000
75-79 2000 1000
80-84 1000 500
85+ 1000 500
Total 100000 100000
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Chapter 8
8 Discussion and Conclusion
8.1 General Discussion
Breast cancer results from genetic and environmental factors leading to the
accumulation of mutations in essential genes. Genetic predisposition may
have a strong, almost singular effect, as with BRCA1 and BRCA2, or may
represent the cumulative effects of multiple low-penetrance susceptibility
genes.
During the last decade has seen many important advances in understanding
genetic susceptibility to breast cancer, there remains much to learn [1.2].
Unanswered questions include the number and nature of genetic variants
that predispose women to breast cancer, the interplay between those
variants and environmental factors, and the optimal use of that information
to reduce both the personal and social costs of breast cancer.
The ultimate aim of all these efforts is to diminish the mortality and
morbidity of breast cancer. In achieving to this aim, most of the studies
have been focused on specific aspects of the breast cancer such as
epidemiological studies (to investigate factors those might involve In
developing of breast cancer), molecular studies (to understand functions of
cancer predisposing genes with a view deeply that lead to designing
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suitable therapeutic drugs), methods and technical development (to
investigate high risk individuals at early stages of breast cancer
development by developing mutation detection methods and making
improvements in medical imaging instruments and techniques) and fmally
studies on cost-effectiveness ofbreast cancer screening in public services.
8.1.1 Clinical point of view
The identification of BRCAI (Miki et al, 1994) and BRCA2 (Wooster et aI,
1995) were landmarks in the investigation of the genetics of breast cancer.
Even before the genes were identified, it was clear that management issues
following on from gene identification would need to be addressed quickly
if the impetus gained from these discoveries was not to be lost. So what are
the keys questions facing clinicians who care for women with BRCA
mutations? One is that of penetrance-that is, what is the likelihood that a
carrier of a mutated allele of a breast-cancer-susceptibility gene will
develop breast cancer by a given age? The next important question is, when
advising individuals at risk, whether counsellors should give more weight
to the mutation itself (the gene affected and the type of mutation), the
position of the mutation along the gene, or the family history? A third
question is whether the prognosis of BRCAI-related breast cancer differs
from that of BRCAI-negative breast cancer. Finally, and most importantly,
there is the question of the choice of medical and surgical preventive
measures.
8.1.2 Penetrance
(Which mutations have a higher penetrance?)
Several population-based studies have demonstrated differences in the
penetrance of BRCA genes (3,4, 5). Thus, efforts are underway to identify
additional high- and low-penetrance genes. Although, it is unlikely that the
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final list of breast-cancer-susceptibility alleles will be divided into high-
and low-penetrance genes, and will more likely represent a spectrum of
penetrance with each modified by multiple gene-gene and gene-
environment interactions. It is now apparent that most familial breast
cancer risk is not accounted for by mutations in the high-penetrance
susceptibility genes BRCAI and BRCAl.
8.1.3 Prevalence and incidence
Breast cancer is the most common cancer in UK and is the most common
female malignancy worldwide. However, according to the latest data from
Iran, oesophageal cancer obtaining the highest incidence rate of cancer
among Iranian population (see chapter seven in great detail). One should
consider a priority of cancer research within a given population or country.
Attempts are now making to address why the prevalence and incidence rate
of breast cancer is much higher in developed countries than undeveloped
countries? Is it due to social and cultural, diet, geographical condition, life
style effects, and efficient cancer registry system and/or resulted in
unknown modifier genes?
8.1.4 Screening pitfalls
• Clinical: Self Breast-Examination (SBE) is the best method for large
scale screening programme either individually or by an expert physician
(every six months) and is highly cost effective but it has yet to be
accepted widely by the general public. The key step here to overcome
such attitudes is education.
• Radiological: Advanced technology such as MRI, which is much more
sensitive than mammography, is too expensive to be affordable in public
services. Of the women screened by mammography, about 10% of the x-
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ray Images record something suspicious, which requires further
investigation. However only a small number of those cases will be
cancerous. Mammography therefore seems not to be sufficiently
sensitive and informative to be used in large-scale screening.
• Molecular: At the present time, despite of the considerable efforts to
develop more sensitive new methods for screening BRCA genes, there is
still no currently available technique that can guarantee the identification
of all cancer-predisposing mutations. All routine diagnostic methods
such as Direct Nucleotide Sequencing, PTT, SSCP, HA, DGGE,
DHPLC, etc suffer two limitations:
1) They are quite laborious and expensive for use in a diagnostic services,
which needs to produce answers quickly and within a modest budget.
2) They detect differences between the patient's sequence and the
published normal sequence but they do not generally distinguish between
pathogenic and non-pathogenic changes.
On the other hand it is nevertheless clear that molecular methods should
form part of any population-screening program. How this is integrated with
conventional methods of clinical investigation requires open debate.
8.1.5 Interpretation of test result
(What distinguishes those who develop cancer from those who do not?)
Since the cloning of BRCAI and BRCAl, genetic testing for breast and
ovarian cancer susceptibility has become more widespread. However,
interpretation of test results is not always straightforward. In many high-
risk families, a deleterious mutation in BReAI or BReA2 is not identified
in an affected proband. Even when a positive result (i.e., a deleterious
mutation) is identified, the associated cancer risks cannot be precisely
quantified and the efficacy of management options is still very uncertain.
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When a negative result is obtained, it could be good news (in the case of a
true negative for a familial mutation), or a negative result could be
completely ambiguous and raise more questions than it answers. There are
several potential explanations for such a finding, namely that an undetected
mutation in BReAI or BRCAl may exist, or there could be a mutation in a
rare or undiscovered gene. In addition, the possibility that women with
breast cancer represent sporadic cases within hereditary cancer families
must also be considered. The occurrence of BRCAl/2 variants of uncertain
significance, often missense mutations, further complicates the risk
assessment. Addressing this issue is especially important because a
significant proportion of high-risk families do not harbour deleterious
mutations in BRCA1 or BRCAl.
In some of these instances, extending testing to relatives can be helpful to
clarify results. When hereditary breast cancer cannot be ruled out,
individuals may still be at increased risk for cancer and therefore need to
obtain appropriate surveillance.
The management of known carriers of breast cancer susceptibility genes
remains controversial. Options include prophylaxis against the
development of breast and/or ovarian cancer, by prophylactic mastectomy,
prophylactic oophorectomy and/or using Tamoxifen for five years, or
careful follow-up with screening for overt disease. Offering any
preventional strategies should absolutely consider age, religion, social and
culture of carries as well as benefit of that. Therefore, balanced information
that includes estimates of the magnitude of survival benefit from these
interventions as well as their potentially adverse effects on quality of life
should be discussed with patients, especially those who are young and have
good prognoses. It must be considered "what the preventional
strategies should be to cover both breast and ovarian cancer?"
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8.1.6 When does cancer develop in breast cancer predisposing
gene carriers?
Many recent studies have shown that the penetrance of BRCAI or BRCAl
mutations is uncertain and probably variable and the prevalence of BRCA I
mutations in the general population is estimated to be between 11500 and
1/1000 (6). Segregation analyses have estimated that about I in 20 women
with breast cancer are carriers of a breast cancer predisposing gene that is
dominantly inherited and highly penetrant. A carrier with a deleterious
mutation in BRCA1 or BRCA2 gene has 80%-90% chance of developing
breast cancer 1'). Assessing of all proband information genetic testing
should be able to predict, not just whether a woman is likely to develop
breast cancer, but when she might get it [8, 9] (See chapter 6 section 6.1.9).
This is the most significant question that should be considered before
genetic counselling and/or testing.
8.1.7 Uncertainty of prognosis
What is the difference of prognosis in carriers and control cases?
Accurate estimates of breast cancer prognosis in individuals with BRCAI
and/or BRCA2 mutations would require prospective longitudinal studies
with large numbers of women. Such studies have yet to be reported.
Most studies on the prognosis of breast cancer have not found a significant
difference in survival between individuals with BRCAI or BRCA2
. d I [10 11, 12 13 14) b nflimutations an contro s r:' " ut co ictmg reports of both better
[15,16) and worse [17, 18) prognoses exist.
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8.2 Technical Discussion
8.2.1 Data collection
One of the most important steps in any research project is data collection,
depending on significance of project's aims. For such a this study, as a PhD
course, which was performed for the first time on this selected group, data
gathering was not a easy task mostly because of time constraint and modest
budget.
Over a period of three months agreements were obtained from two main
centres for cancer research and treatment in Tehran-Iran to establish
collaboration on this study. This was followed by recruiting relevant three
employees for initial jobs, reviewing more than four thousands files to
invite appropriate participants for collection of their relevant personal and
medical information, informing attendants and obtaining their consent and
their blood samples, setting up laboratory equipments and reagents for
DNA extraction. Finally the genomic DNA and other data from more than
one hundred participants were brought to the UK for further analysis.
Additional attempts have been made to collect formal information from the
Iranian Ministry of Health to evaluate the capacity of the Iranian District
Health System for integration of breast cancer screening programme.
8.2.2 Mutation detection methods pitfalls
The advantages and disadvantages of each method those used in this study
have been discussed in the relevant chapters in detail. What I would like to
discuss here is, the cost effectiveness of molecular diagnostic approaches
versus clinical and medical imaging diagnostic methods in breast cancer
screening programme.
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Although new mutation detection techniques have resolved diagnostic
problems for some genetic disorders, breast cancer diagnosis remains
problematic. The following questions still remain unanswered.
I) How many per cent genetic factors contribute to the development of all
types of breast cancer?
2) Would it (detection methods) be readily available (instrumental,
technicians, reagents) in most genetic laboratories worldwide?
3) Would these methods detect all sequence variants in known predisposing
breast cancer genes accurately?
4) Would it be affordable in the public health services? Ifnot, who will pay
for?
Let us assume that there are only two known genes (BRCAI and BRCA2)
that contribute to the development of familial or hereditary breast cancer.
Myriad Genetic Laboratories, Inc. offer BRACAnalysis® to international
customers for $2580 (BRCAI only $1290, BRCA2 only $1555, Single
Amplicon Testing $295). Now a question arises, at the time of offering
BRCA genes analysis by private sectors, how many genetic laboratories are
available to scan guaranteed these genes worldwide?
With such above costs, how many per cent of high-risk families do afford
to take this test?
Answer to the above questions might help to make an informed decision
regarding public breast cancer screening strategies. In my knowledge no
currently available molecular scanning methods is cost effective in offering
diagnostic information to high-risk individuals in the public health services.
However, molecular diagnostic approaches once fully developed might be
applied in hereditary breast cancer for prenatal diagnosis.
Alongside the developmental of mutation detection methods in the last
decade, significant advances have been seen in medical imaging
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technologies. Magnetic resonance imaging (MRI), sonography, digital
mammography and etc are now used in breast cancer screening but all have
both advantages and disadvantages.
Mammography is not sufficient sensitive to detect cancerous from normal
breast tissue in women at age of 20-25 years because of high density
pattern of normal breast tissue in this stage. Further investigation of a
problem detected at the screening stage has involved the patient being
referred for an ultrasound scan to help clarify whether or not their 'lump' is
malignant. More recently scientists at The Institute of Cancer Research
(UK) have developed a modified ultrasound system known as freehand
elastography for diagnosis of breast cancer. The new technique is expected
to differentiate more accurately between benign and malignant tumours and
avoid the need for more invasive procedures such as biopsy.
The new system creates images using information from tissue stiffness, the
same property that gives rise to the sensation of a hard lump found within
suspicious breast tissue when it is felt with the fingers. It is achieved
through a computer process in which images are recorded while the breast
is pressed gently by a hand-held ultrasound probe. Freehand elastography
in conjunction with conventional ultrasound scanning might improve
accuracy of diagnosis and used as a conventional ultrasound equipment
thus minimising costs to public hospitals. It is hoped medical imaging will
form a fundamental part of the diagnosis and treatment ofbreast cancer.
No one approach provides comprehensive breast cancer screening; several
approaches (Clinical, Technological and Molecular) should be deployed
continuously.
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8.3 Conclusion
~To date, gennline mutations in the BRCAI and BRCA2 genes in patients
with early-onset breast and/or ovarian cancer have not been identified
within the Iranian population, so that there are no published data of the
mutation spectrum in this selected group. Although only ten mutations have
been detected (See chapter 3 Table 3.4 and chapter 4 Table 4.5) in one
hundred and four participants tested, some circumstances may have
contributed to this outcome.
Firstly, this number (104 participants) included sixteen unaffected
individuals who were screened and no sequence variant has been detected
among them.
Secondly, I have only analysed hot spot regions for mutations in both
BRCA1 and BRCA2 genes not the entire coding regions. Comparison of
data from other studies suggests that, using this strategy (analysing selected
coding regions) approximately 14% and 22% of mutations in BRCA1 and
BRCAl gene respectively would be missed e9, 20, 21, 22, 23]. However, there
are no data to indicate the presence of population-specific mutations in
Iran, and therefore, these data must be considered preliminary.
Thirdly, genomic DNA has only been analysed for coding regions variants,
mutations in the promoter regions and those within the introns would have
been missed and analysis of cDNA may uncover other alterations.
Finally, SSCP is known to be insufficiently sensitive for the detection of all
sequence variants.
~The 185deiAG BRCA1 germline mutation has been reported in
Ashkenazi Jewish individuals both in familial breast and ovarian cancer
. th rat ulati t nl [24 25 26)and In e gene pop anon mos commo y , , . Moreover, other
Jews and non-Jews population studied showed the same mutation e7, 28, 29).
Sporadic cases of the 185delAG BRCAI germline mutation in Jewish non-
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Ashkenazi breast/ovarian cancer families have previously been reported
(JO).
In this preliminary study 185delAG BRCAI germline mutation was
identified once in an Iranian non-Jewish breast cancer family, none of the
participants tested in this study was Jewish in origin. However, this
particular mutation has previously been detected in one Iranian Jewish
individual diagnosed with breast cancer e7] . Further study such as
haplotype analysis may require for originating this particular mutation
within Iranian population.
~ It has been shown that the histological characteristics of breast cancers
due to BRCA 1 and BRCA2 mutations differ from those of sporadic breast
cancers (31). Several studies shown that invasive ductal carcinoma is the
most frequent (more than 60%) histological type in Iranian women who
diagnosed with breast cancer e2, 33, 34]. In this study, a total of five different
breast/ovarian tumour types were histologically reported in BRCAl/2
mutant carriers and non- carriers. One type, invasive ductal carcinoma was
identified dominantly (See Tables 8.1 and 8.2).
Table 8.1 : Breast/ovarian tumour types observed in Iranian women
carrying the BReA1/2 germline mutation and non-carriers
OV= Ovarian cancer
Tumour type Abbreviation Total observed
cases
Invasive Ductal Carcinoma IDC 71
Papillary Serous Cystadenoma (OV) PSCA 3
Medullary Carcinoma MC 2
Invasive Lobular Carcinoma ILC 1
Granulosa Cell Tumour (OV) GCT 1
.
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Of 104 individuals tested 88 patients were diagnosed with breast or ovarian
cancer, sixteen participants tested were unaffected (See chapter two section
2.1.1) obviously no pathologic reports have been made for them.
Finally a total of seventy-seven pathology reports were available in their
record reviewed from 88 women diagnosed with breast/ovarian cancer
(tumour grading was not requested in questionnaire from).
Table 8.2: Breast/ovarian tumour types in Iranian women carrying
the BRCA1 or BRCA2 germline mutation
Mutation and Tumour Family Age atGene/exon nucleotide Coding effect
change type history diagnosis
BRCAI- 185-186 delAG IDC Frameshift 2BC-IPS 37
exon 2
BRCAI- 181-182 insT IDC Frameshift 1-0V 41exon 2
BRCAI 2335-2336 IDC, Frameshift (2BC<40) 42*exon II delAA MC
BRCA2 6261-6262 IDC Frameshift (2BC<40) 27exon II insGT
BRCA2 3979-3980 IDC Frameshift Negative 40exon II insA
BRCA2 5972 C>T
n.a. Missense Negative 41exon II TI915M
BRCA2- IVSI6-14T>C Close to
exon 17 IVSI6-6T>G n.a. splice site n.a. n.a.
BRCA2- 8345A>G IDC Missense Negative
exon 18 (N2706S) 38
BRCAI- IVS20+48 dup IDC Polymorphism 2BC<42 27exon 20 gtattccactcc
BRCA2- 9266C>T IDC Missense Negative
exon 23 T3013I 31
BC- Breast Cancer OVa Ovarian Cancer ps- Prostate Cancer n.a= notapplicable
IDC= Invasive Ductal Carcinoma MC= Medullary Carcinoma
·This woman who carrying a deleterious BRCA1 mutation was identified histologically
with both IDC and MC type.
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Although IDC was dominantly reported in BRCAl/2 carriers and non-
carriers breast families, due to inadequate cases of hereditary and sporadic
breast/ovarian cancers (control cases) in this study, it is difficult to compare
this observation with the other studies [31, 35] and make a correct
interpretation. Further study consist of a large number of breast/ovarian
families including familial and sporadic breast/ovarian cancer cases
(control cases) and tumour type with the sufficient histological features is
required to investigate potential use of breast tumour type in identifying
carriers with BRCAl/2 mutation in this selected group.
Inclusion of breast-cancer histology in the design of genetic testing
policies, particularly for young women without a family history of breast
cancer, may be clinicallyappropriate and cost-effective.
8.3.1 Mutation detection rate
The present study analysed the BRCA genes based on specific criteria,
therefore the outcome mainly depends on a prior chance of carrier having a
mutation in the BRCA genes as well as on the sensitivity and specificity of
methods used. Mutation detection rates within BRCA1 and BRCA2 genes
have been reported in cohort studies to vary between 6.2% and 16% e6, 36,
37,38,39,40]. The present cohort studied all had early-onset (under the age of
forty-five years) breast cancer; a sub-group had a family history, which was
quite limited in comparison to the majority of other studied e7, 38, 39, 41].
These preliminary data suggest that the spectrum of mutations identified
differs little from that seen in other studied with no recurrent mutation and
with the mutations spread throughout the genes. Among 83 breast cancer
families five putative (Frameshift) mutations were detected in the group as
a whole (6.02% detection rate) in which 4 mutations was detected among
14 individuals with a family history (28.6% detection rate with 95%
binomial confidence interval 0.09-0.58) whilst one mutation was seen in an
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patient among 69 individuals without family history that is apparently
sporadic early-onset breast cancer (1.50/0 detection rate with 95% binomial
confidence interval 0-0.09) [42).
I could find no sequence variant in some cases that diagnosed with early-
onset breast cancer (bilateral) with or without strong family history.
However, it is clear that the known genes cannot explain most of the
variation in breast cancer risk in the population. The difficulties of
identifying further genes by linkage indicate that the remaining genes may
be numerous, with relatively common alleles conferring moderate risks.
Only by identifying these genes with the true pattern of risk and the
mechanism behind them become clear [43).
The detection rate in those individuals with a family history was high
especially when compared with other studies where the selection criteria
for screening required a much stronger family history. This suggests that
the screening, albeit incomplete, was well targeted. The low detection rate
in those with an apparently sporadic early-onset breast cancer suggests that
early-onset occurrence alone is insufficient to warrant breast cancer
screening in the Iranian population.
Identification of these distinct mutations suggests that any given population
should develop a mutation database for its programme of breast cancer
screening. The pattern of mutations seen in the BRCA genes does not
appear to differ from other population studied. Early-onset breast cancer
(less than 45 years) and a limited family history is sufficient to warrant
mutation screening with a detection rate of over 25% in this group whilst
sporadic early-onset breast cancer (detection rate less than 5%) is unlikely
to be cost-effective. If these results were confirmed on a large cohort,
molecular methods might form a vital part of any screening programme in
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Iran; this programme could be readily administered through the Iranian
Primary Health Care Network.
8.3.2 GenBank accession numbers
The sequences variants that identified in the current study were submitted
to the GenBank with accession numbers:
AF274503, AF2848I2, AF288936, AF288937, AF288938, AF3094I3,
AF3I7283, AF3485 15, AY008850, AY008851.
The current study has been published in Breast Cancer Research Journal.
2002~ Vol. 4 No.4
8.3.3 The future prospects
Breast cancer is not only a health problem to the Western countries so we
should consider it globally. Screening programmes can be offered at two
levels: I-public services 2-research. Any given government's policy should
consider this issue.
At the level of public services, medical team (Nurse specialist, General
Physician, Gynaecologist, Surgeon, Psychologist, Genetic Consultant), and
molecular geneticist, both should collaborate very closely. Both should be
aware of the limitations and complexity of breast cancer management, and
must exploit all possible clinical and technical approaches to provide a
much better outcome and benefit to the probands.
At the level of research, international collaboration is critical to understand
those significant factors (environmental, ethnic founder effect, life style
and etc.) additional to genetic predisposing factors that might contribute to
breast cancer development, such global research efforts will also be needed
to investigate other high or low penetrance genes and possible other
unknown breast cancer pathways.
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Previous studies have estimated different penetrances for breast cancer risk
In women with gennline BRCAI and BRCA2 mutations among the
population used for analysis. In summary the existing breast cancer
database that includes epidemiologic factors have been gathered mostly
from selected populations, some other countries may uncover other factors
either genetic or environmental contributing to the development of breast
cancer.
Thus far, present data have revealed that cancer incidence and prevalence
in Iran is much lower than the most parts of the world, confirming that
more studies are urgently needed. However, it seems that there is a strong
correlation between age distribution (Age pyramid) of Iranian population
and the incidence rate of breast cancer.
It appears to be timely for uncovering populations where epidemiologic
factors that may contribute significantly to the development of breast
cancer remain uncharacterised.
The last point is, which I would like to emphasis on that, worldwide breast
cancer incidence rate (new cases) approaches around one million per year,
if we assume that hereditary breast cancer is accounted for 5-9 per cent of
all breast cancers types, the new cases of hereditary breast cancers reach to
100000 so that 900000 new cases remain to be detected at early stage by
any means rather than genetic tests. Taking this figures, are we driving in a
right way? Do we have a clear plan for early detection of all types of breast
cancer? Working together may lead to prevent and cure breast cancer in
near future.
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Abstract 1: Novel mutations in the BRCAI and BRCA2 gene in Iranian
women with early-onsetBreast Cancer. 10th International Congress of
Human Genetics, 15-19 May 2001, Vienna, Austria
Novel germline mutations in the BRCAI and BRCA2 gene in Iranian
women with early-onset Breast Cancer
Vahid R Yassaee (1,5) Sirous Zeinali (2) Iraj Harirchi (3) Mohammed A.
Mohagheghi (4) David Hornby (1) Ann Dalton (5)
(1) Department of Molecular Biology and Biotechnology, The University of Sheffield,
Sheffield, UK (2) Department of Molecular Biotechnology, Pasteur Institute, Tehran-
IRAN(3) Iranian Centre for Breast Cancer (ICBC), Tehran University of Medical
Sciences, Tehran, IRAN(4) Cancer Institute, Tehran University of Medical Sciences,
Tehran, IRAN(5) North Trent Molecular Genetics Laboratory, Sheffield Children's
Hospital, Sheffield, UK
To report the initial experience in identifying germline mutations in the
BRCAl and BRCA2 breast and ovarian cancer susceptibility genes, to
assess the spectrum of such mutations and to determine the frequency of
recurrent mutations in Iranian women with early-onset breast cancer, we
analyzed a total of 90 samples derived from Iranian women under the age
40 years. 70 samples derived from patients diagnosed with early-onset
breast cancer and 20 samples from unaffected women who have first-
degree family history of at least one breast cancer under the age 40.
We distinguished mutations identified by analysing BRCAI exons 2, 3, 5,
11, 13 and 20 and BRCA2 exons 9,10,11, 17, 18 and 23 using Protein
Truncation Test (PTT) and Single Strand Conformation Polymorphism
(SSCP) analysis on PCR-amplified genomic DNA. Modified primers
containing T7 promoter and a perfect Kozak consensus sequence were used
to generate peR products of the whole of exon 11 of BRCAI and exon
exons 10 and 11 ofBRCA2 that were suitable for PIT.
Ten distinct sequence variants were identified. Five frameshifts (putative
mutations-four novel); three missense changes of unknown significance
and two polymorphisms, one seen commonly in both Iranian and British
populations.
Identification of these novel mutations suggests that any given population
should develop a mutation database for its programme of Breast Cancer
screening. The pattern of mutations seen in the BRCA genes does not
appear to differ from other population studied. Further studies should be
performed to address the prevalence of these mutations in Iranian
population.
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It is nevertheless clear that molecular methods should form part of any
population-screening program. How this is integrated with conventional
methods of clinical investigationneeds open discussion.
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Abstract 2: Gene assembling, a new approach in mutation detection
techniques: An application for BRCA genes scanning. (Accepted) Human
Genome Meeting 2002, 14-17 April 2002, Shanghai, China
Gene assembling, a new approach in mutation detection techniques:
An application for SReA genes scanning
Vahid R Yassaee l • 1, Ann Daltonl
I) Dept. of Molecular Biology and Biotechnology, The University of
Sheffield, Sheffield- SI0 2TN, UK
2) North Trent Molecular Genetics laboratory, Sheffield Children's
Hospital, Sheffield - SI0 2TH, UK
Many disease susceptibility genes are large and consist of many exons in
which point mutations are scattered throughout. There has been an
increasing demand for a rapid and accurate method for scanning point
mutations in BRCA genes particularly.
Meta-PCR is a new method for creating chimaeric DNA molecules using a
modified PCR reaction (Wallace et al 1999) that allows maximising the
length of sequence that can be scanned by downstream technique.
Here we present data to demonstrate the assembles of exons 2, 20,23 and
24 of the BRCAI gene and their subsequently analysis by direct
sequencing.
The BRCA I exons 2 and 20 are hot spot regions that are known to harbour
particularly deleterious mutations. In order to avoid missing any mutation
in these two exons, the above four exons were assembled in the following
order of preferences: 23 20, 2 and 24. However, the order of fragments can
be predetermined by primer design.
We verified by direct sequencing that the order and sequence of the
component exons in the Meta-PCR products were as predicted. Meta-PCR
products from three previously ascertained heterozygotes for BRCA1
mutations were directly sequenced and gave the same sequence patterns.
Scanning each exon of BRCA1 and BRCA2 genes individually represent a
tedious task. Meta-Pf'R technique might circumvent this problem and is
likely to be useful for clinical molecular diagnostic laboratories, helping
them to fulfil the demand for scanning for complex genetic diseases at a
lower cost.
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Beckground: Breut cancer is the most common female malignancy and a majorcause of cleath in
middle eged women. So w, germAne mutations in the BRCA 1 and BRCA2 genes in patients with
eerIy-ooeet br-.t erwJIor ovariancancer havenot been identified within the Iranian population.
Methoda: With the coIleboration of two main centres for cancer in Iran. we obtained clinical
informetion, femiy historyand peripheral blood from 83 women under the age of 45 with early-oneat
br-.t cancer for eeanning of germfine mutations in the BRCA1 and BRCA2 genes. We anaJysed
BRCA 1 8llOO8 11 andBRCA2 exone 10 and 11 by the protein truncation test,and BRCA 1 axone 2,
3, 5, 13 and 20 end BRCA2 exone 9, 17, 18 and 23 with the single-strand conformation
polymorphiam~ on genomic DNA amplified by polymerase chain reaction.
ReIuIta: Ten eequence 'NiInta were identified: five frameshifte (putative mutations - four noveO; three
mieeenee chengee of unknown significance and two polymorphisms, one seen commonly in both
IrMen end BritiehpopuIatione.
Conc:Iu.IonI: Identif.cation of theee novel mutations suggests that any given population should
deYeIop e mutation daabue for ita programme of breast cancer screening. The patternof mutations
eeen in the BRCA genes eeemenot to differfromotherpopulations studied. EarIy-onset breast cancer
0- than 45 years) end a limited family history is sufficient to justify mutation screening with a
detection rateof over 25~ in this group, whereas sporadic early-onset breast cancer (detection rate
Ieee then~) ie unlikely to be c:oet-effective.
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Introduction
Worldwide, breast cancer is the moat common cancer
in women, excluding akin cance1'8 (1), with a lifetime risk
of 1()CM) in the general population (2). In spite of earlier
detection and better treatment, largely due to recent
technological advances, it is atin the second leading
cause of cancer death in women, exceeded only by lung
ca.ncer [3]. !he three. commonest cancers, excluding
skin cancer, In the IraOlan population (females, all ages).
are cancers of the oesophagus, breast and cervix, in
diminishing order of incidence [4]. A preliminary study
showed no significant differences in age-specific
PTT - pIOI8in INncItIon ....: SSCP -lingIe-alrllnd confolTnation polymorphism.
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incidences among Iranian women with breast cancer, in
comparison with other studies [5,6).
Hereditary breast cancer is suspected in an individual who
has a family history of breast cancer, or breast and ovarian
cancer, that is consistent with autosomal dominant inheri-
tance [7). Many efforts are now under way to reduce the
high incidence and mortality associated with breast and
ovarian cancer by the early detection of women at high
risk. These women, once identified, can be targeted for
more aggressive prevention programs. Breast cancer is
not a systemic disease at its inception but is progressive;
screening can arrest its development and the treatment of
advanced breast cancer is often futile and disfiguring [8).
In 1990, the first breast cancer susceptibility gene,
BReA 1, was localised by linkage analysis to chromosome
17q21 [9). Miki et el. [10) isolated the BReA 1 gene in
1994. Subsequently, Wooster et el. (11) identified a new
gene, BReA2. Both BReA 1 and BReA2 are large
genes, consisting of 24 and 27 exons, respectively. Muta-
tions in BRCA genes are distributed throughout the
coding region. Women who carry BRCA1 and BRCA2
mutations have a significantly increased chance of devel-
oping breast cancer before the age of 50 years [12-14).
Some studies indicate that 13% of women who are diag-
nosed with breast cancer under the age of 30 years, and
7% of women who are diagnosed with breast cancer
under the age of 35 years, have germline BRCA1 alter-
ations [12,15). No molecular genetics study of BRCA1
and BRCA2 germline mutations has been reported in the
Iranian population and there are few individuals with
strong family histories that have as yet been identified. We
therefore selected women who were most likely to harbour
germline mutations in these genes.
MutMIona'spectrum
At present, over 878 distinct mutations, polymorphisms
and variants throughout the BRCA1 gene have been dis-
covered [16). Over 900 distinct alterations have been
identified in BRCA2 (16) and, as in BReA 1, they are not
limited to a particular region of the gene. Most mutations
in both genes are private [16). BReA 1 is considered to
be responsible for about one-half of all cases of early-
onset breast cancer and for the majority of familial breast
and ovarian cancers [9,17). BReA 1 somatic mutations
have never been reported in sporadic breast cancer [18)
although they have occasionally been found in sporadic
ovarian cancers [19,20).
Meterle" end methods
Design
We performed the present study to obtain initial experi-
ence in identifying germline mutations in the BReA 1 and
BRCA2 genes in Iranian women diagnosed with early-
onset breast cancer.
With the cooperation of two main centres for cancer
research and treatment in Tehran, Iran, namely the Iranian
Centre for Breast Cancer and the Cancer Institute at
Tehran University of Medical Sciences, 83 samples derived
from 82 unrelated Iranianfamilies were selected for screen-
ing of germline mutations in BRCA1 and BRCA2.
During 3 years since 1997, the medical records of 152
women diagnosed with breast cancer at the Iranian
Centre for Breast Cancer were reviewed and 39 patients
were selected for screening. In the 12 months after
December 1999, a consecutive series of 44 patients from
the Cancer Institute who were diagnosed with breast
cancer were chosen for screening. All selected patients
from these two centres were under the age of 45 years.
All selected women were informed that their DNA samples
would be analysedfor known mutations in genes associated
with susceptibility to breast cancer; they were offered the
opportunity to receive the results and were asked to sign a
second consent form if they chose to leam the results.
DNA isolation and mutation ana.,...
Using a Promega DNA purification kit (catalogue no.
LA1620) and in accordance with the manufacturer's pro-
tocols, genomic DNA was extracted from peripheral blood
lymphocytes at the Pasteur Institute in Tehran, Iran.
We analysed BReA 1 exon 11 and BReA2 exons 10 and
11 by the protein truncation test (PTT) [21-23), and
BReA 1 exons 2, 3, 5, 13 and 20 and BReA2 ellons 9
17, 18 and 23 by the single-strand confonnation polymor~
phism (SSCP) assay [24) and heteroduplell analysis [25)
by amplification from genomic DNA with the polymerase
chain reaction (PeR).
Although mutations are scattered throughout both BReA 1
and BReA2, some coding regions were particulariy chosen
for several reasons: first, it has been shown that they have a
significant role in protein function (ellons 2-5, Ring finger
domain (26); exon 11 and exon 20, BRCT domain) (27);
seoond, ellons 10 and 11 cover a large segment of the
gene; third, many putative mutations have been reported in
these regions; and fourth, the coding regions listed above
have been shown in other significant studies [28-32) to be
most likely to harbour germline BReA 1 and BRCA2 muta-
tions. A comparison of data from other studies suggests
that, with this strategy, about 14% and 22% of mutations in
BReA 1 and BReA2, respectively, would be miseed.
However, there are no data to indicate the presence of pop-
ulation-specific mutations in Iran; these data must therefore
be considered preliminary [28-32).
The PrJ metllod
Most mutations reported in BReA 1 and BReA2 cause
premature termination of translation, which is readily
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detectable by PTT; PIT is a very sensitive and efficient
tool for mutation detection (28).
Modified primers containing a T7 promoter and a perfect
Kozak consensus sequence were used to generate PCR
product. of the whole of 8lIon 11 of BReA 1 and exons 10
and 11 of BRCA2 that were suitable for PTT. Each primer
pair amplified 3446 base pairs (bp) and 4959 bp for
BRCA 1 exon 11 and BRCA2 exon 11, respectively.
Regions (the fS' and 3' ends) of exon 11 in both genes
were screened separatety to identify any potential
decrea8e in the sensivity of PIT resulting from the use of
such large fragments.
PCRprog..........
PCRs were perforrnecl with genomic DNA containing
~ ng of genomic DNA, 1 ~I of each primer at 5 pmol/~I,
2 J1I of a mixture of dNTPs (each at 2.5 mM), 2.5 J1I of
6 )( PeR buffer A [300 mM Tria-SO. (pH 9.1 at 26°C),
90 mM (NH4)2S0. and 5 roM MgSO,J and 2.5 ~I of
buffer B (300 mM Tris-SO. (pH 9.1 at 250(;), 90 mM
(NH4)2S0. and 10 mM MgSO,J, 1 111 of EIongase~
Enzyme Mix (Invitrogen, Paisley, UK) in accordance with
manufacturer's recommendations. and diatHIed water was
added to a final volume of 25 J1I. For ampIiflC8tion, each
sample was denatured at 940C for 1 min and subjected to
31 cycles of PeR (~·C for 25 .. 56°C for 1 min, and
extension at 6S-C for 4 min on an Applied Biosystems
DNA thermal cycler, Applera Europe BV, Cheshire, UK);
this was followed by incubation at 880C for 10 min. The
PeR products were checked on 8 0.7% 8gal'088 gel and
a 1 J1I sample was used for a coupled transcription-trans-
lation reaction (TNTa T7 Quick for PeR DNA kit from
Promega. Southampton, UK; catalogue no. L5640), in
accordance with the instructions of the manufacturer. Full-
length artificial proteins of BRCA1 and BRCA2 exon 11,
128 and 182 kDs. respectively, labeled with 3&8, were
detected after SDS-PAGE (33) (1188 Ag. 2) on a 2 x Mini-
Protean system (Bio-Rad, Hertfordshire, UK, catalogue no.
185-3301).
TlleSSCP....,
BReA 1 exons 2, 3, 5, 13 and 20, BRCA2 exons 9, 17,
18 and 23 and the 5' and 3' ends of exon 11 of BRCA 1
and BRCA2 were analyaed with the SSCP method.
PCR was performed on 50 ng of genomic DNA, 1 J1I of
5 prnoUJ1I forward primer, 1 J1I of 5 pmoIIJ1I reverse primer,
1.8 J1I of a mixture of dNTPa (each at 2.5 mM), 2 J1I of
10 x PCR reaction buffer [750 mM Tris-HCI (pH 8.8 at
250(;), 200mM (NH4)2S0. and 0.1% (vlv) Tween 20],
0.7 unit of Red Hot TIKI DNA poIymeraee, made up to a
final volume of 20 J1I with distiled water. For amplification,
each sample was denatured at 940C for 2 min and sub-
jected to 28-30 cycles of PCR (at 940C for 30 s, at
55-60°C for 1 min, and extension at 740(; for 1 min on a
AYllll8ble online htlp:llbl888t-canoer-l'888arch.comlcontentJ4/4/R6
Perkin-Elmer-Cetus DNA thermal cycler) : this was fa/-
lowed by incubation at 72°C for 5 min. Annealing temper-
atures varied according to the melting temperature, T
m
, of
the primer template.
SSCP analysis for point mutations was performed under
the following conditions: a mixture of 5 J.l.I of a 28-cycle
PCR product and 5 J1I of loading buffer was denatured for
10 min at 95°C, cooled rapidly on ice and separated on 8
non-denaturing 14% polyacrylamide gel (57: 1 aery-
lamide:bisacrylamide, 3-10% glycerol) in 0.5 x Tris-
borate-EDTA buffer at 12-16°C for 16-20 h at 245 V.
Bands were revealed by silver staining.
DIrectsequendlll
An sequence variants were confirmed by using the PCR
products of each sequence variant and Big Dye dideoxy-
terminator chemistry (Perkin-Elmer) on an ABI 377 DNA
sequencer (Applied Biosystems).
Prtmer d.lgn
For SSCP, splice junctions were included in the analysis
in all cases. In addition, four sets of primers were used to
screen the 6' and 3' ends of exon 11 of BRCA 1 and
BReA2. For PTT, two sets of primers were designed to
screen the whole of exon 11 of BRCA 1 and BRCA2.
Results
We have identified ten sequence variants in this cohort:
five f~eshifts, four of which were novel (Figs 1 and 2),
three rmssense changes of unknown significance and two
polymorphisms.
A common polymorphism in BRCA2 OVS16-14T>C] was
identified in both Iranian and British populations. No
sequence variant was detected at the 5' and 3' ends of
exon 11 in BReA 1 and BReA2 by SSCP analysis, sug-
gesting that there was no loss of sensitivity in analysing
such large fragments by PTT.
Tables 1 and 2 describe the distribution of BReA 1 and
BRCA2 mutations respectively by the type of mutations.
Dlscus.lon
This is the first report to describe mutations in the BRCA
genes in the Iranian population. The cohort studied all had
early-on~t (less than 46 years) breast cancer; a subgroup
had a fal1llly history that was quite limited (Tables 1 and 2)
in comparison with most other studies [34-37). These
preliminary data suggest that the spectrum of mutations
identified differs little from that seen in other studies, with
no recurrent mutation and the mutations spread through-
out the genes. rIVe putative (frameshift) mutations were
detected in the group as 8 whole (6.02% detection rate)
in which four mutations were detected among 14 individu-
als with a family history (28.6% detection rate with 95%
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11 233&-2S3ed11M 741 (fAA) Frameahift PIT 2 BC<40 42
~ 12bp c:t.Ip OTAlTCCAC'ICC IVS2O'H8 Polymorphism SSCP/HA 2 BC<42 27
.,... pMiInt aIIo ha • frwneIhift mutation in .-an 11 of BRCA2. Be, breast cancer (euly-onaet ages are al80 shown); HA, heteroduplex analysis;
av,~ C8IlC*; PS.Jl"lII*~ PTT, protein WrlOIIIion teet; SSCP, eingle-atrand conformation polymorphism 8888y.
Tltblel
-.nI1................MCM...
MtMtIon.cl Stop codon Screening Ageat diagnoais
&on nucleotide dwIge at amino8Cid Coding effect method Family hiatory (yeara)
11· e2e1-t2tS2 ineGT 2040 (fAA) Frameahift PIT 2 BC<40 27
11 3878-3MO ineA 1284 (fAA) Frameahift PIT Negative 40
11 5872 C>TT1e15M M..,se OS Negative 41
17f 1V81e-14'DC 1V81HT.>G Close to splice site SSCPIHA n.L n.L
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